id	sid	tid	token	lemma	pos
dpc-5639	1	1	dermatology	dermatology	NOUN
dpc-5639	1	2	:	:	PUNCT
dpc-5639	1	3	practical	practical	ADJ
dpc-5639	1	4	and	and	CCONJ
dpc-5639	1	5	conceptual	conceptual	ADJ
dpc-5639	1	6	original	original	ADJ
dpc-5639	1	7	article	article	NOUN
dpc-5639	1	8	|	|	ADV
dpc-5639	1	9	dermatol	dermatol	ADJ
dpc-5639	1	10	pract	pract	NOUN
dpc-5639	1	11	concept	concept	NOUN
dpc-5639	1	12	.	.	PUNCT
dpc-5639	2	1	2025;15(4):5639	2025;15(4):5639	NUM
dpc-5639	2	2	1	1	NUM
dpc-5639	2	3	dupilumab	dupilumab	NOUN
dpc-5639	2	4	:	:	PUNCT
dpc-5639	2	5	an	an	DET
dpc-5639	2	6	additional	additional	ADJ
dpc-5639	2	7	arrow	arrow	NOUN
dpc-5639	2	8	in	in	ADP
dpc-5639	2	9	the	the	DET
dpc-5639	2	10	quiver	quiver	NOUN
dpc-5639	2	11	for	for	ADP
dpc-5639	2	12	prurigo	prurigo	PROPN
dpc-5639	2	13	nodularis	nodularis	PROPN
dpc-5639	2	14	?	?	PUNCT
dpc-5639	3	1	data	datum	NOUN
dpc-5639	3	2	from	from	ADP
dpc-5639	3	3	a	a	DET
dpc-5639	3	4	real	real	ADJ
dpc-5639	3	5	-	-	PUNCT
dpc-5639	3	6	life	life	NOUN
dpc-5639	3	7	setting	set	VERB
dpc-5639	3	8	roberta	roberta	PROPN
dpc-5639	3	9	di	di	PROPN
dpc-5639	3	10	caprio1	caprio1	PROPN
dpc-5639	3	11	,	,	PUNCT
dpc-5639	3	12	stefano	stefano	PROPN
dpc-5639	3	13	caccavale1	caccavale1	PROPN
dpc-5639	3	14	,	,	PUNCT
dpc-5639	3	15	eugenia	eugenia	PROPN
dpc-5639	3	16	veronica	veronica	PROPN
dpc-5639	3	17	di	di	PROPN
dpc-5639	3	18	brizzi1	brizzi1	PROPN
dpc-5639	3	19	,	,	PUNCT
dpc-5639	3	20	caterina	caterina	PROPN
dpc-5639	3	21	mariarosaria	mariarosaria	PROPN
dpc-5639	3	22	giorgio1	giorgio1	PROPN
dpc-5639	3	23	,	,	PUNCT
dpc-5639	3	24	aleksandra	aleksandra	PROPN
dpc-5639	3	25	stefaniak1	stefaniak1	PROPN
dpc-5639	3	26	,	,	PUNCT
dpc-5639	3	27	giuseppe	giuseppe	PROPN
dpc-5639	3	28	argenziano1	argenziano1	PROPN
dpc-5639	3	29	,	,	PUNCT
dpc-5639	3	30	anna	anna	PROPN
dpc-5639	3	31	balato1	balato1	NOUN
dpc-5639	3	32	1	1	NUM
dpc-5639	3	33	dermatology	dermatology	NOUN
dpc-5639	3	34	unit	unit	NOUN
dpc-5639	3	35	,	,	PUNCT
dpc-5639	3	36	university	university	PROPN
dpc-5639	3	37	of	of	ADP
dpc-5639	3	38	campania	campania	PROPN
dpc-5639	3	39	“	"	PUNCT
dpc-5639	3	40	luigi	luigi	PROPN
dpc-5639	3	41	vanvitelli	vanvitelli	PROPN
dpc-5639	3	42	”	"	PUNCT
dpc-5639	3	43	,	,	PUNCT
dpc-5639	3	44	naples	naples	PROPN
dpc-5639	3	45	,	,	PUNCT
dpc-5639	3	46	italy	italy	PROPN
dpc-5639	3	47	key	key	PROPN
dpc-5639	3	48	words	word	NOUN
dpc-5639	3	49	:	:	PUNCT
dpc-5639	3	50	prurigo	prurigo	PROPN
dpc-5639	3	51	nodularis	nodularis	NOUN
dpc-5639	3	52	,	,	PUNCT
dpc-5639	3	53	real	real	ADJ
dpc-5639	3	54	-	-	PUNCT
dpc-5639	3	55	life	life	NOUN
dpc-5639	3	56	setting	setting	NOUN
dpc-5639	3	57	,	,	PUNCT
dpc-5639	3	58	dupilumab	dupilumab	NOUN
dpc-5639	3	59	,	,	PUNCT
dpc-5639	3	60	antidepressants	antidepressant	VERB
dpc-5639	3	61	citation	citation	NOUN
dpc-5639	3	62	:	:	PUNCT
dpc-5639	3	63	di	di	PROPN
dpc-5639	3	64	caprio	caprio	PROPN
dpc-5639	3	65	r	r	PROPN
dpc-5639	3	66	,	,	PUNCT
dpc-5639	3	67	caccavale	caccavale	PROPN
dpc-5639	3	68	s	s	PROPN
dpc-5639	3	69	,	,	PUNCT
dpc-5639	3	70	di	di	PROPN
dpc-5639	3	71	brizzi	brizzi	PROPN
dpc-5639	3	72	ev	ev	PROPN
dpc-5639	3	73	,	,	PUNCT
dpc-5639	4	1	et	et	PROPN
dpc-5639	4	2	al	al	PROPN
dpc-5639	4	3	.	.	PUNCT
dpc-5639	4	4	dupilumab	dupilumab	NOUN
dpc-5639	4	5	:	:	PUNCT
dpc-5639	4	6	an	an	DET
dpc-5639	4	7	additional	additional	ADJ
dpc-5639	4	8	arrow	arrow	NOUN
dpc-5639	4	9	in	in	ADP
dpc-5639	4	10	the	the	DET
dpc-5639	4	11	quiver	quiver	NOUN
dpc-5639	4	12	for	for	ADP
dpc-5639	4	13	prurigo	prurigo	PROPN
dpc-5639	4	14	nodularis	nodularis	PROPN
dpc-5639	4	15	?	?	PUNCT
dpc-5639	5	1	data	datum	NOUN
dpc-5639	5	2	from	from	ADP
dpc-5639	5	3	a	a	DET
dpc-5639	5	4	real	real	ADJ
dpc-5639	5	5	-	-	PUNCT
dpc-5639	5	6	life	life	NOUN
dpc-5639	5	7	setting	setting	NOUN
dpc-5639	5	8	.	.	PUNCT
dpc-5639	6	1	dermatol	dermatol	NOUN
dpc-5639	6	2	pract	pract	PROPN
dpc-5639	6	3	concept	concept	NOUN
dpc-5639	6	4	.	.	PUNCT
dpc-5639	7	1	2025;15(4):5639	2025;15(4):5639	NUM
dpc-5639	7	2	.	.	PUNCT
dpc-5639	8	1	doi	doi	PROPN
dpc-5639	8	2	:	:	PUNCT
dpc-5639	8	3	https://doi.org/10.5826/dpc.1504a5639	https://doi.org/10.5826/dpc.1504a5639	PROPN
dpc-5639	8	4	accepted	accept	VERB
dpc-5639	8	5	:	:	PUNCT
dpc-5639	8	6	july	july	PROPN
dpc-5639	8	7	20	20	NUM
dpc-5639	8	8	,	,	PUNCT
dpc-5639	8	9	2025	2025	NUM
dpc-5639	8	10	;	;	PUNCT
dpc-5639	8	11	published	publish	VERB
dpc-5639	8	12	:	:	PUNCT
dpc-5639	9	1	october	october	PROPN
dpc-5639	9	2	2025	2025	NUM
dpc-5639	9	3	copyright	copyright	NOUN
dpc-5639	9	4	:	:	PUNCT
dpc-5639	9	5	©	©	PROPN
dpc-5639	9	6	2025	2025	NUM
dpc-5639	9	7	di	di	X
dpc-5639	9	8	caprio	caprio	PROPN
dpc-5639	9	9	et	et	PROPN
dpc-5639	9	10	al	al	PROPN
dpc-5639	9	11	.	.	PUNCT
dpc-5639	10	1	this	this	PRON
dpc-5639	10	2	is	be	AUX
dpc-5639	10	3	an	an	DET
dpc-5639	10	4	open	open	ADJ
dpc-5639	10	5	-	-	PUNCT
dpc-5639	10	6	access	access	NOUN
dpc-5639	10	7	article	article	NOUN
dpc-5639	10	8	distributed	distribute	VERB
dpc-5639	10	9	under	under	ADP
dpc-5639	10	10	the	the	DET
dpc-5639	10	11	terms	term	NOUN
dpc-5639	10	12	of	of	ADP
dpc-5639	10	13	the	the	DET
dpc-5639	10	14	creative	creative	ADJ
dpc-5639	10	15	commons	common	NOUN
dpc-5639	10	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-5639	10	17	license	license	NOUN
dpc-5639	10	18	(	(	PUNCT
dpc-5639	10	19	by	by	ADP
dpc-5639	10	20	-	-	PUNCT
dpc-5639	10	21	nc-4.0	nc-4.0	NOUN
dpc-5639	10	22	)	)	PUNCT
dpc-5639	10	23	,	,	PUNCT
dpc-5639	10	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5639	10	25	,	,	PUNCT
dpc-5639	10	26	which	which	PRON
dpc-5639	10	27	permits	permit	VERB
dpc-5639	10	28	unrestricted	unrestricted	ADJ
dpc-5639	10	29	noncommercial	noncommercial	ADJ
dpc-5639	10	30	use	use	NOUN
dpc-5639	10	31	,	,	PUNCT
dpc-5639	10	32	distribution	distribution	NOUN
dpc-5639	10	33	,	,	PUNCT
dpc-5639	10	34	and	and	CCONJ
dpc-5639	10	35	reproduction	reproduction	NOUN
dpc-5639	10	36	in	in	ADP
dpc-5639	10	37	any	any	DET
dpc-5639	10	38	medium	medium	NOUN
dpc-5639	10	39	,	,	PUNCT
dpc-5639	10	40	provided	provide	VERB
dpc-5639	10	41	the	the	DET
dpc-5639	10	42	original	original	ADJ
dpc-5639	10	43	authors	author	NOUN
dpc-5639	10	44	and	and	CCONJ
dpc-5639	10	45	source	source	NOUN
dpc-5639	10	46	are	be	AUX
dpc-5639	10	47	credited	credit	VERB
dpc-5639	10	48	.	.	PUNCT
dpc-5639	11	1	funding	funding	NOUN
dpc-5639	11	2	:	:	PUNCT
dpc-5639	11	3	none	none	NOUN
dpc-5639	11	4	.	.	PUNCT
dpc-5639	12	1	competing	compete	VERB
dpc-5639	12	2	interests	interest	NOUN
dpc-5639	12	3	:	:	PUNCT
dpc-5639	12	4	none	none	NOUN
dpc-5639	12	5	.	.	PUNCT
dpc-5639	13	1	authorship	authorship	NOUN
dpc-5639	13	2	:	:	PUNCT
dpc-5639	13	3	all	all	DET
dpc-5639	13	4	authors	author	NOUN
dpc-5639	13	5	have	have	AUX
dpc-5639	13	6	contributed	contribute	VERB
dpc-5639	13	7	significantly	significantly	ADV
dpc-5639	13	8	to	to	ADP
dpc-5639	13	9	this	this	DET
dpc-5639	13	10	publication	publication	NOUN
dpc-5639	13	11	.	.	PUNCT
dpc-5639	14	1	corresponding	correspond	VERB
dpc-5639	14	2	author	author	NOUN
dpc-5639	14	3	:	:	PUNCT
dpc-5639	14	4	stefano	stefano	PROPN
dpc-5639	14	5	caccavale	caccavale	PROPN
dpc-5639	14	6	,	,	PUNCT
dpc-5639	14	7	md	md	PROPN
dpc-5639	14	8	,	,	PUNCT
dpc-5639	14	9	dermatology	dermatology	NOUN
dpc-5639	14	10	unit	unit	NOUN
dpc-5639	14	11	,	,	PUNCT
dpc-5639	14	12	university	university	PROPN
dpc-5639	14	13	of	of	ADP
dpc-5639	14	14	campania	campania	PROPN
dpc-5639	14	15	“	"	PUNCT
dpc-5639	14	16	luigi	luigi	PROPN
dpc-5639	14	17	vanvitelli	vanvitelli	PROPN
dpc-5639	14	18	”	"	PUNCT
dpc-5639	14	19	,	,	PUNCT
dpc-5639	14	20	via	via	ADP
dpc-5639	14	21	pansini	pansini	NOUN
dpc-5639	14	22	5	5	NUM
dpc-5639	14	23	,	,	PUNCT
dpc-5639	14	24	80131	80131	NUM
dpc-5639	14	25	naples	naples	PROPN
dpc-5639	14	26	,	,	PUNCT
dpc-5639	14	27	italy	italy	PROPN
dpc-5639	14	28	.	.	PUNCT
dpc-5639	15	1	orcid	orcid	PROPN
dpc-5639	16	1	i	i	PRON
dpc-5639	16	2	d	d	NOUN
dpc-5639	16	3	:	:	PUNCT
dpc-5639	16	4	0000	0000	NUM
dpc-5639	16	5	-	-	PUNCT
dpc-5639	16	6	0001	0001	NUM
dpc-5639	16	7	-	-	PUNCT
dpc-5639	16	8	7433	7433	NUM
dpc-5639	16	9	-	-	PUNCT
dpc-5639	16	10	9283	9283	NUM
dpc-5639	16	11	.	.	PUNCT
dpc-5639	17	1	e	e	X
dpc-5639	17	2	-	-	NOUN
dpc-5639	17	3	mail	mail	NOUN
dpc-5639	17	4	:	:	PUNCT
dpc-5639	17	5	stefano85med@libero.it	stefano85med@libero.it	NOUN
dpc-5639	17	6	introduction	introduction	NOUN
dpc-5639	17	7	:	:	PUNCT
dpc-5639	17	8	prurigo	prurigo	PROPN
dpc-5639	17	9	nodularis	nodularis	PROPN
dpc-5639	17	10	(	(	PUNCT
dpc-5639	17	11	pn	pn	NOUN
dpc-5639	17	12	)	)	PUNCT
dpc-5639	17	13	management	management	NOUN
dpc-5639	17	14	remains	remain	VERB
dpc-5639	17	15	a	a	DET
dpc-5639	17	16	significant	significant	ADJ
dpc-5639	17	17	challenge	challenge	NOUN
dpc-5639	17	18	due	due	ADP
dpc-5639	17	19	to	to	ADP
dpc-5639	17	20	its	its	PRON
dpc-5639	17	21	chronicity	chronicity	NOUN
dpc-5639	17	22	,	,	PUNCT
dpc-5639	17	23	treatment	treatment	NOUN
dpc-5639	17	24	resistance	resistance	NOUN
dpc-5639	17	25	,	,	PUNCT
dpc-5639	17	26	and	and	CCONJ
dpc-5639	17	27	scarcity	scarcity	NOUN
dpc-5639	17	28	of	of	ADP
dpc-5639	17	29	approved	approve	VERB
dpc-5639	17	30	treatments	treatment	NOUN
dpc-5639	17	31	and	and	CCONJ
dpc-5639	17	32	to	to	ADP
dpc-5639	17	33	its	its	PRON
dpc-5639	17	34	impact	impact	NOUN
dpc-5639	17	35	on	on	ADP
dpc-5639	17	36	patients	patient	NOUN
dpc-5639	17	37	’	'	PUNCT
dpc-5639	17	38	quality	quality	NOUN
dpc-5639	17	39	of	of	ADP
dpc-5639	17	40	life	life	NOUN
dpc-5639	17	41	.	.	PUNCT
dpc-5639	18	1	objective	objective	NOUN
dpc-5639	18	2	:	:	PUNCT
dpc-5639	18	3	the	the	DET
dpc-5639	18	4	aim	aim	NOUN
dpc-5639	18	5	of	of	ADP
dpc-5639	18	6	this	this	DET
dpc-5639	18	7	study	study	NOUN
dpc-5639	18	8	was	be	AUX
dpc-5639	18	9	to	to	PART
dpc-5639	18	10	assess	assess	VERB
dpc-5639	18	11	pn	pn	PROPN
dpc-5639	18	12	therapeutic	therapeutic	ADJ
dpc-5639	18	13	management	management	NOUN
dpc-5639	18	14	in	in	ADP
dpc-5639	18	15	a	a	DET
dpc-5639	18	16	real	real	ADJ
dpc-5639	18	17	-	-	PUNCT
dpc-5639	18	18	life	life	NOUN
dpc-5639	18	19	setting	setting	NOUN
dpc-5639	18	20	.	.	PUNCT
dpc-5639	19	1	methods	method	NOUN
dpc-5639	19	2	:	:	PUNCT
dpc-5639	19	3	in	in	ADP
dpc-5639	19	4	this	this	DET
dpc-5639	19	5	prospective	prospective	ADJ
dpc-5639	19	6	observational	observational	ADJ
dpc-5639	19	7	study	study	NOUN
dpc-5639	19	8	,	,	PUNCT
dpc-5639	19	9	90	90	NUM
dpc-5639	19	10	patients	patient	NOUN
dpc-5639	19	11	diagnosed	diagnose	VERB
dpc-5639	19	12	with	with	ADP
dpc-5639	19	13	moderate	moderate	ADJ
dpc-5639	19	14	-	-	PUNCT
dpc-5639	19	15	to	to	ADP
dpc-5639	19	16	-	-	PUNCT
dpc-5639	19	17	severe	severe	ADJ
dpc-5639	19	18	pn	pn	NOUN
dpc-5639	19	19	were	be	AUX
dpc-5639	19	20	included	include	VERB
dpc-5639	19	21	.	.	PUNCT
dpc-5639	20	1	patients	patient	NOUN
dpc-5639	20	2	were	be	AUX
dpc-5639	20	3	each	each	DET
dpc-5639	20	4	prescribed	prescribed	ADJ
dpc-5639	20	5	therapies	therapy	NOUN
dpc-5639	20	6	available	available	ADJ
dpc-5639	20	7	for	for	ADP
dpc-5639	20	8	pn	pn	PROPN
dpc-5639	20	9	according	accord	VERB
dpc-5639	20	10	to	to	ADP
dpc-5639	20	11	symptom	symptom	NOUN
dpc-5639	20	12	severity	severity	NOUN
dpc-5639	20	13	,	,	PUNCT
dpc-5639	20	14	consistent	consistent	ADJ
dpc-5639	20	15	with	with	ADP
dpc-5639	20	16	treatment	treatment	NOUN
dpc-5639	20	17	guidelines	guideline	NOUN
dpc-5639	20	18	;	;	PUNCT
dpc-5639	20	19	only	only	ADV
dpc-5639	20	20	those	those	PRON
dpc-5639	20	21	undergoing	undergo	VERB
dpc-5639	20	22	systemic	systemic	ADJ
dpc-5639	20	23	therapies	therapy	NOUN
dpc-5639	20	24	were	be	AUX
dpc-5639	20	25	included	include	VERB
dpc-5639	20	26	.	.	PUNCT
dpc-5639	21	1	disease	disease	NOUN
dpc-5639	21	2	severity	severity	NOUN
dpc-5639	21	3	was	be	AUX
dpc-5639	21	4	evaluated	evaluate	VERB
dpc-5639	21	5	through	through	ADP
dpc-5639	21	6	the	the	DET
dpc-5639	21	7	measurements	measurement	NOUN
dpc-5639	21	8	of	of	ADP
dpc-5639	21	9	investigator	investigator	NOUN
dpc-5639	21	10	’s	’s	PART
dpc-5639	21	11	global	global	ADJ
dpc-5639	21	12	assessment	assessment	NOUN
dpc-5639	21	13	(	(	PUNCT
dpc-5639	21	14	iga	iga	PROPN
dpc-5639	21	15	)	)	PUNCT
dpc-5639	21	16	score	score	NOUN
dpc-5639	21	17	,	,	PUNCT
dpc-5639	21	18	numeric	numeric	ADJ
dpc-5639	21	19	rating	rating	NOUN
dpc-5639	21	20	scale	scale	NOUN
dpc-5639	21	21	(	(	PUNCT
dpc-5639	21	22	nrs	nrs	PROPN
dpc-5639	21	23	)	)	PUNCT
dpc-5639	21	24	for	for	ADP
dpc-5639	21	25	pruritus	pruritus	PROPN
dpc-5639	21	26	,	,	PUNCT
dpc-5639	21	27	and	and	CCONJ
dpc-5639	21	28	dermatology	dermatology	NOUN
dpc-5639	21	29	life	life	NOUN
dpc-5639	21	30	quality	quality	NOUN
dpc-5639	21	31	index	index	NOUN
dpc-5639	21	32	(	(	PUNCT
dpc-5639	21	33	dlqi	dlqi	ADJ
dpc-5639	21	34	)	)	PUNCT
dpc-5639	21	35	at	at	ADP
dpc-5639	21	36	the	the	DET
dpc-5639	21	37	beginning	beginning	NOUN
dpc-5639	21	38	of	of	ADP
dpc-5639	21	39	the	the	DET
dpc-5639	21	40	study	study	NOUN
dpc-5639	21	41	(	(	PUNCT
dpc-5639	21	42	week	week	NOUN
dpc-5639	21	43	0	0	NUM
dpc-5639	21	44	–	–	PUNCT
dpc-5639	21	45	w0	w0	PROPN
dpc-5639	21	46	)	)	PUNCT
dpc-5639	21	47	and	and	CCONJ
dpc-5639	21	48	after	after	ADP
dpc-5639	21	49	a	a	DET
dpc-5639	21	50	6	6	NUM
dpc-5639	21	51	-	-	PUNCT
dpc-5639	21	52	month	month	NOUN
dpc-5639	21	53	period	period	NOUN
dpc-5639	21	54	of	of	ADP
dpc-5639	21	55	treatment	treatment	NOUN
dpc-5639	21	56	(	(	PUNCT
dpc-5639	21	57	w24	w24	PROPN
dpc-5639	21	58	)	)	PUNCT
dpc-5639	21	59	.	.	PUNCT
dpc-5639	22	1	results	result	NOUN
dpc-5639	22	2	:	:	PUNCT
dpc-5639	22	3	at	at	ADP
dpc-5639	22	4	w0	w0	PROPN
dpc-5639	22	5	,	,	PUNCT
dpc-5639	22	6	patients	patient	NOUN
dpc-5639	22	7	were	be	AUX
dpc-5639	22	8	prescribed	prescribe	VERB
dpc-5639	22	9	antidepressants	antidepressant	NOUN
dpc-5639	22	10	(	(	PUNCT
dpc-5639	22	11	41.0	41.0	NUM
dpc-5639	22	12	%	%	NOUN
dpc-5639	22	13	)	)	PUNCT
dpc-5639	22	14	,	,	PUNCT
dpc-5639	22	15	dupilumab	dupilumab	NOUN
dpc-5639	22	16	(	(	PUNCT
dpc-5639	22	17	34.0	34.0	NUM
dpc-5639	22	18	%	%	NOUN
dpc-5639	22	19	)	)	PUNCT
dpc-5639	22	20	,	,	PUNCT
dpc-5639	22	21	antihistamines	antihistamine	NOUN
dpc-5639	22	22	(	(	PUNCT
dpc-5639	22	23	23.0	23.0	NUM
dpc-5639	22	24	%	%	NOUN
dpc-5639	22	25	)	)	PUNCT
dpc-5639	22	26	,	,	PUNCT
dpc-5639	22	27	phototherapy	phototherapy	NOUN
dpc-5639	22	28	(	(	PUNCT
dpc-5639	22	29	4.0	4.0	NUM
dpc-5639	22	30	%	%	NOUN
dpc-5639	22	31	)	)	PUNCT
dpc-5639	22	32	or	or	CCONJ
dpc-5639	22	33	nemolizumab	nemolizumab	NOUN
dpc-5639	22	34	(	(	PUNCT
dpc-5639	22	35	2.0	2.0	NUM
dpc-5639	22	36	%	%	NOUN
dpc-5639	22	37	)	)	PUNCT
dpc-5639	22	38	.	.	PUNCT
dpc-5639	23	1	at	at	ADP
dpc-5639	23	2	w24	w24	PROPN
dpc-5639	23	3	,	,	PUNCT
dpc-5639	23	4	patients	patient	NOUN
dpc-5639	23	5	on	on	ADP
dpc-5639	23	6	dupilumab	dupilumab	NOUN
dpc-5639	23	7	achieved	achieve	VERB
dpc-5639	23	8	an	an	DET
dpc-5639	23	9	iga	iga	PROPN
dpc-5639	23	10	score	score	NOUN
dpc-5639	23	11	of	of	ADP
dpc-5639	23	12	0	0	NUM
dpc-5639	23	13	or	or	CCONJ
dpc-5639	23	14	1	1	NUM
dpc-5639	23	15	and	and	CCONJ
dpc-5639	23	16	a	a	DET
dpc-5639	23	17	≥4	≥4	ADJ
dpc-5639	23	18	-	-	PUNCT
dpc-5639	23	19	point	point	NOUN
dpc-5639	23	20	nrs	nrs	NOUN
dpc-5639	23	21	reduction	reduction	NOUN
dpc-5639	23	22	,	,	PUNCT
dpc-5639	23	23	more	more	ADJ
dpc-5639	23	24	than	than	ADP
dpc-5639	23	25	those	those	PRON
dpc-5639	23	26	on	on	ADP
dpc-5639	23	27	antidepressants	antidepressant	NOUN
dpc-5639	23	28	(	(	PUNCT
dpc-5639	23	29	44.5	44.5	NUM
dpc-5639	23	30	%	%	NOUN
dpc-5639	23	31	vs	vs	ADP
dpc-5639	23	32	16.7	16.7	NUM
dpc-5639	23	33	%	%	NOUN
dpc-5639	23	34	and	and	CCONJ
dpc-5639	23	35	54.4	54.4	NUM
dpc-5639	23	36	%	%	NOUN
dpc-5639	23	37	vs	vs	ADP
dpc-5639	23	38	16.7	16.7	NUM
dpc-5639	23	39	%	%	NOUN
dpc-5639	23	40	,	,	PUNCT
dpc-5639	23	41	respectively	respectively	ADV
dpc-5639	23	42	)	)	PUNCT
dpc-5639	23	43	.	.	PUNCT
dpc-5639	24	1	the	the	DET
dpc-5639	24	2	average	average	ADJ
dpc-5639	24	3	dlqi	dlqi	ADJ
dpc-5639	24	4	score	score	NOUN
dpc-5639	24	5	was	be	AUX
dpc-5639	24	6	reduced	reduce	VERB
dpc-5639	24	7	by	by	ADP
dpc-5639	24	8	14	14	NUM
dpc-5639	24	9	points	point	NOUN
dpc-5639	24	10	in	in	ADP
dpc-5639	24	11	the	the	DET
dpc-5639	24	12	dupilumab	dupilumab	NOUN
dpc-5639	24	13	group	group	NOUN
dpc-5639	24	14	,	,	PUNCT
dpc-5639	24	15	compared	compare	VERB
dpc-5639	24	16	to	to	ADP
dpc-5639	24	17	a	a	DET
dpc-5639	24	18	6	6	NUM
dpc-5639	24	19	-	-	PUNCT
dpc-5639	24	20	point	point	NOUN
dpc-5639	24	21	reduction	reduction	NOUN
dpc-5639	24	22	in	in	ADP
dpc-5639	24	23	the	the	DET
dpc-5639	24	24	antidepressant	antidepressant	ADJ
dpc-5639	24	25	group	group	NOUN
dpc-5639	24	26	.	.	PUNCT
dpc-5639	25	1	conclusions	conclusion	NOUN
dpc-5639	25	2	:	:	PUNCT
dpc-5639	25	3	our	our	PRON
dpc-5639	25	4	findings	finding	NOUN
dpc-5639	25	5	reflect	reflect	VERB
dpc-5639	25	6	the	the	DET
dpc-5639	25	7	real	real	ADJ
dpc-5639	25	8	-	-	PUNCT
dpc-5639	25	9	world	world	NOUN
dpc-5639	25	10	practice	practice	NOUN
dpc-5639	25	11	of	of	ADP
dpc-5639	25	12	treating	treat	VERB
dpc-5639	25	13	pn	pn	PROPN
dpc-5639	25	14	and	and	CCONJ
dpc-5639	25	15	support	support	VERB
dpc-5639	25	16	the	the	DET
dpc-5639	25	17	use	use	NOUN
dpc-5639	25	18	of	of	ADP
dpc-5639	25	19	dupilumab	dupilumab	NOUN
dpc-5639	25	20	as	as	ADP
dpc-5639	25	21	a	a	DET
dpc-5639	25	22	new	new	ADJ
dpc-5639	25	23	effective	effective	ADJ
dpc-5639	25	24	treatment	treatment	NOUN
dpc-5639	25	25	option	option	NOUN
dpc-5639	25	26	,	,	PUNCT
dpc-5639	25	27	with	with	ADP
dpc-5639	25	28	significant	significant	ADJ
dpc-5639	25	29	improvements	improvement	NOUN
dpc-5639	25	30	in	in	ADP
dpc-5639	25	31	pruritus	pruritus	PROPN
dpc-5639	25	32	,	,	PUNCT
dpc-5639	25	33	quality	quality	NOUN
dpc-5639	25	34	of	of	ADP
dpc-5639	25	35	life	life	NOUN
dpc-5639	25	36	,	,	PUNCT
dpc-5639	25	37	and	and	CCONJ
dpc-5639	25	38	disease	disease	NOUN
dpc-5639	25	39	severity	severity	NOUN
dpc-5639	25	40	compared	compare	VERB
dpc-5639	25	41	to	to	ADP
dpc-5639	25	42	antidepressant	antidepressant	ADJ
dpc-5639	25	43	therapy	therapy	NOUN
dpc-5639	25	44	,	,	PUNCT
dpc-5639	25	45	suggesting	suggest	VERB
dpc-5639	25	46	its	its	PRON
dpc-5639	25	47	potential	potential	NOUN
dpc-5639	25	48	as	as	ADP
dpc-5639	25	49	a	a	DET
dpc-5639	25	50	preferred	preferred	ADJ
dpc-5639	25	51	therapeutic	therapeutic	ADJ
dpc-5639	25	52	option	option	NOUN
dpc-5639	25	53	for	for	ADP
dpc-5639	25	54	pn	pn	PROPN
dpc-5639	25	55	.	.	PUNCT
dpc-5639	25	56	abstract	abstract	ADJ
dpc-5639	25	57	2	2	NUM
dpc-5639	25	58	original	original	ADJ
dpc-5639	25	59	article	article	NOUN
dpc-5639	25	60	|	|	ADV
dpc-5639	25	61	dermatol	dermatol	ADJ
dpc-5639	25	62	pract	pract	NOUN
dpc-5639	25	63	concept	concept	NOUN
dpc-5639	25	64	.	.	PUNCT
dpc-5639	26	1	2025;15(4):5639	2025;15(4):5639	NUM
dpc-5639	26	2	introduction	introduction	NOUN
dpc-5639	26	3	prurigo	prurigo	PROPN
dpc-5639	26	4	nodularis	nodularis	PROPN
dpc-5639	26	5	(	(	PUNCT
dpc-5639	26	6	pn	pn	NOUN
dpc-5639	26	7	)	)	PUNCT
dpc-5639	26	8	is	be	AUX
dpc-5639	26	9	an	an	DET
dpc-5639	26	10	inflammatory	inflammatory	ADJ
dpc-5639	26	11	skin	skin	NOUN
dpc-5639	26	12	condition	condition	NOUN
dpc-5639	26	13	with	with	ADP
dpc-5639	26	14	highly	highly	ADV
dpc-5639	26	15	pruritic	pruritic	ADJ
dpc-5639	26	16	,	,	PUNCT
dpc-5639	26	17	hyperkeratotic	hyperkeratotic	ADJ
dpc-5639	26	18	papules	papule	NOUN
dpc-5639	26	19	or	or	CCONJ
dpc-5639	26	20	nodules	nodule	NOUN
dpc-5639	26	21	arising	arise	VERB
dpc-5639	26	22	in	in	ADP
dpc-5639	26	23	the	the	DET
dpc-5639	26	24	setting	setting	NOUN
dpc-5639	26	25	of	of	ADP
dpc-5639	26	26	chronic	chronic	ADJ
dpc-5639	26	27	pruritus	pruritus	NOUN
dpc-5639	26	28	,	,	PUNCT
dpc-5639	26	29	which	which	PRON
dpc-5639	26	30	can	can	AUX
dpc-5639	26	31	greatly	greatly	ADV
dpc-5639	26	32	impact	impact	VERB
dpc-5639	26	33	patients	patient	NOUN
dpc-5639	26	34	’	'	PUNCT
dpc-5639	26	35	quality	quality	NOUN
dpc-5639	26	36	of	of	ADP
dpc-5639	26	37	life	life	NOUN
dpc-5639	26	38	[	[	X
dpc-5639	26	39	1,2	1,2	NUM
dpc-5639	26	40	]	]	PUNCT
dpc-5639	26	41	.	.	PUNCT
dpc-5639	27	1	these	these	DET
dpc-5639	27	2	nodules	nodule	NOUN
dpc-5639	27	3	,	,	PUNCT
dpc-5639	27	4	often	often	ADV
dpc-5639	27	5	resulting	result	VERB
dpc-5639	27	6	from	from	ADP
dpc-5639	27	7	a	a	DET
dpc-5639	27	8	relentless	relentless	ADJ
dpc-5639	27	9	itch	itch	NOUN
dpc-5639	27	10	-	-	PUNCT
dpc-5639	27	11	scratch	scratch	NOUN
dpc-5639	27	12	cycle	cycle	NOUN
dpc-5639	27	13	,	,	PUNCT
dpc-5639	27	14	can	can	AUX
dpc-5639	27	15	lead	lead	VERB
dpc-5639	27	16	to	to	ADP
dpc-5639	27	17	significant	significant	ADJ
dpc-5639	27	18	skin	skin	NOUN
dpc-5639	27	19	thickening	thickening	NOUN
dpc-5639	27	20	and	and	CCONJ
dpc-5639	27	21	lichenification	lichenification	NOUN
dpc-5639	28	1	[	[	X
dpc-5639	28	2	3	3	NUM
dpc-5639	28	3	]	]	PUNCT
dpc-5639	28	4	.	.	PUNCT
dpc-5639	29	1	the	the	DET
dpc-5639	29	2	prevalence	prevalence	NOUN
dpc-5639	29	3	of	of	ADP
dpc-5639	29	4	pn	pn	PROPN
dpc-5639	29	5	is	be	AUX
dpc-5639	29	6	not	not	PART
dpc-5639	29	7	well	well	ADV
dpc-5639	29	8	documented	document	VERB
dpc-5639	29	9	,	,	PUNCT
dpc-5639	29	10	but	but	CCONJ
dpc-5639	29	11	it	it	PRON
dpc-5639	29	12	is	be	AUX
dpc-5639	29	13	known	know	VERB
dpc-5639	29	14	to	to	PART
dpc-5639	29	15	affect	affect	VERB
dpc-5639	29	16	both	both	DET
dpc-5639	29	17	sexes	sex	NOUN
dpc-5639	29	18	and	and	CCONJ
dpc-5639	29	19	all	all	DET
dpc-5639	29	20	races	race	NOUN
dpc-5639	29	21	,	,	PUNCT
dpc-5639	29	22	with	with	ADP
dpc-5639	29	23	a	a	DET
dpc-5639	29	24	slight	slight	ADJ
dpc-5639	29	25	predominance	predominance	NOUN
dpc-5639	29	26	in	in	ADP
dpc-5639	29	27	middle	middle	NOUN
dpc-5639	29	28	-	-	PUNCT
dpc-5639	29	29	aged	aged	ADJ
dpc-5639	29	30	and	and	CCONJ
dpc-5639	29	31	elderly	elderly	ADJ
dpc-5639	29	32	individuals	individual	NOUN
dpc-5639	29	33	[	[	X
dpc-5639	29	34	1	1	NUM
dpc-5639	29	35	]	]	PUNCT
dpc-5639	29	36	.	.	PUNCT
dpc-5639	30	1	pn	pn	PROPN
dpc-5639	30	2	pathogenesis	pathogenesis	PROPN
dpc-5639	30	3	is	be	AUX
dpc-5639	30	4	multifactorial	multifactorial	ADJ
dpc-5639	30	5	and	and	CCONJ
dpc-5639	30	6	not	not	PART
dpc-5639	30	7	yet	yet	ADV
dpc-5639	30	8	fully	fully	ADV
dpc-5639	30	9	understood	understand	VERB
dpc-5639	30	10	.	.	PUNCT
dpc-5639	31	1	it	it	PRON
dpc-5639	31	2	is	be	AUX
dpc-5639	31	3	thought	think	VERB
dpc-5639	31	4	to	to	PART
dpc-5639	31	5	involve	involve	VERB
dpc-5639	31	6	a	a	DET
dpc-5639	31	7	complex	complex	ADJ
dpc-5639	31	8	interplay	interplay	NOUN
dpc-5639	31	9	between	between	ADP
dpc-5639	31	10	neurogenic	neurogenic	ADJ
dpc-5639	31	11	,	,	PUNCT
dpc-5639	31	12	immunologic	immunologic	ADJ
dpc-5639	31	13	,	,	PUNCT
dpc-5639	31	14	and	and	CCONJ
dpc-5639	31	15	psychogenic	psychogenic	ADJ
dpc-5639	31	16	factors	factor	NOUN
dpc-5639	31	17	.	.	PUNCT
dpc-5639	32	1	neurogenic	neurogenic	ADJ
dpc-5639	32	2	factors	factor	NOUN
dpc-5639	32	3	include	include	VERB
dpc-5639	32	4	increased	increase	VERB
dpc-5639	32	5	nerve	nerve	NOUN
dpc-5639	32	6	growth	growth	NOUN
dpc-5639	32	7	factor	factor	NOUN
dpc-5639	32	8	expression	expression	NOUN
dpc-5639	32	9	,	,	PUNCT
dpc-5639	32	10	and	and	CCONJ
dpc-5639	32	11	increased	increase	VERB
dpc-5639	32	12	nerve	nerve	NOUN
dpc-5639	32	13	fiber	fiber	NOUN
dpc-5639	32	14	density	density	NOUN
dpc-5639	32	15	in	in	ADP
dpc-5639	32	16	pruritic	pruritic	ADJ
dpc-5639	32	17	skin	skin	NOUN
dpc-5639	32	18	,	,	PUNCT
dpc-5639	32	19	which	which	PRON
dpc-5639	32	20	can	can	AUX
dpc-5639	32	21	lead	lead	VERB
dpc-5639	32	22	to	to	ADP
dpc-5639	32	23	heightened	heightened	ADJ
dpc-5639	32	24	itch	itch	NOUN
dpc-5639	32	25	perception	perception	NOUN
dpc-5639	32	26	.	.	PUNCT
dpc-5639	33	1	immunologic	immunologic	ADJ
dpc-5639	33	2	factors	factor	NOUN
dpc-5639	33	3	involve	involve	VERB
dpc-5639	33	4	elevated	elevated	ADJ
dpc-5639	33	5	levels	level	NOUN
dpc-5639	33	6	of	of	ADP
dpc-5639	33	7	circulating	circulate	VERB
dpc-5639	33	8	and	and	CCONJ
dpc-5639	33	9	skin	skin	NOUN
dpc-5639	33	10	-	-	PUNCT
dpc-5639	33	11	resident	resident	NOUN
dpc-5639	33	12	th2	th2	PROPN
dpc-5639	33	13	cells	cell	NOUN
dpc-5639	33	14	,	,	PUNCT
dpc-5639	33	15	mast	mast	NOUN
dpc-5639	33	16	cells	cell	NOUN
dpc-5639	33	17	,	,	PUNCT
dpc-5639	33	18	and	and	CCONJ
dpc-5639	33	19	eosinophils	eosinophil	NOUN
dpc-5639	33	20	,	,	PUNCT
dpc-5639	33	21	which	which	PRON
dpc-5639	33	22	contribute	contribute	VERB
dpc-5639	33	23	to	to	ADP
dpc-5639	33	24	inflammation	inflammation	NOUN
dpc-5639	33	25	and	and	CCONJ
dpc-5639	33	26	pruritus	pruritus	PROPN
dpc-5639	33	27	.	.	PUNCT
dpc-5639	34	1	psychogenic	psychogenic	ADJ
dpc-5639	34	2	factors	factor	NOUN
dpc-5639	34	3	such	such	ADJ
dpc-5639	34	4	as	as	ADP
dpc-5639	34	5	stress	stress	NOUN
dpc-5639	34	6	and	and	CCONJ
dpc-5639	34	7	anxiety	anxiety	NOUN
dpc-5639	34	8	can	can	AUX
dpc-5639	34	9	also	also	ADV
dpc-5639	34	10	exacerbate	exacerbate	VERB
dpc-5639	34	11	pruritus	pruritus	NOUN
dpc-5639	34	12	and	and	CCONJ
dpc-5639	34	13	scratching	scratching	NOUN
dpc-5639	34	14	behavior	behavior	NOUN
dpc-5639	34	15	,	,	PUNCT
dpc-5639	34	16	leading	lead	VERB
dpc-5639	34	17	to	to	ADP
dpc-5639	34	18	a	a	DET
dpc-5639	34	19	vicious	vicious	ADJ
dpc-5639	34	20	itch	itch	NOUN
dpc-5639	34	21	-	-	PUNCT
dpc-5639	34	22	scratch	scratch	NOUN
dpc-5639	34	23	cycle	cycle	NOUN
dpc-5639	34	24	[	[	X
dpc-5639	34	25	4	4	NUM
dpc-5639	34	26	-	-	SYM
dpc-5639	34	27	6	6	NUM
dpc-5639	34	28	]	]	PUNCT
dpc-5639	34	29	.	.	PUNCT
dpc-5639	35	1	pn	pn	PROPN
dpc-5639	35	2	management	management	NOUN
dpc-5639	35	3	remains	remain	VERB
dpc-5639	35	4	a	a	DET
dpc-5639	35	5	significant	significant	ADJ
dpc-5639	35	6	challenge	challenge	NOUN
dpc-5639	35	7	due	due	ADP
dpc-5639	35	8	to	to	ADP
dpc-5639	35	9	the	the	DET
dpc-5639	35	10	chronic	chronic	ADJ
dpc-5639	35	11	nature	nature	NOUN
dpc-5639	35	12	of	of	ADP
dpc-5639	35	13	the	the	DET
dpc-5639	35	14	disease	disease	NOUN
dpc-5639	35	15	,	,	PUNCT
dpc-5639	35	16	treatment	treatment	NOUN
dpc-5639	35	17	resistance	resistance	NOUN
dpc-5639	35	18	,	,	PUNCT
dpc-5639	35	19	and	and	CCONJ
dpc-5639	35	20	its	its	PRON
dpc-5639	35	21	substantial	substantial	ADJ
dpc-5639	35	22	impact	impact	NOUN
dpc-5639	35	23	on	on	ADP
dpc-5639	35	24	patients	patient	NOUN
dpc-5639	35	25	’	'	PUNCT
dpc-5639	35	26	quality	quality	NOUN
dpc-5639	35	27	of	of	ADP
dpc-5639	35	28	life	life	NOUN
dpc-5639	35	29	[	[	X
dpc-5639	35	30	7	7	NUM
dpc-5639	35	31	]	]	PUNCT
dpc-5639	35	32	.	.	PUNCT
dpc-5639	36	1	traditional	traditional	ADJ
dpc-5639	36	2	treatments	treatment	NOUN
dpc-5639	36	3	consist	consist	VERB
dpc-5639	36	4	of	of	ADP
dpc-5639	36	5	topical	topical	ADJ
dpc-5639	36	6	corticosteroids	corticosteroid	NOUN
dpc-5639	36	7	(	(	PUNCT
dpc-5639	36	8	tcs	tcs	NOUN
dpc-5639	36	9	)	)	PUNCT
dpc-5639	36	10	and	and	CCONJ
dpc-5639	36	11	selective	selective	ADJ
dpc-5639	36	12	topical	topical	ADJ
dpc-5639	36	13	calcineurin	calcineurin	NOUN
dpc-5639	36	14	inhibitors	inhibitor	NOUN
dpc-5639	36	15	(	(	PUNCT
dpc-5639	36	16	tci	tci	NOUN
dpc-5639	36	17	)	)	PUNCT
dpc-5639	36	18	administered	administer	VERB
dpc-5639	36	19	either	either	CCONJ
dpc-5639	36	20	alone	alone	ADJ
dpc-5639	36	21	or	or	CCONJ
dpc-5639	36	22	with	with	ADP
dpc-5639	36	23	antihistamines	antihistamine	NOUN
dpc-5639	36	24	,	,	PUNCT
dpc-5639	36	25	followed	follow	VERB
dpc-5639	36	26	by	by	ADP
dpc-5639	36	27	phototherapy	phototherapy	NOUN
dpc-5639	36	28	and	and	CCONJ
dpc-5639	36	29	other	other	ADJ
dpc-5639	36	30	systemic	systemic	ADJ
dpc-5639	36	31	treatments	treatment	NOUN
dpc-5639	36	32	(	(	PUNCT
dpc-5639	36	33	gabapentin	gabapentin	NOUN
dpc-5639	36	34	,	,	PUNCT
dpc-5639	36	35	antidepressants	antidepressant	NOUN
dpc-5639	36	36	,	,	PUNCT
dpc-5639	36	37	corticosteroids	corticosteroid	NOUN
dpc-5639	36	38	,	,	PUNCT
dpc-5639	36	39	or	or	CCONJ
dpc-5639	36	40	immunosuppressants	immunosuppressant	NOUN
dpc-5639	36	41	)	)	PUNCT
dpc-5639	37	1	[	[	X
dpc-5639	37	2	8	8	NUM
dpc-5639	37	3	]	]	PUNCT
dpc-5639	37	4	.	.	PUNCT
dpc-5639	38	1	however	however	ADV
dpc-5639	38	2	,	,	PUNCT
dpc-5639	38	3	these	these	DET
dpc-5639	38	4	treatments	treatment	NOUN
dpc-5639	38	5	often	often	ADV
dpc-5639	38	6	provide	provide	VERB
dpc-5639	38	7	incomplete	incomplete	ADJ
dpc-5639	38	8	relief	relief	NOUN
dpc-5639	38	9	and	and	CCONJ
dpc-5639	38	10	can	can	AUX
dpc-5639	38	11	have	have	VERB
dpc-5639	38	12	undesirable	undesirable	ADJ
dpc-5639	38	13	side	side	NOUN
dpc-5639	38	14	effects	effect	NOUN
dpc-5639	38	15	,	,	PUNCT
dpc-5639	38	16	such	such	ADJ
dpc-5639	38	17	as	as	ADP
dpc-5639	38	18	skin	skin	NOUN
dpc-5639	38	19	atrophy	atrophy	NOUN
dpc-5639	38	20	caused	cause	VERB
dpc-5639	38	21	by	by	ADP
dpc-5639	38	22	the	the	DET
dpc-5639	38	23	long	long	ADJ
dpc-5639	38	24	-	-	PUNCT
dpc-5639	38	25	term	term	NOUN
dpc-5639	38	26	topical	topical	ADJ
dpc-5639	38	27	corticosteroid	corticosteroid	ADJ
dpc-5639	38	28	use	use	NOUN
dpc-5639	38	29	and	and	CCONJ
dpc-5639	38	30	sedation	sedation	NOUN
dpc-5639	38	31	caused	cause	VERB
dpc-5639	38	32	by	by	ADP
dpc-5639	38	33	antihistamines	antihistamine	NOUN
dpc-5639	38	34	[	[	X
dpc-5639	38	35	9	9	NUM
dpc-5639	38	36	]	]	PUNCT
dpc-5639	38	37	.	.	PUNCT
dpc-5639	39	1	dupilumab	dupilumab	NOUN
dpc-5639	39	2	,	,	PUNCT
dpc-5639	39	3	a	a	DET
dpc-5639	39	4	fully	fully	ADV
dpc-5639	39	5	human	human	ADJ
dpc-5639	39	6	monoclonal	monoclonal	NOUN
dpc-5639	39	7	igg4	igg4	NOUN
dpc-5639	39	8	antibody	antibody	NOUN
dpc-5639	39	9	,	,	PUNCT
dpc-5639	39	10	has	have	AUX
dpc-5639	39	11	recently	recently	ADV
dpc-5639	39	12	emerged	emerge	VERB
dpc-5639	39	13	as	as	ADP
dpc-5639	39	14	a	a	DET
dpc-5639	39	15	promising	promising	ADJ
dpc-5639	39	16	new	new	ADJ
dpc-5639	39	17	treatment	treatment	NOUN
dpc-5639	39	18	option	option	NOUN
dpc-5639	39	19	for	for	ADP
dpc-5639	39	20	pn	pn	PROPN
dpc-5639	39	21	.	.	PUNCT
dpc-5639	40	1	it	it	PRON
dpc-5639	40	2	blocks	block	VERB
dpc-5639	40	3	interleukin	interleukin	NOUN
dpc-5639	40	4	(	(	PUNCT
dpc-5639	40	5	il)-4	il)-4	NOUN
dpc-5639	40	6	and	and	CCONJ
dpc-5639	40	7	il-13	il-13	ADP
dpc-5639	40	8	signaling	signal	VERB
dpc-5639	40	9	by	by	ADP
dpc-5639	40	10	specifically	specifically	ADV
dpc-5639	40	11	binding	bind	VERB
dpc-5639	40	12	to	to	ADP
dpc-5639	40	13	il-4	il-4	PRON
dpc-5639	40	14	receptor	receptor	NOUN
dpc-5639	40	15	alpha	alpha	NOUN
dpc-5639	40	16	subunit	subunit	NOUN
dpc-5639	40	17	shared	share	VERB
dpc-5639	40	18	by	by	ADP
dpc-5639	40	19	both	both	DET
dpc-5639	40	20	il-4	il-4	X
dpc-5639	40	21	and	and	CCONJ
dpc-5639	40	22	il-13	il-13	ADP
dpc-5639	40	23	receptor	receptor	NOUN
dpc-5639	40	24	complexes	complex	NOUN
dpc-5639	40	25	and	and	CCONJ
dpc-5639	40	26	has	have	AUX
dpc-5639	40	27	demonstrated	demonstrate	VERB
dpc-5639	40	28	good	good	ADJ
dpc-5639	40	29	efficacy	efficacy	NOUN
dpc-5639	40	30	and	and	CCONJ
dpc-5639	40	31	safety	safety	NOUN
dpc-5639	40	32	in	in	ADP
dpc-5639	40	33	a	a	DET
dpc-5639	40	34	variety	variety	NOUN
dpc-5639	40	35	of	of	ADP
dpc-5639	40	36	diseases	disease	NOUN
dpc-5639	40	37	with	with	ADP
dpc-5639	40	38	type	type	NOUN
dpc-5639	40	39	2	2	NUM
dpc-5639	40	40	inflammation	inflammation	NOUN
dpc-5639	40	41	,	,	PUNCT
dpc-5639	40	42	like	like	ADP
dpc-5639	40	43	atopic	atopic	NOUN
dpc-5639	40	44	dermatitis	dermatitis	NOUN
dpc-5639	40	45	and	and	CCONJ
dpc-5639	40	46	asthma	asthma	NOUN
dpc-5639	41	1	[	[	X
dpc-5639	41	2	10,11	10,11	NOUN
dpc-5639	41	3	]	]	PUNCT
dpc-5639	41	4	.	.	PUNCT
dpc-5639	42	1	based	base	VERB
dpc-5639	42	2	on	on	ADP
dpc-5639	42	3	favorable	favorable	ADJ
dpc-5639	42	4	results	result	NOUN
dpc-5639	42	5	from	from	ADP
dpc-5639	42	6	clinical	clinical	ADJ
dpc-5639	42	7	trials	trial	NOUN
dpc-5639	42	8	substantiating	substantiate	VERB
dpc-5639	42	9	type	type	NOUN
dpc-5639	42	10	2	2	NUM
dpc-5639	42	11	cytokines	cytokine	NOUN
dpc-5639	42	12	il-4	il-4	AUX
dpc-5639	42	13	and	and	CCONJ
dpc-5639	42	14	il-13	il-13	ADP
dpc-5639	42	15	implication	implication	NOUN
dpc-5639	42	16	in	in	ADP
dpc-5639	42	17	steering	steer	VERB
dpc-5639	42	18	the	the	DET
dpc-5639	42	19	pathogenesis	pathogenesis	NOUN
dpc-5639	42	20	of	of	ADP
dpc-5639	42	21	pn	pn	PROPN
dpc-5639	42	22	,	,	PUNCT
dpc-5639	42	23	dupilumab	dupilumab	NOUN
dpc-5639	42	24	has	have	AUX
dpc-5639	42	25	been	be	AUX
dpc-5639	42	26	approved	approve	VERB
dpc-5639	42	27	by	by	ADP
dpc-5639	42	28	the	the	DET
dpc-5639	42	29	u.s	u.s	PROPN
dpc-5639	42	30	.	.	PROPN
dpc-5639	42	31	food	food	PROPN
dpc-5639	42	32	and	and	CCONJ
dpc-5639	42	33	drug	drug	PROPN
dpc-5639	42	34	administration	administration	PROPN
dpc-5639	42	35	(	(	PUNCT
dpc-5639	42	36	fda	fda	PROPN
dpc-5639	42	37	)	)	PUNCT
dpc-5639	42	38	as	as	ADP
dpc-5639	42	39	the	the	DET
dpc-5639	42	40	first	first	ADJ
dpc-5639	42	41	specific	specific	ADJ
dpc-5639	42	42	drug	drug	NOUN
dpc-5639	42	43	for	for	ADP
dpc-5639	42	44	the	the	DET
dpc-5639	42	45	treatment	treatment	NOUN
dpc-5639	42	46	of	of	ADP
dpc-5639	42	47	pn	pn	PROPN
dpc-5639	43	1	[	[	X
dpc-5639	43	2	12	12	NUM
dpc-5639	43	3	]	]	PUNCT
dpc-5639	43	4	.	.	PUNCT
dpc-5639	44	1	however	however	ADV
dpc-5639	44	2	,	,	PUNCT
dpc-5639	44	3	data	datum	NOUN
dpc-5639	44	4	on	on	ADP
dpc-5639	44	5	dupilumab	dupilumab	NOUN
dpc-5639	44	6	efficacy	efficacy	NOUN
dpc-5639	44	7	from	from	ADP
dpc-5639	44	8	real	real	ADJ
dpc-5639	44	9	-	-	PUNCT
dpc-5639	44	10	world	world	NOUN
dpc-5639	44	11	studies	study	NOUN
dpc-5639	44	12	are	be	AUX
dpc-5639	44	13	lacking	lack	VERB
dpc-5639	44	14	,	,	PUNCT
dpc-5639	44	15	and	and	CCONJ
dpc-5639	44	16	the	the	DET
dpc-5639	44	17	range	range	NOUN
dpc-5639	44	18	and	and	CCONJ
dpc-5639	44	19	degree	degree	NOUN
dpc-5639	44	20	of	of	ADP
dpc-5639	44	21	the	the	DET
dpc-5639	44	22	disease	disease	NOUN
dpc-5639	44	23	burden	burden	NOUN
dpc-5639	44	24	and	and	CCONJ
dpc-5639	44	25	how	how	SCONJ
dpc-5639	44	26	it	it	PRON
dpc-5639	44	27	impacts	impact	VERB
dpc-5639	44	28	treatment	treatment	NOUN
dpc-5639	44	29	satisfaction	satisfaction	NOUN
dpc-5639	44	30	in	in	ADP
dpc-5639	44	31	patients	patient	NOUN
dpc-5639	44	32	with	with	ADP
dpc-5639	44	33	pn	pn	PROPN
dpc-5639	44	34	remains	remain	VERB
dpc-5639	44	35	not	not	PART
dpc-5639	44	36	well	well	ADV
dpc-5639	44	37	investigated	investigate	VERB
dpc-5639	44	38	.	.	PUNCT
dpc-5639	45	1	objective	objective	ADJ
dpc-5639	45	2	our	our	PRON
dpc-5639	45	3	aim	aim	NOUN
dpc-5639	45	4	was	be	AUX
dpc-5639	45	5	to	to	PART
dpc-5639	45	6	conduct	conduct	VERB
dpc-5639	45	7	a	a	DET
dpc-5639	45	8	prospective	prospective	ADJ
dpc-5639	45	9	observational	observational	ADJ
dpc-5639	45	10	study	study	NOUN
dpc-5639	45	11	to	to	PART
dpc-5639	45	12	assess	assess	VERB
dpc-5639	45	13	the	the	DET
dpc-5639	45	14	therapeutic	therapeutic	ADJ
dpc-5639	45	15	management	management	NOUN
dpc-5639	45	16	of	of	ADP
dpc-5639	45	17	pn	pn	PROPN
dpc-5639	45	18	in	in	ADP
dpc-5639	45	19	a	a	DET
dpc-5639	45	20	real	real	ADJ
dpc-5639	45	21	-	-	PUNCT
dpc-5639	45	22	life	life	NOUN
dpc-5639	45	23	setting	setting	NOUN
dpc-5639	45	24	.	.	PUNCT
dpc-5639	46	1	methods	method	NOUN
dpc-5639	46	2	study	study	NOUN
dpc-5639	46	3	design	design	VERB
dpc-5639	46	4	this	this	DET
dpc-5639	46	5	prospective	prospective	ADJ
dpc-5639	46	6	observational	observational	ADJ
dpc-5639	46	7	study	study	NOUN
dpc-5639	46	8	was	be	AUX
dpc-5639	46	9	conducted	conduct	VERB
dpc-5639	46	10	over	over	ADP
dpc-5639	46	11	a	a	DET
dpc-5639	46	12	27	27	NUM
dpc-5639	46	13	-	-	PUNCT
dpc-5639	46	14	month	month	NOUN
dpc-5639	46	15	period	period	NOUN
dpc-5639	46	16	(	(	PUNCT
dpc-5639	46	17	october	october	NOUN
dpc-5639	46	18	2021	2021	NUM
dpc-5639	46	19	–	–	PUNCT
dpc-5639	46	20	december	december	PROPN
dpc-5639	46	21	2023	2023	NUM
dpc-5639	46	22	)	)	PUNCT
dpc-5639	46	23	and	and	CCONJ
dpc-5639	46	24	involved	involve	VERB
dpc-5639	46	25	90	90	NUM
dpc-5639	46	26	consecutive	consecutive	ADJ
dpc-5639	46	27	patients	patient	NOUN
dpc-5639	46	28	diagnosed	diagnose	VERB
dpc-5639	46	29	with	with	ADP
dpc-5639	46	30	pn	pn	PROPN
dpc-5639	46	31	at	at	ADP
dpc-5639	46	32	the	the	DET
dpc-5639	46	33	dermatology	dermatology	NOUN
dpc-5639	46	34	unit	unit	NOUN
dpc-5639	46	35	,	,	PUNCT
dpc-5639	46	36	university	university	PROPN
dpc-5639	46	37	of	of	ADP
dpc-5639	46	38	campania	campania	PROPN
dpc-5639	46	39	luigi	luigi	PROPN
dpc-5639	46	40	vanvitelli	vanvitelli	PROPN
dpc-5639	46	41	,	,	PUNCT
dpc-5639	46	42	naples	naples	PROPN
dpc-5639	46	43	,	,	PUNCT
dpc-5639	46	44	italy	italy	PROPN
dpc-5639	46	45	.	.	PUNCT
dpc-5639	47	1	patient	patient	PROPN
dpc-5639	47	2	demographic	demographic	ADJ
dpc-5639	47	3	details	detail	NOUN
dpc-5639	47	4	are	be	AUX
dpc-5639	47	5	shown	show	VERB
dpc-5639	47	6	in	in	ADP
dpc-5639	47	7	table	table	NOUN
dpc-5639	47	8	1	1	NUM
dpc-5639	47	9	.	.	PUNCT
dpc-5639	48	1	inclusion	inclusion	NOUN
dpc-5639	48	2	criteria	criterion	NOUN
dpc-5639	48	3	were	be	AUX
dpc-5639	48	4	:	:	PUNCT
dpc-5639	48	5	males	male	NOUN
dpc-5639	48	6	or	or	CCONJ
dpc-5639	48	7	females	female	NOUN
dpc-5639	48	8	aged	age	VERB
dpc-5639	48	9	18–80	18–80	NUM
dpc-5639	48	10	years	year	NOUN
dpc-5639	48	11	at	at	ADP
dpc-5639	48	12	the	the	DET
dpc-5639	48	13	time	time	NOUN
dpc-5639	48	14	of	of	ADP
dpc-5639	48	15	signing	sign	VERB
dpc-5639	48	16	the	the	DET
dpc-5639	48	17	informed	informed	ADJ
dpc-5639	48	18	consent	consent	NOUN
dpc-5639	48	19	,	,	PUNCT
dpc-5639	48	20	a	a	DET
dpc-5639	48	21	minimum	minimum	NOUN
dpc-5639	48	22	of	of	ADP
dpc-5639	48	23	10	10	NUM
dpc-5639	48	24	pn	pn	NOUN
dpc-5639	48	25	lesions	lesion	NOUN
dpc-5639	48	26	in	in	ADP
dpc-5639	48	27	total	total	NOUN
dpc-5639	48	28	on	on	ADP
dpc-5639	48	29	both	both	DET
dpc-5639	48	30	legs	leg	NOUN
dpc-5639	48	31	,	,	PUNCT
dpc-5639	48	32	and/or	and/or	CCONJ
dpc-5639	48	33	both	both	DET
dpc-5639	48	34	arms	arm	NOUN
dpc-5639	48	35	and/	and/	NOUN
dpc-5639	48	36	or	or	CCONJ
dpc-5639	48	37	trunk	trunk	NOUN
dpc-5639	48	38	at	at	ADP
dpc-5639	48	39	screening	screening	NOUN
dpc-5639	48	40	visit	visit	NOUN
dpc-5639	48	41	,	,	PUNCT
dpc-5639	48	42	and	and	CCONJ
dpc-5639	48	43	patients	patient	NOUN
dpc-5639	48	44	with	with	ADP
dpc-5639	48	45	pn	pn	PROPN
dpc-5639	48	46	who	who	PRON
dpc-5639	48	47	are	be	AUX
dpc-5639	48	48	inadequately	inadequately	ADV
dpc-5639	48	49	controlled	control	VERB
dpc-5639	48	50	on	on	ADP
dpc-5639	48	51	topical	topical	ADJ
dpc-5639	48	52	prescription	prescription	NOUN
dpc-5639	48	53	therapies	therapy	NOUN
dpc-5639	48	54	or	or	CCONJ
dpc-5639	48	55	when	when	SCONJ
dpc-5639	48	56	those	those	DET
dpc-5639	48	57	therapies	therapy	NOUN
dpc-5639	48	58	are	be	AUX
dpc-5639	48	59	not	not	PART
dpc-5639	48	60	advisable	advisable	ADJ
dpc-5639	48	61	.	.	PUNCT
dpc-5639	49	1	moreover	moreover	ADV
dpc-5639	49	2	,	,	PUNCT
dpc-5639	49	3	as	as	ADP
dpc-5639	49	4	regarded	regard	VERB
dpc-5639	49	5	patients	patient	NOUN
dpc-5639	49	6	scheduled	schedule	VERB
dpc-5639	49	7	with	with	ADP
dpc-5639	49	8	dupilumab	dupilumab	NOUN
dpc-5639	49	9	,	,	PUNCT
dpc-5639	49	10	those	those	PRON
dpc-5639	49	11	who	who	PRON
dpc-5639	49	12	did	do	AUX
dpc-5639	49	13	not	not	PART
dpc-5639	49	14	respond	respond	VERB
dpc-5639	49	15	to	to	ADP
dpc-5639	49	16	or	or	CCONJ
dpc-5639	49	17	showed	show	VERB
dpc-5639	49	18	contraindications	contraindication	NOUN
dpc-5639	49	19	table	table	NOUN
dpc-5639	49	20	1	1	NUM
dpc-5639	49	21	.	.	PUNCT
dpc-5639	49	22	clinical	clinical	ADJ
dpc-5639	49	23	and	and	CCONJ
dpc-5639	49	24	demographic	demographic	ADJ
dpc-5639	49	25	patient	patient	ADJ
dpc-5639	49	26	characteristics	characteristic	NOUN
dpc-5639	49	27	.	.	PUNCT
dpc-5639	50	1	n	n	PRON
dpc-5639	51	1	%	%	NOUN
dpc-5639	51	2	population	population	NOUN
dpc-5639	51	3	90	90	NUM
dpc-5639	51	4	100	100	NUM
dpc-5639	51	5	sex	sex	NOUN
dpc-5639	51	6	male	male	NOUN
dpc-5639	51	7	35	35	NUM
dpc-5639	51	8	39	39	NUM
dpc-5639	51	9	female	female	ADJ
dpc-5639	51	10	55	55	NUM
dpc-5639	51	11	61	61	NUM
dpc-5639	51	12	age	age	NOUN
dpc-5639	51	13	,	,	PUNCT
dpc-5639	51	14	y	y	PROPN
dpc-5639	51	15	≤	≤	NUM
dpc-5639	51	16	18	18	NUM
dpc-5639	51	17	1	1	NUM
dpc-5639	51	18	1	1	NUM
dpc-5639	51	19	>	>	SYM
dpc-5639	51	20	18≤35	18≤35	NUM
dpc-5639	51	21	5	5	NUM
dpc-5639	51	22	6	6	NUM
dpc-5639	51	23	>	>	SYM
dpc-5639	51	24	35≤65	35≤65	NUM
dpc-5639	51	25	44	44	NUM
dpc-5639	51	26	49	49	NUM
dpc-5639	51	27	>	>	SYM
dpc-5639	51	28	65	65	NUM
dpc-5639	51	29	40	40	NUM
dpc-5639	51	30	44	44	NUM
dpc-5639	51	31	comorbidities	comorbiditie	NOUN
dpc-5639	51	32	diabetes	diabetes	VERB
dpc-5639	51	33	15	15	NUM
dpc-5639	51	34	16.7	16.7	NUM
dpc-5639	51	35	dyslipidemia	dyslipidemia	NOUN
dpc-5639	51	36	23	23	NUM
dpc-5639	51	37	25.5	25.5	NUM
dpc-5639	51	38	hypertension	hypertension	NOUN
dpc-5639	51	39	33	33	NUM
dpc-5639	51	40	36.7	36.7	NUM
dpc-5639	51	41	heart	heart	NOUN
dpc-5639	51	42	diseases	disease	NOUN
dpc-5639	51	43	4	4	NUM
dpc-5639	51	44	4.4	4.4	NUM
dpc-5639	51	45	others	other	NOUN
dpc-5639	51	46	27	27	NUM
dpc-5639	51	47	30	30	NUM
dpc-5639	51	48	iga	iga	PROPN
dpc-5639	51	49	1	1	NUM
dpc-5639	51	50	22	22	NUM
dpc-5639	51	51	24.4	24.4	NUM
dpc-5639	51	52	2	2	NUM
dpc-5639	51	53	36	36	NUM
dpc-5639	51	54	40	40	NUM
dpc-5639	51	55	3	3	NUM
dpc-5639	51	56	19	19	NUM
dpc-5639	51	57	21.2	21.2	NUM
dpc-5639	51	58	4	4	NUM
dpc-5639	51	59	13	13	NUM
dpc-5639	51	60	14.4	14.4	NUM
dpc-5639	51	61	nrs	nrs	NOUN
dpc-5639	51	62	0	0	NUM
dpc-5639	51	63	-	-	SYM
dpc-5639	51	64	5	5	NUM
dpc-5639	51	65	17	17	NUM
dpc-5639	51	66	18.9	18.9	NUM
dpc-5639	51	67	6	6	NUM
dpc-5639	51	68	-	-	SYM
dpc-5639	51	69	10	10	NUM
dpc-5639	51	70	73	73	NUM
dpc-5639	51	71	81.1	81.1	NUM
dpc-5639	51	72	dlqi	dlqi	NOUN
dpc-5639	51	73	≤2	≤2	NOUN
dpc-5639	51	74	>	>	NOUN
dpc-5639	51	75	2≤10	2≤10	NUM
dpc-5639	51	76	>	>	SYM
dpc-5639	51	77	10	10	NUM
dpc-5639	51	78	9	9	NUM
dpc-5639	51	79	45	45	NUM
dpc-5639	51	80	36	36	NUM
dpc-5639	51	81	10	10	NUM
dpc-5639	51	82	50	50	NUM
dpc-5639	51	83	40	40	NUM
dpc-5639	51	84	abbreviations	abbreviation	NOUN
dpc-5639	51	85	:	:	PUNCT
dpc-5639	51	86	dlqi	dlqi	ADJ
dpc-5639	51	87	:	:	PUNCT
dpc-5639	51	88	dermatology	dermatology	NOUN
dpc-5639	51	89	life	life	NOUN
dpc-5639	51	90	quality	quality	NOUN
dpc-5639	51	91	index	index	NOUN
dpc-5639	51	92	;	;	PUNCT
dpc-5639	51	93	iga	iga	PROPN
dpc-5639	51	94	:	:	PUNCT
dpc-5639	51	95	investigator	investigator	NOUN
dpc-5639	51	96	’s	’s	PART
dpc-5639	51	97	global	global	ADJ
dpc-5639	51	98	assessment	assessment	NOUN
dpc-5639	51	99	score	score	NOUN
dpc-5639	51	100	;	;	PUNCT
dpc-5639	51	101	nrs	nrs	PROPN
dpc-5639	51	102	:	:	PUNCT
dpc-5639	51	103	numeric	numeric	ADJ
dpc-5639	51	104	rating	rating	NOUN
dpc-5639	51	105	scale	scale	NOUN
dpc-5639	51	106	.	.	PUNCT
dpc-5639	52	1	original	original	ADJ
dpc-5639	52	2	article	article	NOUN
dpc-5639	52	3	|	|	ADV
dpc-5639	52	4	dermatol	dermatol	ADJ
dpc-5639	52	5	pract	pract	NOUN
dpc-5639	52	6	concept	concept	NOUN
dpc-5639	52	7	.	.	PUNCT
dpc-5639	53	1	2025;15(4):5639	2025;15(4):5639	NUM
dpc-5639	53	2	3	3	NUM
dpc-5639	53	3	or	or	CCONJ
dpc-5639	53	4	side	side	NOUN
dpc-5639	53	5	effects	effect	NOUN
dpc-5639	53	6	to	to	ADP
dpc-5639	53	7	at	at	ADV
dpc-5639	53	8	least	least	ADV
dpc-5639	53	9	one	one	NUM
dpc-5639	53	10	conventional	conventional	ADJ
dpc-5639	53	11	systemic	systemic	ADJ
dpc-5639	53	12	therapy	therapy	NOUN
dpc-5639	53	13	according	accord	VERB
dpc-5639	53	14	to	to	ADP
dpc-5639	53	15	italian	italian	ADJ
dpc-5639	53	16	law	law	NOUN
dpc-5639	53	17	were	be	AUX
dpc-5639	53	18	included	include	VERB
dpc-5639	53	19	.	.	PUNCT
dpc-5639	54	1	exclusion	exclusion	NOUN
dpc-5639	54	2	criteria	criterion	NOUN
dpc-5639	54	3	were	be	AUX
dpc-5639	54	4	:	:	PUNCT
dpc-5639	54	5	active	active	ADJ
dpc-5639	54	6	chronic	chronic	ADJ
dpc-5639	54	7	or	or	CCONJ
dpc-5639	54	8	acute	acute	ADJ
dpc-5639	54	9	infection	infection	NOUN
dpc-5639	54	10	(	(	PUNCT
dpc-5639	54	11	except	except	SCONJ
dpc-5639	54	12	well	well	ADV
dpc-5639	54	13	-	-	PUNCT
dpc-5639	54	14	controlled	control	VERB
dpc-5639	54	15	hiv	hiv	PROPN
dpc-5639	54	16	infection	infection	NOUN
dpc-5639	54	17	)	)	PUNCT
dpc-5639	54	18	,	,	PUNCT
dpc-5639	54	19	pn	pn	X
dpc-5639	54	20	secondary	secondary	ADJ
dpc-5639	54	21	to	to	ADP
dpc-5639	54	22	medications	medication	NOUN
dpc-5639	54	23	or	or	CCONJ
dpc-5639	54	24	medical	medical	ADJ
dpc-5639	54	25	conditions	condition	NOUN
dpc-5639	54	26	,	,	PUNCT
dpc-5639	54	27	such	such	ADJ
dpc-5639	54	28	as	as	ADP
dpc-5639	54	29	neuropathy	neuropathy	ADJ
dpc-5639	54	30	or	or	CCONJ
dpc-5639	54	31	psychiatric	psychiatric	ADJ
dpc-5639	54	32	disease	disease	NOUN
dpc-5639	54	33	,	,	PUNCT
dpc-5639	54	34	known	know	VERB
dpc-5639	54	35	or	or	CCONJ
dpc-5639	54	36	suspected	suspect	VERB
dpc-5639	54	37	immunodeficiency	immunodeficiency	NOUN
dpc-5639	54	38	,	,	PUNCT
dpc-5639	54	39	severe	severe	ADJ
dpc-5639	54	40	renal	renal	ADJ
dpc-5639	54	41	conditions	condition	NOUN
dpc-5639	54	42	,	,	PUNCT
dpc-5639	54	43	moderate	moderate	ADJ
dpc-5639	54	44	-	-	PUNCT
dpc-5639	54	45	to	to	ADP
dpc-5639	54	46	-	-	PUNCT
dpc-5639	54	47	severe	severe	ADJ
dpc-5639	54	48	atopic	atopic	NOUN
dpc-5639	54	49	dermatitis	dermatitis	NOUN
dpc-5639	54	50	(	(	PUNCT
dpc-5639	54	51	ad	ad	NOUN
dpc-5639	54	52	)	)	PUNCT
dpc-5639	54	53	within	within	ADP
dpc-5639	54	54	six	six	NUM
dpc-5639	54	55	months	month	NOUN
dpc-5639	54	56	before	before	ADP
dpc-5639	54	57	the	the	DET
dpc-5639	54	58	screening	screening	NOUN
dpc-5639	54	59	visit	visit	NOUN
dpc-5639	54	60	,	,	PUNCT
dpc-5639	54	61	or	or	CCONJ
dpc-5639	54	62	documented	document	VERB
dpc-5639	54	63	diagnosis	diagnosis	NOUN
dpc-5639	54	64	of	of	ADP
dpc-5639	54	65	moderate	moderate	ADJ
dpc-5639	54	66	-	-	PUNCT
dpc-5639	54	67	to	to	ADP
dpc-5639	54	68	-	-	PUNCT
dpc-5639	54	69	severe	severe	ADJ
dpc-5639	54	70	ad	ad	NOUN
dpc-5639	54	71	from	from	ADP
dpc-5639	54	72	screening	screen	VERB
dpc-5639	54	73	visit	visit	NOUN
dpc-5639	54	74	to	to	ADP
dpc-5639	54	75	randomization	randomization	NOUN
dpc-5639	54	76	visit	visit	NOUN
dpc-5639	54	77	,	,	PUNCT
dpc-5639	54	78	active	active	ADJ
dpc-5639	54	79	malignancy	malignancy	NOUN
dpc-5639	54	80	or	or	CCONJ
dpc-5639	54	81	history	history	NOUN
dpc-5639	54	82	of	of	ADP
dpc-5639	54	83	malignancy	malignancy	NOUN
dpc-5639	54	84	within	within	ADP
dpc-5639	54	85	five	five	NUM
dpc-5639	54	86	years	year	NOUN
dpc-5639	54	87	of	of	ADP
dpc-5639	54	88	baseline	baseline	NOUN
dpc-5639	54	89	.	.	PUNCT
dpc-5639	55	1	at	at	ADP
dpc-5639	55	2	enrollment	enrollment	NOUN
dpc-5639	55	3	,	,	PUNCT
dpc-5639	55	4	clinical	clinical	ADJ
dpc-5639	55	5	and	and	CCONJ
dpc-5639	55	6	demographic	demographic	ADJ
dpc-5639	55	7	data	datum	NOUN
dpc-5639	55	8	,	,	PUNCT
dpc-5639	55	9	including	include	VERB
dpc-5639	55	10	sex	sex	NOUN
dpc-5639	55	11	,	,	PUNCT
dpc-5639	55	12	age	age	NOUN
dpc-5639	55	13	,	,	PUNCT
dpc-5639	55	14	comorbidities	comorbiditie	NOUN
dpc-5639	55	15	,	,	PUNCT
dpc-5639	55	16	and	and	CCONJ
dpc-5639	55	17	previous	previous	ADJ
dpc-5639	55	18	treatments	treatment	NOUN
dpc-5639	55	19	,	,	PUNCT
dpc-5639	55	20	were	be	AUX
dpc-5639	55	21	collected	collect	VERB
dpc-5639	55	22	.	.	PUNCT
dpc-5639	56	1	to	to	ADP
dpc-5639	56	2	date	date	NOUN
dpc-5639	56	3	,	,	PUNCT
dpc-5639	56	4	guidelines	guideline	NOUN
dpc-5639	56	5	for	for	ADP
dpc-5639	56	6	the	the	DET
dpc-5639	56	7	treatment	treatment	NOUN
dpc-5639	56	8	of	of	ADP
dpc-5639	56	9	pn	pn	PROPN
dpc-5639	56	10	have	have	AUX
dpc-5639	56	11	been	be	AUX
dpc-5639	56	12	published	publish	VERB
dpc-5639	56	13	only	only	ADV
dpc-5639	56	14	by	by	ADP
dpc-5639	56	15	the	the	DET
dpc-5639	56	16	japanese	japanese	ADJ
dpc-5639	56	17	dermatological	dermatological	ADJ
dpc-5639	56	18	association	association	NOUN
dpc-5639	56	19	(	(	PUNCT
dpc-5639	56	20	jda	jda	NOUN
dpc-5639	56	21	)	)	PUNCT
dpc-5639	56	22	and	and	CCONJ
dpc-5639	56	23	by	by	ADP
dpc-5639	56	24	the	the	DET
dpc-5639	56	25	international	international	ADJ
dpc-5639	56	26	forum	forum	NOUN
dpc-5639	56	27	for	for	ADP
dpc-5639	56	28	the	the	DET
dpc-5639	56	29	study	study	NOUN
dpc-5639	56	30	of	of	ADP
dpc-5639	56	31	itch	itch	NOUN
dpc-5639	56	32	(	(	PUNCT
dpc-5639	56	33	ifsi	ifsi	PROPN
dpc-5639	56	34	)	)	PUNCT
dpc-5639	57	1	[	[	X
dpc-5639	57	2	13	13	NUM
dpc-5639	57	3	]	]	PUNCT
dpc-5639	57	4	.	.	PUNCT
dpc-5639	58	1	both	both	PRON
dpc-5639	58	2	recommend	recommend	VERB
dpc-5639	58	3	a	a	DET
dpc-5639	58	4	step	step	NOUN
dpc-5639	58	5	-	-	PUNCT
dpc-5639	58	6	by	by	ADP
dpc-5639	58	7	-	-	PUNCT
dpc-5639	58	8	step	step	NOUN
dpc-5639	58	9	treatment	treatment	NOUN
dpc-5639	58	10	approach	approach	NOUN
dpc-5639	58	11	(	(	PUNCT
dpc-5639	58	12	step	step	NOUN
dpc-5639	58	13	1	1	NUM
dpc-5639	58	14	:	:	PUNCT
dpc-5639	58	15	tcs	tcs	NOUN
dpc-5639	58	16	,	,	PUNCT
dpc-5639	58	17	tci	tci	PROPN
dpc-5639	58	18	,	,	PUNCT
dpc-5639	58	19	and	and	CCONJ
dpc-5639	58	20	h1	h1	NOUN
dpc-5639	58	21	antihistamines	antihistamine	NOUN
dpc-5639	58	22	;	;	PUNCT
dpc-5639	58	23	step	step	NOUN
dpc-5639	58	24	2	2	NUM
dpc-5639	58	25	:	:	PUNCT
dpc-5639	58	26	topical	topical	ADJ
dpc-5639	58	27	capsaicin	capsaicin	NOUN
dpc-5639	58	28	,	,	PUNCT
dpc-5639	58	29	intralesional	intralesional	ADJ
dpc-5639	58	30	corticosteroids	corticosteroid	NOUN
dpc-5639	58	31	,	,	PUNCT
dpc-5639	58	32	and	and	CCONJ
dpc-5639	58	33	uv	uv	NOUN
dpc-5639	58	34	therapy	therapy	NOUN
dpc-5639	58	35	;	;	PUNCT
dpc-5639	58	36	step	step	NOUN
dpc-5639	58	37	3	3	NUM
dpc-5639	58	38	:	:	PUNCT
dpc-5639	58	39	gabapentin	gabapentin	NOUN
dpc-5639	58	40	,	,	PUNCT
dpc-5639	58	41	pregabalin	pregabalin	NOUN
dpc-5639	58	42	,	,	PUNCT
dpc-5639	58	43	or	or	CCONJ
dpc-5639	58	44	antidepressants	antidepressant	NOUN
dpc-5639	58	45	in	in	ADP
dpc-5639	58	46	case	case	NOUN
dpc-5639	58	47	of	of	ADP
dpc-5639	58	48	predominating	predominate	VERB
dpc-5639	58	49	neuropathic	neuropathic	ADJ
dpc-5639	58	50	characteristics	characteristic	NOUN
dpc-5639	58	51	versus	versus	ADP
dpc-5639	58	52	cyclosporine	cyclosporine	NOUN
dpc-5639	58	53	or	or	CCONJ
dpc-5639	58	54	methotrexate	methotrexate	VERB
dpc-5639	58	55	in	in	ADP
dpc-5639	58	56	cases	case	NOUN
dpc-5639	58	57	of	of	ADP
dpc-5639	58	58	predominant	predominant	ADJ
dpc-5639	58	59	inflammation	inflammation	NOUN
dpc-5639	58	60	;	;	PUNCT
dpc-5639	58	61	step	step	NOUN
dpc-5639	58	62	4	4	NUM
dpc-5639	58	63	:	:	PUNCT
dpc-5639	58	64	neurokinin	neurokinin	ADJ
dpc-5639	58	65	1	1	NUM
dpc-5639	58	66	receptor	receptor	NOUN
dpc-5639	58	67	(	(	PUNCT
dpc-5639	58	68	nk1r	nk1r	NOUN
dpc-5639	58	69	)	)	PUNCT
dpc-5639	58	70	antagonist	antagonist	NOUN
dpc-5639	58	71	,	,	PUNCT
dpc-5639	58	72	μ	μ	NOUN
dpc-5639	58	73	-	-	ADJ
dpc-5639	58	74	opioid	opioid	ADJ
dpc-5639	58	75	receptor	receptor	NOUN
dpc-5639	58	76	antagonists	antagonist	NOUN
dpc-5639	58	77	,	,	PUNCT
dpc-5639	58	78	dupilumab	dupilumab	NOUN
dpc-5639	58	79	,	,	PUNCT
dpc-5639	58	80	nemolizumab	nemolizumab	NOUN
dpc-5639	58	81	(	(	PUNCT
dpc-5639	58	82	currently	currently	ADV
dpc-5639	58	83	under	under	ADP
dpc-5639	58	84	investigation	investigation	NOUN
dpc-5639	58	85	)	)	PUNCT
dpc-5639	59	1	[	[	X
dpc-5639	59	2	8	8	NUM
dpc-5639	59	3	]	]	PUNCT
dpc-5639	59	4	.	.	PUNCT
dpc-5639	60	1	enrolled	enrol	VERB
dpc-5639	60	2	patients	patient	NOUN
dpc-5639	60	3	could	could	AUX
dpc-5639	60	4	be	be	AUX
dpc-5639	60	5	prescribed	prescribe	VERB
dpc-5639	60	6	any	any	PRON
dpc-5639	60	7	of	of	ADP
dpc-5639	60	8	the	the	DET
dpc-5639	60	9	aforementioned	aforementioned	ADJ
dpc-5639	60	10	available	available	ADJ
dpc-5639	60	11	therapies	therapy	NOUN
dpc-5639	60	12	,	,	PUNCT
dpc-5639	60	13	according	accord	VERB
dpc-5639	60	14	to	to	ADP
dpc-5639	60	15	symptom	symptom	NOUN
dpc-5639	60	16	severity	severity	NOUN
dpc-5639	60	17	,	,	PUNCT
dpc-5639	60	18	consistent	consistent	ADJ
dpc-5639	60	19	with	with	ADP
dpc-5639	60	20	treatment	treatment	NOUN
dpc-5639	60	21	guidelines	guideline	NOUN
dpc-5639	60	22	.	.	PUNCT
dpc-5639	61	1	the	the	DET
dpc-5639	61	2	entry	entry	NOUN
dpc-5639	61	3	into	into	ADP
dpc-5639	61	4	the	the	DET
dpc-5639	61	5	study	study	NOUN
dpc-5639	61	6	did	do	AUX
dpc-5639	61	7	not	not	PART
dpc-5639	61	8	influence	influence	VERB
dpc-5639	61	9	the	the	DET
dpc-5639	61	10	therapeutic	therapeutic	ADJ
dpc-5639	61	11	decision	decision	NOUN
dpc-5639	61	12	.	.	PUNCT
dpc-5639	62	1	clinical	clinical	ADJ
dpc-5639	62	2	response	response	NOUN
dpc-5639	62	3	was	be	AUX
dpc-5639	62	4	closely	closely	ADV
dpc-5639	62	5	monitored	monitor	VERB
dpc-5639	62	6	throughout	throughout	ADP
dpc-5639	62	7	the	the	DET
dpc-5639	62	8	treatment	treatment	NOUN
dpc-5639	62	9	period	period	NOUN
dpc-5639	62	10	to	to	PART
dpc-5639	62	11	aid	aid	VERB
dpc-5639	62	12	in	in	ADP
dpc-5639	62	13	the	the	DET
dpc-5639	62	14	evaluation	evaluation	NOUN
dpc-5639	62	15	of	of	ADP
dpc-5639	62	16	the	the	DET
dpc-5639	62	17	therapy	therapy	NOUN
dpc-5639	62	18	efficacy	efficacy	NOUN
dpc-5639	62	19	.	.	PUNCT
dpc-5639	63	1	for	for	ADP
dpc-5639	63	2	all	all	DET
dpc-5639	63	3	patients	patient	NOUN
dpc-5639	63	4	,	,	PUNCT
dpc-5639	63	5	disease	disease	NOUN
dpc-5639	63	6	severity	severity	NOUN
dpc-5639	63	7	was	be	AUX
dpc-5639	63	8	evaluated	evaluate	VERB
dpc-5639	63	9	through	through	ADP
dpc-5639	63	10	the	the	DET
dpc-5639	63	11	measurements	measurement	NOUN
dpc-5639	63	12	of	of	ADP
dpc-5639	63	13	investigator	investigator	NOUN
dpc-5639	63	14	’s	’s	PART
dpc-5639	63	15	global	global	ADJ
dpc-5639	63	16	assessment	assessment	NOUN
dpc-5639	63	17	(	(	PUNCT
dpc-5639	63	18	iga	iga	PROPN
dpc-5639	63	19	)	)	PUNCT
dpc-5639	63	20	score	score	NOUN
dpc-5639	64	1	[	[	X
dpc-5639	64	2	14	14	NUM
dpc-5639	64	3	]	]	PUNCT
dpc-5639	64	4	,	,	PUNCT
dpc-5639	64	5	numeric	numeric	ADJ
dpc-5639	64	6	rating	rating	NOUN
dpc-5639	64	7	scale	scale	NOUN
dpc-5639	64	8	(	(	PUNCT
dpc-5639	64	9	nrs	nrs	PROPN
dpc-5639	64	10	)	)	PUNCT
dpc-5639	64	11	for	for	ADP
dpc-5639	64	12	pruritus	pruritus	NOUN
dpc-5639	64	13	[	[	X
dpc-5639	64	14	15	15	NUM
dpc-5639	64	15	]	]	PUNCT
dpc-5639	64	16	,	,	PUNCT
dpc-5639	64	17	and	and	CCONJ
dpc-5639	64	18	dermatology	dermatology	NOUN
dpc-5639	64	19	life	life	NOUN
dpc-5639	64	20	quality	quality	NOUN
dpc-5639	64	21	index	index	NOUN
dpc-5639	64	22	(	(	PUNCT
dpc-5639	64	23	dlqi	dlqi	PROPN
dpc-5639	64	24	)	)	PUNCT
dpc-5639	65	1	[	[	X
dpc-5639	65	2	16	16	NUM
dpc-5639	65	3	]	]	X
dpc-5639	65	4	,	,	PUNCT
dpc-5639	65	5	at	at	ADP
dpc-5639	65	6	the	the	DET
dpc-5639	65	7	beginning	beginning	NOUN
dpc-5639	65	8	of	of	ADP
dpc-5639	65	9	the	the	DET
dpc-5639	65	10	study	study	NOUN
dpc-5639	65	11	(	(	PUNCT
dpc-5639	65	12	week	week	NOUN
dpc-5639	65	13	0	0	PUNCT
dpc-5639	65	14	[	[	X
dpc-5639	65	15	w0	w0	PROPN
dpc-5639	65	16	]	]	PUNCT
dpc-5639	65	17	)	)	PUNCT
dpc-5639	65	18	and	and	CCONJ
dpc-5639	65	19	after	after	ADP
dpc-5639	65	20	6	6	NUM
dpc-5639	65	21	-	-	PUNCT
dpc-5639	65	22	month	month	NOUN
dpc-5639	65	23	period	period	NOUN
dpc-5639	65	24	of	of	ADP
dpc-5639	65	25	systemic	systemic	ADJ
dpc-5639	65	26	treatment	treatment	NOUN
dpc-5639	65	27	(	(	PUNCT
dpc-5639	65	28	w24	w24	PROPN
dpc-5639	65	29	)	)	PUNCT
dpc-5639	65	30	.	.	PUNCT
dpc-5639	66	1	the	the	DET
dpc-5639	66	2	iga	iga	PROPN
dpc-5639	66	3	score	score	NOUN
dpc-5639	66	4	is	be	AUX
dpc-5639	66	5	a	a	DET
dpc-5639	66	6	5	5	NUM
dpc-5639	66	7	-	-	PUNCT
dpc-5639	66	8	point	point	NOUN
dpc-5639	66	9	scale	scale	NOUN
dpc-5639	66	10	used	use	VERB
dpc-5639	66	11	to	to	PART
dpc-5639	66	12	rate	rate	VERB
dpc-5639	66	13	the	the	DET
dpc-5639	66	14	severity	severity	NOUN
dpc-5639	66	15	of	of	ADP
dpc-5639	66	16	the	the	DET
dpc-5639	66	17	disease	disease	NOUN
dpc-5639	66	18	.	.	PUNCT
dpc-5639	67	1	the	the	DET
dpc-5639	67	2	nrs	nrs	PROPN
dpc-5639	67	3	is	be	AUX
dpc-5639	67	4	a	a	DET
dpc-5639	67	5	patient	patient	NOUN
dpc-5639	67	6	-	-	PUNCT
dpc-5639	67	7	reported	report	VERB
dpc-5639	67	8	outcome	outcome	NOUN
dpc-5639	67	9	measure	measure	NOUN
dpc-5639	67	10	used	use	VERB
dpc-5639	67	11	to	to	PART
dpc-5639	67	12	assess	assess	VERB
dpc-5639	67	13	the	the	DET
dpc-5639	67	14	severity	severity	NOUN
dpc-5639	67	15	of	of	ADP
dpc-5639	67	16	itching	itching	NOUN
dpc-5639	67	17	.	.	PUNCT
dpc-5639	68	1	the	the	DET
dpc-5639	68	2	dlqi	dlqi	NOUN
dpc-5639	68	3	,	,	PUNCT
dpc-5639	68	4	because	because	SCONJ
dpc-5639	68	5	of	of	ADP
dpc-5639	68	6	its	its	PRON
dpc-5639	68	7	self	self	NOUN
dpc-5639	68	8	-	-	PUNCT
dpc-5639	68	9	explanatory	explanatory	ADJ
dpc-5639	68	10	questions	question	NOUN
dpc-5639	68	11	,	,	PUNCT
dpc-5639	68	12	is	be	AUX
dpc-5639	68	13	one	one	NUM
dpc-5639	68	14	of	of	ADP
dpc-5639	68	15	the	the	DET
dpc-5639	68	16	most	most	ADV
dpc-5639	68	17	commonly	commonly	ADV
dpc-5639	68	18	used	use	VERB
dpc-5639	68	19	tools	tool	NOUN
dpc-5639	68	20	for	for	ADP
dpc-5639	68	21	the	the	DET
dpc-5639	68	22	assessment	assessment	NOUN
dpc-5639	68	23	of	of	ADP
dpc-5639	68	24	health	health	NOUN
dpc-5639	68	25	-	-	PUNCT
dpc-5639	68	26	related	relate	VERB
dpc-5639	68	27	quality	quality	NOUN
dpc-5639	68	28	of	of	ADP
dpc-5639	68	29	life	life	NOUN
dpc-5639	68	30	(	(	PUNCT
dpc-5639	68	31	hrqol	hrqol	NOUN
dpc-5639	68	32	)	)	PUNCT
dpc-5639	68	33	in	in	ADP
dpc-5639	68	34	dermatology	dermatology	NOUN
dpc-5639	68	35	.	.	PUNCT
dpc-5639	69	1	the	the	DET
dpc-5639	69	2	dlqi	dlqi	ADJ
dpc-5639	69	3	score	score	NOUN
dpc-5639	69	4	ranges	range	VERB
dpc-5639	69	5	from	from	ADP
dpc-5639	69	6	0	0	NUM
dpc-5639	69	7	to	to	PART
dpc-5639	69	8	30	30	NUM
dpc-5639	69	9	points	point	NOUN
dpc-5639	69	10	,	,	PUNCT
dpc-5639	69	11	with	with	ADP
dpc-5639	69	12	a	a	DET
dpc-5639	69	13	lower	low	ADJ
dpc-5639	69	14	score	score	NOUN
dpc-5639	69	15	indicating	indicate	VERB
dpc-5639	69	16	better	well	ADJ
dpc-5639	69	17	hrqol	hrqol	NOUN
dpc-5639	69	18	.	.	PUNCT
dpc-5639	70	1	according	accord	VERB
dpc-5639	70	2	to	to	ADP
dpc-5639	70	3	the	the	DET
dpc-5639	70	4	classification	classification	NOUN
dpc-5639	70	5	of	of	ADP
dpc-5639	70	6	dlqi	dlqi	ADJ
dpc-5639	70	7	score	score	NOUN
dpc-5639	70	8	proposed	propose	VERB
dpc-5639	70	9	by	by	ADP
dpc-5639	70	10	hongbo	hongbo	PROPN
dpc-5639	70	11	et	et	PROPN
dpc-5639	70	12	al	al	PROPN
dpc-5639	70	13	.	.	PUNCT
dpc-5639	71	1	[	[	X
dpc-5639	71	2	17	17	NUM
dpc-5639	71	3	]	]	PUNCT
dpc-5639	71	4	,	,	PUNCT
dpc-5639	71	5	0	0	NUM
dpc-5639	71	6	to	to	PART
dpc-5639	71	7	1	1	NUM
dpc-5639	71	8	point	point	NOUN
dpc-5639	71	9	indicates	indicate	VERB
dpc-5639	71	10	normal	normal	ADJ
dpc-5639	71	11	qol	qol	NOUN
dpc-5639	71	12	,	,	PUNCT
dpc-5639	71	13	2–5	2–5	PROPN
dpc-5639	71	14	points	point	NOUN
dpc-5639	71	15	indicate	indicate	VERB
dpc-5639	71	16	slightly	slightly	ADV
dpc-5639	71	17	,	,	PUNCT
dpc-5639	71	18	6–10	6–10	NOUN
dpc-5639	71	19	points	point	NOUN
dpc-5639	71	20	severely	severely	ADV
dpc-5639	71	21	,	,	PUNCT
dpc-5639	71	22	11–20	11–20	NUM
dpc-5639	71	23	points	point	NOUN
dpc-5639	71	24	very	very	ADV
dpc-5639	71	25	severely	severely	ADV
dpc-5639	71	26	,	,	PUNCT
dpc-5639	71	27	and	and	CCONJ
dpc-5639	71	28	21–30	21–30	NUM
dpc-5639	71	29	extremely	extremely	ADV
dpc-5639	71	30	severely	severely	ADV
dpc-5639	71	31	impaired	impair	VERB
dpc-5639	71	32	hrqol	hrqol	NOUN
dpc-5639	71	33	.	.	PUNCT
dpc-5639	72	1	the	the	DET
dpc-5639	72	2	baseline	baseline	PROPN
dpc-5639	72	3	characteristics	characteristic	NOUN
dpc-5639	72	4	(	(	PUNCT
dpc-5639	72	5	e.g.	e.g.	ADV
dpc-5639	72	6	,	,	PUNCT
dpc-5639	72	7	iga	iga	PROPN
dpc-5639	72	8	,	,	PUNCT
dpc-5639	72	9	nrs	nrs	PROPN
dpc-5639	72	10	,	,	PUNCT
dpc-5639	72	11	dlqi	dlqi	ADJ
dpc-5639	72	12	,	,	PUNCT
dpc-5639	72	13	comorbidities	comorbiditie	NOUN
dpc-5639	72	14	)	)	PUNCT
dpc-5639	72	15	between	between	ADP
dpc-5639	72	16	the	the	DET
dpc-5639	72	17	two	two	NUM
dpc-5639	72	18	subgroups	subgroup	NOUN
dpc-5639	72	19	treated	treat	VERB
dpc-5639	72	20	with	with	ADP
dpc-5639	72	21	dupilumab	dupilumab	NOUN
dpc-5639	72	22	or	or	CCONJ
dpc-5639	72	23	antidepressants	antidepressant	NOUN
dpc-5639	72	24	were	be	AUX
dpc-5639	72	25	similar	similar	ADJ
dpc-5639	72	26	and	and	CCONJ
dpc-5639	72	27	quite	quite	ADV
dpc-5639	72	28	comparable	comparable	ADJ
dpc-5639	72	29	.	.	PUNCT
dpc-5639	73	1	the	the	DET
dpc-5639	73	2	study	study	NOUN
dpc-5639	73	3	was	be	AUX
dpc-5639	73	4	conducted	conduct	VERB
dpc-5639	73	5	in	in	ADP
dpc-5639	73	6	accordance	accordance	NOUN
dpc-5639	73	7	with	with	ADP
dpc-5639	73	8	the	the	DET
dpc-5639	73	9	principles	principle	NOUN
dpc-5639	73	10	of	of	ADP
dpc-5639	73	11	the	the	DET
dpc-5639	73	12	declaration	declaration	NOUN
dpc-5639	73	13	of	of	ADP
dpc-5639	73	14	helsinki	helsinki	PROPN
dpc-5639	73	15	and	and	CCONJ
dpc-5639	73	16	good	good	ADJ
dpc-5639	73	17	clinical	clinical	ADJ
dpc-5639	73	18	practice	practice	NOUN
dpc-5639	73	19	guidelines	guideline	NOUN
dpc-5639	73	20	.	.	PUNCT
dpc-5639	74	1	all	all	DET
dpc-5639	74	2	patients	patient	NOUN
dpc-5639	74	3	provided	provide	VERB
dpc-5639	74	4	informed	informed	ADJ
dpc-5639	74	5	consent	consent	NOUN
dpc-5639	74	6	before	before	ADP
dpc-5639	74	7	participating	participate	VERB
dpc-5639	74	8	in	in	ADP
dpc-5639	74	9	the	the	DET
dpc-5639	74	10	study	study	NOUN
dpc-5639	74	11	.	.	PUNCT
dpc-5639	75	1	statistical	statistical	ADJ
dpc-5639	75	2	analysis	analysis	NOUN
dpc-5639	75	3	the	the	DET
dpc-5639	75	4	data	datum	NOUN
dpc-5639	75	5	are	be	AUX
dpc-5639	75	6	expressed	express	VERB
dpc-5639	75	7	in	in	ADP
dpc-5639	75	8	the	the	DET
dpc-5639	75	9	form	form	NOUN
dpc-5639	75	10	of	of	ADP
dpc-5639	75	11	mean	mean	NOUN
dpc-5639	75	12	for	for	ADP
dpc-5639	75	13	continuous	continuous	ADJ
dpc-5639	75	14	variables	variable	NOUN
dpc-5639	75	15	,	,	PUNCT
dpc-5639	75	16	while	while	SCONJ
dpc-5639	75	17	categorical	categorical	ADJ
dpc-5639	75	18	variables	variable	NOUN
dpc-5639	75	19	are	be	AUX
dpc-5639	75	20	presented	present	VERB
dpc-5639	75	21	as	as	ADP
dpc-5639	75	22	numbers	number	NOUN
dpc-5639	75	23	and	and	CCONJ
dpc-5639	75	24	percentages	percentage	NOUN
dpc-5639	75	25	.	.	PUNCT
dpc-5639	76	1	data	datum	NOUN
dpc-5639	76	2	that	that	PRON
dpc-5639	76	3	passed	pass	VERB
dpc-5639	76	4	the	the	DET
dpc-5639	76	5	normality	normality	NOUN
dpc-5639	76	6	test	test	NOUN
dpc-5639	76	7	were	be	AUX
dpc-5639	76	8	analyzed	analyze	VERB
dpc-5639	76	9	using	use	VERB
dpc-5639	76	10	a	a	DET
dpc-5639	76	11	two	two	NUM
dpc-5639	76	12	-	-	PUNCT
dpc-5639	76	13	tailed	tail	VERB
dpc-5639	76	14	t	t	NOUN
dpc-5639	76	15	-	-	PUNCT
dpc-5639	76	16	test	test	NOUN
dpc-5639	76	17	;	;	PUNCT
dpc-5639	76	18	otherwise	otherwise	ADV
dpc-5639	76	19	,	,	PUNCT
dpc-5639	76	20	the	the	DET
dpc-5639	76	21	mann	mann	PROPN
dpc-5639	76	22	-	-	PUNCT
dpc-5639	76	23	whitney	whitney	PROPN
dpc-5639	76	24	test	test	NOUN
dpc-5639	76	25	was	be	AUX
dpc-5639	76	26	used	use	VERB
dpc-5639	76	27	to	to	PART
dpc-5639	76	28	calculate	calculate	VERB
dpc-5639	76	29	statistical	statistical	ADJ
dpc-5639	76	30	differences	difference	NOUN
dpc-5639	76	31	.	.	PUNCT
dpc-5639	77	1	statistical	statistical	ADJ
dpc-5639	77	2	significance	significance	NOUN
dpc-5639	77	3	was	be	AUX
dpc-5639	77	4	established	establish	VERB
dpc-5639	77	5	at	at	ADP
dpc-5639	77	6	p<0.05	p<0.05	PROPN
dpc-5639	77	7	.	.	PUNCT
dpc-5639	78	1	bonferroni	bonferroni	PROPN
dpc-5639	78	2	test	test	NOUN
dpc-5639	78	3	correction	correction	NOUN
dpc-5639	78	4	for	for	ADP
dpc-5639	78	5	multiple	multiple	ADJ
dpc-5639	78	6	comparisons	comparison	NOUN
dpc-5639	78	7	was	be	AUX
dpc-5639	78	8	applied	apply	VERB
dpc-5639	78	9	for	for	ADP
dpc-5639	78	10	the	the	DET
dpc-5639	78	11	analysis	analysis	NOUN
dpc-5639	78	12	of	of	ADP
dpc-5639	78	13	iga	iga	PROPN
dpc-5639	78	14	improvement	improvement	NOUN
dpc-5639	78	15	,	,	PUNCT
dpc-5639	78	16	≥4	≥4	PROPN
dpc-5639	78	17	points	point	VERB
dpc-5639	78	18	nrs	nrs	NOUN
dpc-5639	78	19	,	,	PUNCT
dpc-5639	78	20	and	and	CCONJ
dpc-5639	78	21	dlqi	dlqi	ADJ
dpc-5639	78	22	reduction	reduction	NOUN
dpc-5639	78	23	from	from	ADP
dpc-5639	78	24	baseline	baseline	NOUN
dpc-5639	78	25	between	between	ADP
dpc-5639	78	26	patients	patient	NOUN
dpc-5639	78	27	on	on	ADP
dpc-5639	78	28	dupilumab	dupilumab	NOUN
dpc-5639	78	29	and	and	CCONJ
dpc-5639	78	30	patients	patient	NOUN
dpc-5639	78	31	on	on	ADP
dpc-5639	78	32	antidepressant	antidepressant	ADJ
dpc-5639	78	33	treatment	treatment	NOUN
dpc-5639	78	34	.	.	PUNCT
dpc-5639	79	1	statistical	statistical	ADJ
dpc-5639	79	2	analyses	analysis	NOUN
dpc-5639	79	3	were	be	AUX
dpc-5639	79	4	performed	perform	VERB
dpc-5639	79	5	using	use	VERB
dpc-5639	79	6	graphpad	graphpad	NOUN
dpc-5639	79	7	prism	prism	NOUN
dpc-5639	79	8	6.0	6.0	NUM
dpc-5639	79	9	(	(	PUNCT
dpc-5639	79	10	graphpad	graphpad	PROPN
dpc-5639	79	11	software	software	PROPN
dpc-5639	79	12	inc	inc	PROPN
dpc-5639	79	13	,	,	PUNCT
dpc-5639	79	14	la	la	PROPN
dpc-5639	79	15	jolla	jolla	PROPN
dpc-5639	79	16	,	,	PUNCT
dpc-5639	79	17	ca	ca	PROPN
dpc-5639	79	18	,	,	PUNCT
dpc-5639	79	19	usa	usa	PROPN
dpc-5639	79	20	)	)	PUNCT
dpc-5639	79	21	or	or	CCONJ
dpc-5639	79	22	sas	sa	VERB
dpc-5639	79	23	software	software	NOUN
dpc-5639	79	24	v	v	ADP
dpc-5639	79	25	9.3	9.3	NUM
dpc-5639	79	26	(	(	PUNCT
dpc-5639	79	27	sas	sas	PROPN
dpc-5639	79	28	institute	institute	PROPN
dpc-5639	79	29	inc	inc	PROPN
dpc-5639	79	30	.	.	PROPN
dpc-5639	79	31	,	,	PUNCT
dpc-5639	79	32	cary	cary	PROPN
dpc-5639	79	33	,	,	PUNCT
dpc-5639	79	34	nc	nc	PROPN
dpc-5639	79	35	,	,	PUNCT
dpc-5639	79	36	usa	usa	PROPN
dpc-5639	79	37	)	)	PUNCT
dpc-5639	79	38	.	.	PUNCT
dpc-5639	80	1	results	result	NOUN
dpc-5639	80	2	in	in	ADP
dpc-5639	80	3	all	all	PRON
dpc-5639	80	4	,	,	PUNCT
dpc-5639	80	5	90	90	NUM
dpc-5639	80	6	patients	patient	NOUN
dpc-5639	80	7	,	,	PUNCT
dpc-5639	80	8	35	35	NUM
dpc-5639	80	9	(	(	PUNCT
dpc-5639	80	10	39	39	NUM
dpc-5639	80	11	%	%	NOUN
dpc-5639	80	12	)	)	PUNCT
dpc-5639	80	13	males	male	NOUN
dpc-5639	80	14	and	and	CCONJ
dpc-5639	80	15	55	55	NUM
dpc-5639	80	16	(	(	PUNCT
dpc-5639	80	17	61	61	NUM
dpc-5639	80	18	%	%	NOUN
dpc-5639	80	19	)	)	PUNCT
dpc-5639	80	20	females	female	NOUN
dpc-5639	80	21	,	,	PUNCT
dpc-5639	80	22	aged	aged	ADJ
dpc-5639	80	23	18–80	18–80	NUM
dpc-5639	80	24	,	,	PUNCT
dpc-5639	80	25	were	be	AUX
dpc-5639	80	26	enrolled	enrol	VERB
dpc-5639	80	27	into	into	ADP
dpc-5639	80	28	the	the	DET
dpc-5639	80	29	study	study	NOUN
dpc-5639	80	30	.	.	PUNCT
dpc-5639	81	1	among	among	ADP
dpc-5639	81	2	the	the	DET
dpc-5639	81	3	participants	participant	NOUN
dpc-5639	81	4	,	,	PUNCT
dpc-5639	81	5	15	15	NUM
dpc-5639	81	6	(	(	PUNCT
dpc-5639	81	7	16.7	16.7	NUM
dpc-5639	81	8	%	%	NOUN
dpc-5639	81	9	)	)	PUNCT
dpc-5639	81	10	patients	patient	NOUN
dpc-5639	81	11	had	have	VERB
dpc-5639	81	12	diabetes	diabetes	NOUN
dpc-5639	81	13	,	,	PUNCT
dpc-5639	81	14	23	23	NUM
dpc-5639	81	15	(	(	PUNCT
dpc-5639	81	16	25.5	25.5	NUM
dpc-5639	81	17	%	%	NOUN
dpc-5639	81	18	)	)	PUNCT
dpc-5639	81	19	dyslipidemia	dyslipidemia	NOUN
dpc-5639	81	20	,	,	PUNCT
dpc-5639	81	21	33	33	NUM
dpc-5639	81	22	(	(	PUNCT
dpc-5639	81	23	36.7	36.7	NUM
dpc-5639	81	24	%	%	NOUN
dpc-5639	81	25	)	)	PUNCT
dpc-5639	81	26	hypertension	hypertension	NOUN
dpc-5639	81	27	,	,	PUNCT
dpc-5639	81	28	and	and	CCONJ
dpc-5639	81	29	four	four	NUM
dpc-5639	81	30	cardiovascular	cardiovascular	ADJ
dpc-5639	81	31	diseases	disease	NOUN
dpc-5639	81	32	(	(	PUNCT
dpc-5639	81	33	4.4	4.4	NUM
dpc-5639	81	34	%	%	NOUN
dpc-5639	81	35	)	)	PUNCT
dpc-5639	81	36	.	.	PUNCT
dpc-5639	82	1	other	other	ADJ
dpc-5639	82	2	comorbidities	comorbiditie	NOUN
dpc-5639	82	3	were	be	AUX
dpc-5639	82	4	present	present	ADJ
dpc-5639	82	5	in	in	ADP
dpc-5639	82	6	27	27	NUM
dpc-5639	82	7	(	(	PUNCT
dpc-5639	82	8	30	30	NUM
dpc-5639	82	9	%	%	NOUN
dpc-5639	82	10	)	)	PUNCT
dpc-5639	82	11	of	of	ADP
dpc-5639	82	12	the	the	DET
dpc-5639	82	13	patients	patient	NOUN
dpc-5639	82	14	.	.	PUNCT
dpc-5639	83	1	baseline	baseline	VERB
dpc-5639	83	2	demographic	demographic	ADJ
dpc-5639	83	3	and	and	CCONJ
dpc-5639	83	4	clinical	clinical	ADJ
dpc-5639	83	5	data	datum	NOUN
dpc-5639	83	6	are	be	AUX
dpc-5639	83	7	summarized	summarize	VERB
dpc-5639	83	8	in	in	ADP
dpc-5639	83	9	table	table	NOUN
dpc-5639	83	10	1	1	NUM
dpc-5639	83	11	.	.	PUNCT
dpc-5639	84	1	pn	pn	PROPN
dpc-5639	84	2	was	be	AUX
dpc-5639	84	3	diagnosed	diagnose	VERB
dpc-5639	84	4	in	in	ADP
dpc-5639	84	5	73	73	NUM
dpc-5639	84	6	%	%	NOUN
dpc-5639	84	7	of	of	ADP
dpc-5639	84	8	cases	case	NOUN
dpc-5639	84	9	by	by	ADP
dpc-5639	84	10	clinical	clinical	ADJ
dpc-5639	84	11	evaluation	evaluation	NOUN
dpc-5639	84	12	only	only	ADV
dpc-5639	84	13	,	,	PUNCT
dpc-5639	84	14	while	while	SCONJ
dpc-5639	84	15	the	the	DET
dpc-5639	84	16	remaining	remain	VERB
dpc-5639	84	17	27	27	NUM
dpc-5639	84	18	%	%	NOUN
dpc-5639	84	19	by	by	ADP
dpc-5639	84	20	a	a	DET
dpc-5639	84	21	combination	combination	NOUN
dpc-5639	84	22	of	of	ADP
dpc-5639	84	23	clinical	clinical	ADJ
dpc-5639	84	24	and	and	CCONJ
dpc-5639	84	25	histological	histological	ADJ
dpc-5639	84	26	examinations	examination	NOUN
dpc-5639	84	27	.	.	PUNCT
dpc-5639	85	1	the	the	DET
dpc-5639	85	2	distribution	distribution	NOUN
dpc-5639	85	3	of	of	ADP
dpc-5639	85	4	the	the	DET
dpc-5639	85	5	pruritic	pruritic	ADJ
dpc-5639	85	6	nodules	nodule	NOUN
dpc-5639	85	7	varied	varied	ADJ
dpc-5639	85	8	among	among	ADP
dpc-5639	85	9	the	the	DET
dpc-5639	85	10	patients	patient	NOUN
dpc-5639	85	11	,	,	PUNCT
dpc-5639	85	12	with	with	ADP
dpc-5639	85	13	the	the	DET
dpc-5639	85	14	upper	upper	ADJ
dpc-5639	85	15	limbs	limb	NOUN
dpc-5639	85	16	59	59	NUM
dpc-5639	85	17	(	(	PUNCT
dpc-5639	85	18	66	66	NUM
dpc-5639	85	19	%	%	NOUN
dpc-5639	85	20	)	)	PUNCT
dpc-5639	85	21	,	,	PUNCT
dpc-5639	85	22	lower	low	ADJ
dpc-5639	85	23	limbs	limb	NOUN
dpc-5639	85	24	51	51	NUM
dpc-5639	85	25	(	(	PUNCT
dpc-5639	85	26	57	57	NUM
dpc-5639	85	27	%	%	NOUN
dpc-5639	85	28	)	)	PUNCT
dpc-5639	85	29	,	,	PUNCT
dpc-5639	85	30	and	and	CCONJ
dpc-5639	85	31	trunk	trunk	NOUN
dpc-5639	85	32	48	48	NUM
dpc-5639	85	33	(	(	PUNCT
dpc-5639	85	34	53.3	53.3	NUM
dpc-5639	85	35	%	%	NOUN
dpc-5639	85	36	)	)	PUNCT
dpc-5639	85	37	being	be	AUX
dpc-5639	85	38	the	the	DET
dpc-5639	85	39	most	most	ADV
dpc-5639	85	40	commonly	commonly	ADV
dpc-5639	85	41	affected	affect	VERB
dpc-5639	85	42	areas	area	NOUN
dpc-5639	85	43	.	.	PUNCT
dpc-5639	86	1	the	the	DET
dpc-5639	86	2	back	back	NOUN
dpc-5639	86	3	(	(	PUNCT
dpc-5639	86	4	n=17	n=17	NOUN
dpc-5639	86	5	,	,	PUNCT
dpc-5639	86	6	18.9	18.9	NUM
dpc-5639	86	7	%	%	NOUN
dpc-5639	86	8	)	)	PUNCT
dpc-5639	86	9	and	and	CCONJ
dpc-5639	86	10	face	face	NOUN
dpc-5639	86	11	(	(	PUNCT
dpc-5639	86	12	n=13	n=13	NOUN
dpc-5639	86	13	,	,	PUNCT
dpc-5639	86	14	14.4	14.4	NUM
dpc-5639	86	15	%	%	NOUN
dpc-5639	86	16	)	)	PUNCT
dpc-5639	86	17	were	be	AUX
dpc-5639	86	18	less	less	ADV
dpc-5639	86	19	commonly	commonly	ADV
dpc-5639	86	20	affected	affect	VERB
dpc-5639	86	21	.	.	PUNCT
dpc-5639	87	1	regarding	regard	VERB
dpc-5639	87	2	disease	disease	NOUN
dpc-5639	87	3	severity	severity	NOUN
dpc-5639	87	4	indices	index	NOUN
dpc-5639	87	5	,	,	PUNCT
dpc-5639	87	6	at	at	ADP
dpc-5639	87	7	baseline	baseline	PROPN
dpc-5639	87	8	(	(	PUNCT
dpc-5639	87	9	w0	w0	PROPN
dpc-5639	87	10	)	)	PUNCT
dpc-5639	87	11	,	,	PUNCT
dpc-5639	87	12	22	22	NUM
dpc-5639	87	13	(	(	PUNCT
dpc-5639	87	14	24.4	24.4	NUM
dpc-5639	87	15	%	%	NOUN
dpc-5639	87	16	)	)	PUNCT
dpc-5639	87	17	patients	patient	NOUN
dpc-5639	87	18	presented	present	VERB
dpc-5639	87	19	grade	grade	NOUN
dpc-5639	87	20	1	1	NUM
dpc-5639	87	21	iga	iga	PROPN
dpc-5639	87	22	score	score	NOUN
dpc-5639	87	23	,	,	PUNCT
dpc-5639	87	24	36	36	NUM
dpc-5639	87	25	(	(	PUNCT
dpc-5639	87	26	40.0	40.0	NUM
dpc-5639	87	27	%	%	NOUN
dpc-5639	87	28	)	)	PUNCT
dpc-5639	87	29	had	have	VERB
dpc-5639	87	30	grade	grade	NOUN
dpc-5639	87	31	2	2	NUM
dpc-5639	87	32	,	,	PUNCT
dpc-5639	87	33	19	19	NUM
dpc-5639	87	34	(	(	PUNCT
dpc-5639	87	35	21.2	21.2	NUM
dpc-5639	87	36	%	%	NOUN
dpc-5639	87	37	)	)	PUNCT
dpc-5639	87	38	had	have	AUX
dpc-5639	87	39	iga	iga	PROPN
dpc-5639	87	40	3	3	NUM
dpc-5639	87	41	,	,	PUNCT
dpc-5639	87	42	and	and	CCONJ
dpc-5639	87	43	13	13	NUM
dpc-5639	87	44	(	(	PUNCT
dpc-5639	87	45	14.4	14.4	NUM
dpc-5639	87	46	%	%	NOUN
dpc-5639	87	47	)	)	PUNCT
dpc-5639	87	48	had	have	VERB
dpc-5639	87	49	iga4	iga4	PROPN
dpc-5639	87	50	.	.	PUNCT
dpc-5639	88	1	moreover	moreover	ADV
dpc-5639	88	2	,	,	PUNCT
dpc-5639	88	3	17	17	NUM
dpc-5639	88	4	(	(	PUNCT
dpc-5639	88	5	18.9	18.9	NUM
dpc-5639	88	6	%	%	NOUN
dpc-5639	88	7	)	)	PUNCT
dpc-5639	88	8	patients	patient	NOUN
dpc-5639	88	9	had	have	VERB
dpc-5639	88	10	nrs	nrs	NOUN
dpc-5639	88	11	itching	itching	NOUN
dpc-5639	88	12	score	score	NOUN
dpc-5639	88	13	between	between	ADP
dpc-5639	88	14	0–5	0–5	NOUN
dpc-5639	88	15	,	,	PUNCT
dpc-5639	88	16	while	while	SCONJ
dpc-5639	88	17	the	the	DET
dpc-5639	88	18	remaining	remain	VERB
dpc-5639	88	19	73	73	NUM
dpc-5639	88	20	(	(	PUNCT
dpc-5639	88	21	81.1	81.1	NUM
dpc-5639	88	22	%	%	NOUN
dpc-5639	88	23	)	)	PUNCT
dpc-5639	88	24	between	between	ADP
dpc-5639	88	25	6–10	6–10	NOUN
dpc-5639	88	26	,	,	PUNCT
dpc-5639	88	27	suggesting	suggest	VERB
dpc-5639	88	28	a	a	DET
dpc-5639	88	29	moderate	moderate	ADJ
dpc-5639	88	30	-	-	PUNCT
dpc-5639	88	31	to	to	ADP
dpc-5639	88	32	-	-	PUNCT
dpc-5639	88	33	very	very	ADV
dpc-5639	88	34	severe	severe	ADJ
dpc-5639	88	35	level	level	NOUN
dpc-5639	88	36	of	of	ADP
dpc-5639	88	37	pruritus	pruritus	PROPN
dpc-5639	88	38	.	.	PUNCT
dpc-5639	89	1	the	the	DET
dpc-5639	89	2	mean	mean	ADJ
dpc-5639	89	3	dlqi	dlqi	ADJ
dpc-5639	89	4	score	score	NOUN
dpc-5639	89	5	at	at	ADP
dpc-5639	89	6	baseline	baseline	PROPN
dpc-5639	89	7	was	be	AUX
dpc-5639	89	8	16.2	16.2	NUM
dpc-5639	89	9	,	,	PUNCT
dpc-5639	89	10	indicating	indicate	VERB
dpc-5639	89	11	a	a	DET
dpc-5639	89	12	very	very	ADV
dpc-5639	89	13	large	large	ADJ
dpc-5639	89	14	effect	effect	NOUN
dpc-5639	89	15	of	of	ADP
dpc-5639	89	16	the	the	DET
dpc-5639	89	17	disease	disease	NOUN
dpc-5639	89	18	on	on	ADP
dpc-5639	89	19	patients	patient	NOUN
dpc-5639	89	20	’	'	PUNCT
dpc-5639	89	21	life	life	NOUN
dpc-5639	89	22	.	.	PUNCT
dpc-5639	90	1	in	in	ADP
dpc-5639	90	2	detail	detail	NOUN
dpc-5639	90	3	,	,	PUNCT
dpc-5639	90	4	dlqi	dlqi	ADJ
dpc-5639	90	5	≤2	≤2	NOUN
dpc-5639	90	6	was	be	AUX
dpc-5639	90	7	observed	observe	VERB
dpc-5639	90	8	in	in	ADP
dpc-5639	90	9	nine	nine	NUM
dpc-5639	90	10	(	(	PUNCT
dpc-5639	90	11	10	10	NUM
dpc-5639	90	12	%	%	NOUN
dpc-5639	90	13	)	)	PUNCT
dpc-5639	90	14	,	,	PUNCT
dpc-5639	90	15	dlqi	dlqi	VERB
dpc-5639	90	16	>	>	X
dpc-5639	90	17	2≤10	2≤10	NUM
dpc-5639	90	18	in	in	ADP
dpc-5639	90	19	45	45	NUM
dpc-5639	90	20	(	(	PUNCT
dpc-5639	90	21	50	50	NUM
dpc-5639	90	22	%	%	NOUN
dpc-5639	90	23	)	)	PUNCT
dpc-5639	90	24	,	,	PUNCT
dpc-5639	90	25	and	and	CCONJ
dpc-5639	90	26	dlqi	dlqi	VERB
dpc-5639	90	27	>	>	PROPN
dpc-5639	90	28	10	10	NUM
dpc-5639	90	29	in	in	ADP
dpc-5639	90	30	36	36	NUM
dpc-5639	90	31	(	(	PUNCT
dpc-5639	90	32	40	40	NUM
dpc-5639	90	33	%	%	NOUN
dpc-5639	90	34	)	)	PUNCT
dpc-5639	91	1	patients(table	patients(table	PROPN
dpc-5639	91	2	1	1	NUM
dpc-5639	91	3	)	)	PUNCT
dpc-5639	91	4	.	.	PUNCT
dpc-5639	92	1	all	all	DET
dpc-5639	92	2	patients	patient	NOUN
dpc-5639	92	3	had	have	AUX
dpc-5639	92	4	previously	previously	ADV
dpc-5639	92	5	under	under	ADV
dpc-5639	92	6	gone	go	VERB
dpc-5639	92	7	various	various	ADJ
dpc-5639	92	8	treatments	treatment	NOUN
dpc-5639	92	9	for	for	ADP
dpc-5639	92	10	pn	pn	PROPN
dpc-5639	92	11	,	,	PUNCT
dpc-5639	92	12	including	include	VERB
dpc-5639	92	13	topical	topical	ADJ
dpc-5639	92	14	corticosteroids	corticosteroid	NOUN
dpc-5639	92	15	(	(	PUNCT
dpc-5639	92	16	n=55	n=55	ADV
dpc-5639	92	17	,	,	PUNCT
dpc-5639	92	18	61.1	61.1	NUM
dpc-5639	92	19	%	%	NOUN
dpc-5639	92	20	)	)	PUNCT
dpc-5639	92	21	,	,	PUNCT
dpc-5639	92	22	antihistamines	antihistamine	NOUN
dpc-5639	92	23	(	(	PUNCT
dpc-5639	92	24	n=40	n=40	ADJ
dpc-5639	92	25	,	,	PUNCT
dpc-5639	92	26	44.4	44.4	NUM
dpc-5639	92	27	%	%	NOUN
dpc-5639	92	28	)	)	PUNCT
dpc-5639	92	29	,	,	PUNCT
dpc-5639	92	30	antidepressants	antidepressant	NOUN
dpc-5639	92	31	(	(	PUNCT
dpc-5639	92	32	n=49	n=49	NUM
dpc-5639	92	33	,	,	PUNCT
dpc-5639	92	34	54.4	54.4	NUM
dpc-5639	92	35	%	%	NOUN
dpc-5639	92	36	,	,	PUNCT
dpc-5639	92	37	of	of	ADP
dpc-5639	92	38	whom	whom	PRON
dpc-5639	92	39	94	94	NUM
dpc-5639	92	40	%	%	NOUN
dpc-5639	92	41	amitriptyline	amitriptyline	NOUN
dpc-5639	92	42	,	,	PUNCT
dpc-5639	92	43	4	4	NUM
dpc-5639	92	44	%	%	NOUN
dpc-5639	92	45	mirtazapine	mirtazapine	NOUN
dpc-5639	92	46	,	,	PUNCT
dpc-5639	92	47	and	and	CCONJ
dpc-5639	92	48	2	2	NUM
dpc-5639	92	49	%	%	NOUN
dpc-5639	92	50	escitalopram	escitalopram	NOUN
dpc-5639	92	51	)	)	PUNCT
dpc-5639	92	52	,	,	PUNCT
dpc-5639	92	53	systemic	systemic	ADJ
dpc-5639	92	54	corticosteroids	corticosteroid	NOUN
dpc-5639	92	55	(	(	PUNCT
dpc-5639	92	56	n=9	n=9	NOUN
dpc-5639	92	57	,	,	PUNCT
dpc-5639	92	58	10.0	10.0	NUM
dpc-5639	92	59	%	%	NOUN
dpc-5639	92	60	)	)	PUNCT
dpc-5639	92	61	,	,	PUNCT
dpc-5639	92	62	and	and	CCONJ
dpc-5639	92	63	other	other	ADJ
dpc-5639	92	64	immunosuppressants	immunosuppressant	NOUN
dpc-5639	92	65	(	(	PUNCT
dpc-5639	92	66	n=7	n=7	PROPN
dpc-5639	92	67	,	,	PUNCT
dpc-5639	92	68	7.8	7.8	NUM
dpc-5639	92	69	%	%	NOUN
dpc-5639	92	70	)	)	PUNCT
dpc-5639	92	71	.	.	PUNCT
dpc-5639	93	1	at	at	ADP
dpc-5639	93	2	w0	w0	PROPN
dpc-5639	93	3	,	,	PUNCT
dpc-5639	93	4	patients	patient	NOUN
dpc-5639	93	5	4	4	NUM
dpc-5639	93	6	original	original	ADJ
dpc-5639	93	7	article	article	NOUN
dpc-5639	93	8	|	|	ADV
dpc-5639	93	9	dermatol	dermatol	ADJ
dpc-5639	93	10	pract	pract	NOUN
dpc-5639	93	11	concept	concept	NOUN
dpc-5639	93	12	.	.	PUNCT
dpc-5639	94	1	2025;15(4):5639	2025;15(4):5639	NUM
dpc-5639	94	2	as	as	ADV
dpc-5639	94	3	well	well	ADV
dpc-5639	94	4	as	as	ADP
dpc-5639	94	5	in	in	ADP
dpc-5639	94	6	enhancing	enhance	VERB
dpc-5639	94	7	overall	overall	ADJ
dpc-5639	94	8	quality	quality	NOUN
dpc-5639	94	9	of	of	ADP
dpc-5639	94	10	life	life	NOUN
dpc-5639	94	11	.	.	PUNCT
dpc-5639	95	1	indeed	indeed	ADV
dpc-5639	95	2	,	,	PUNCT
dpc-5639	95	3	in	in	ADP
dpc-5639	95	4	two	two	NUM
dpc-5639	95	5	parallel	parallel	ADJ
dpc-5639	95	6	phase	phase	NOUN
dpc-5639	95	7	3	3	NUM
dpc-5639	95	8	trials	trial	NOUN
dpc-5639	95	9	of	of	ADP
dpc-5639	95	10	similar	similar	ADJ
dpc-5639	95	11	design	design	NOUN
dpc-5639	95	12	,	,	PUNCT
dpc-5639	95	13	liberty	liberty	NOUN
dpc-5639	95	14	-	-	PUNCT
dpc-5639	95	15	pn	pn	PROPN
dpc-5639	95	16	prime	prime	NOUN
dpc-5639	95	17	and	and	CCONJ
dpc-5639	95	18	prime2	prime2	PROPN
dpc-5639	95	19	,	,	PUNCT
dpc-5639	95	20	dupilumab	dupilumab	NOUN
dpc-5639	95	21	resulted	result	VERB
dpc-5639	95	22	in	in	ADP
dpc-5639	95	23	a	a	DET
dpc-5639	95	24	≥4	≥4	NOUN
dpc-5639	95	25	-	-	PUNCT
dpc-5639	95	26	point	point	NOUN
dpc-5639	95	27	worst	bad	ADJ
dpc-5639	95	28	itch	itch	NOUN
dpc-5639	95	29	(	(	PUNCT
dpc-5639	95	30	wi)-nrs	wi)-nrs	NOUN
dpc-5639	95	31	reduction	reduction	NOUN
dpc-5639	95	32	in	in	ADP
dpc-5639	95	33	60	60	NUM
dpc-5639	95	34	%	%	NOUN
dpc-5639	95	35	and	and	CCONJ
dpc-5639	95	36	18	18	NUM
dpc-5639	95	37	%	%	NOUN
dpc-5639	95	38	of	of	ADP
dpc-5639	95	39	patients	patient	NOUN
dpc-5639	95	40	(	(	PUNCT
dpc-5639	95	41	prime	prime	NOUN
dpc-5639	95	42	)	)	PUNCT
dpc-5639	95	43	or	or	CCONJ
dpc-5639	95	44	57.7	57.7	NUM
dpc-5639	95	45	%	%	NOUN
dpc-5639	95	46	and	and	CCONJ
dpc-5639	95	47	19.0	19.0	NUM
dpc-5639	95	48	%	%	NOUN
dpc-5639	95	49	(	(	PUNCT
dpc-5639	95	50	prime2	prime2	PROPN
dpc-5639	95	51	)	)	PUNCT
dpc-5639	95	52	at	at	ADP
dpc-5639	95	53	week	week	NOUN
dpc-5639	95	54	24	24	NUM
dpc-5639	95	55	,	,	PUNCT
dpc-5639	95	56	in	in	ADP
dpc-5639	95	57	the	the	DET
dpc-5639	95	58	dupilumab	dupilumab	NOUN
dpc-5639	95	59	and	and	CCONJ
dpc-5639	95	60	placebo	placebo	NOUN
dpc-5639	95	61	arms	arm	NOUN
dpc-5639	95	62	,	,	PUNCT
dpc-5639	95	63	respectively	respectively	ADV
dpc-5639	95	64	[	[	X
dpc-5639	95	65	12	12	NUM
dpc-5639	95	66	]	]	PUNCT
dpc-5639	95	67	.	.	PUNCT
dpc-5639	96	1	moreover	moreover	ADV
dpc-5639	96	2	,	,	PUNCT
dpc-5639	96	3	iga	iga	PROPN
dpc-5639	96	4	of	of	ADP
dpc-5639	96	5	clear	clear	ADJ
dpc-5639	96	6	-	-	PUNCT
dpc-5639	96	7	to	to	ADP
dpc-5639	96	8	-	-	PUNCT
dpc-5639	96	9	almost	almost	ADV
dpc-5639	96	10	clear	clear	ADJ
dpc-5639	96	11	(	(	PUNCT
dpc-5639	96	12	0–1	0–1	NOUN
dpc-5639	96	13	)	)	PUNCT
dpc-5639	96	14	was	be	AUX
dpc-5639	96	15	achieved	achieve	VERB
dpc-5639	96	16	in	in	ADP
dpc-5639	96	17	48	48	NUM
dpc-5639	96	18	%	%	NOUN
dpc-5639	96	19	vs	vs	ADP
dpc-5639	96	20	18.4	18.4	NUM
dpc-5639	96	21	%	%	NOUN
dpc-5639	96	22	as	as	ADV
dpc-5639	96	23	well	well	ADV
dpc-5639	96	24	as	as	ADP
dpc-5639	96	25	in	in	ADP
dpc-5639	96	26	44.9	44.9	NUM
dpc-5639	96	27	%	%	NOUN
dpc-5639	96	28	vs	vs	ADP
dpc-5639	96	29	15.9	15.9	NUM
dpc-5639	96	30	%	%	NOUN
dpc-5639	96	31	in	in	ADP
dpc-5639	96	32	the	the	DET
dpc-5639	96	33	two	two	NUM
dpc-5639	96	34	trials	trial	NOUN
dpc-5639	96	35	,	,	PUNCT
dpc-5639	96	36	respectively	respectively	ADV
dpc-5639	96	37	.	.	PUNCT
dpc-5639	97	1	dupilumab	dupilumab	NOUN
dpc-5639	97	2	-	-	PUNCT
dpc-5639	97	3	treated	treat	VERB
dpc-5639	97	4	patients	patient	NOUN
dpc-5639	97	5	also	also	ADV
dpc-5639	97	6	had	have	VERB
dpc-5639	97	7	significant	significant	ADJ
dpc-5639	97	8	improvements	improvement	NOUN
dpc-5639	97	9	in	in	ADP
dpc-5639	97	10	qol	qol	NOUN
dpc-5639	97	11	,	,	PUNCT
dpc-5639	97	12	as	as	SCONJ
dpc-5639	97	13	measured	measure	VERB
dpc-5639	97	14	by	by	ADP
dpc-5639	97	15	mean	mean	ADJ
dpc-5639	97	16	change	change	NOUN
dpc-5639	97	17	in	in	ADP
dpc-5639	97	18	dlqi	dlqi	ADJ
dpc-5639	97	19	score	score	NOUN
dpc-5639	97	20	from	from	ADP
dpc-5639	97	21	baseline	baseline	NOUN
dpc-5639	97	22	to	to	ADP
dpc-5639	97	23	week	week	NOUN
dpc-5639	97	24	24	24	NUM
dpc-5639	97	25	:	:	PUNCT
dpc-5639	97	26	prime	prime	ADJ
dpc-5639	97	27	,	,	PUNCT
dpc-5639	97	28	-12.0	-12.0	NOUN
dpc-5639	97	29	;	;	PUNCT
dpc-5639	97	30	prime2	prime2	PROPN
dpc-5639	97	31	,	,	PUNCT
dpc-5639	97	32	-13.2	-13.2	PUNCT
dpc-5639	97	33	.	.	PUNCT
dpc-5639	98	1	[	[	X
dpc-5639	98	2	12	12	NUM
dpc-5639	98	3	]	]	PUNCT
dpc-5639	98	4	.	.	PUNCT
dpc-5639	99	1	thus	thus	ADV
dpc-5639	99	2	,	,	PUNCT
dpc-5639	99	3	these	these	DET
dpc-5639	99	4	data	datum	NOUN
dpc-5639	99	5	confirmed	confirm	VERB
dpc-5639	99	6	the	the	DET
dpc-5639	99	7	involvement	involvement	NOUN
dpc-5639	99	8	of	of	ADP
dpc-5639	99	9	an	an	DET
dpc-5639	99	10	activated	activate	VERB
dpc-5639	99	11	th2	th2	PROPN
dpc-5639	99	12	cytokine	cytokine	ADJ
dpc-5639	99	13	pathway	pathway	NOUN
dpc-5639	99	14	in	in	ADP
dpc-5639	99	15	pn	pn	PROPN
dpc-5639	99	16	pathogenesis	pathogenesis	NOUN
dpc-5639	99	17	.	.	PUNCT
dpc-5639	100	1	however	however	ADV
dpc-5639	100	2	,	,	PUNCT
dpc-5639	100	3	although	although	SCONJ
dpc-5639	100	4	randomized	randomize	VERB
dpc-5639	100	5	controlled	control	VERB
dpc-5639	100	6	trials	trial	NOUN
dpc-5639	100	7	allow	allow	VERB
dpc-5639	100	8	assessing	assess	VERB
dpc-5639	100	9	treatment	treatment	NOUN
dpc-5639	100	10	efficacy	efficacy	NOUN
dpc-5639	100	11	,	,	PUNCT
dpc-5639	100	12	their	their	PRON
dpc-5639	100	13	applicability	applicability	NOUN
dpc-5639	100	14	is	be	AUX
dpc-5639	100	15	restricted	restrict	VERB
dpc-5639	100	16	to	to	ADP
dpc-5639	100	17	ideal	ideal	ADJ
dpc-5639	100	18	conditions	condition	NOUN
dpc-5639	100	19	,	,	PUNCT
dpc-5639	100	20	and	and	CCONJ
dpc-5639	100	21	this	this	PRON
dpc-5639	100	22	limits	limit	VERB
dpc-5639	100	23	their	their	PRON
dpc-5639	100	24	ability	ability	NOUN
dpc-5639	100	25	to	to	PART
dpc-5639	100	26	portray	portray	VERB
dpc-5639	100	27	what	what	PRON
dpc-5639	100	28	happens	happen	VERB
dpc-5639	100	29	in	in	ADP
dpc-5639	100	30	the	the	DET
dpc-5639	100	31	real	real	ADJ
dpc-5639	100	32	world	world	NOUN
dpc-5639	100	33	.	.	PUNCT
dpc-5639	101	1	moreover	moreover	ADV
dpc-5639	101	2	,	,	PUNCT
dpc-5639	101	3	as	as	SCONJ
dpc-5639	101	4	strict	strict	ADJ
dpc-5639	101	5	inclusion	inclusion	NOUN
dpc-5639	101	6	and	and	CCONJ
dpc-5639	101	7	exclusion	exclusion	NOUN
dpc-5639	101	8	criteria	criterion	NOUN
dpc-5639	101	9	might	might	AUX
dpc-5639	101	10	limit	limit	VERB
dpc-5639	101	11	generalizability	generalizability	NOUN
dpc-5639	101	12	and	and	CCONJ
dpc-5639	101	13	applicability	applicability	NOUN
dpc-5639	101	14	of	of	ADP
dpc-5639	101	15	trial	trial	NOUN
dpc-5639	101	16	results	result	NOUN
dpc-5639	101	17	to	to	ADP
dpc-5639	101	18	the	the	DET
dpc-5639	101	19	broader	broad	ADJ
dpc-5639	101	20	pn	pn	NOUN
dpc-5639	101	21	population	population	NOUN
dpc-5639	101	22	,	,	PUNCT
dpc-5639	101	23	disease	disease	NOUN
dpc-5639	101	24	treatment	treatment	NOUN
dpc-5639	101	25	remains	remain	VERB
dpc-5639	101	26	difficult	difficult	ADJ
dpc-5639	101	27	and	and	CCONJ
dpc-5639	101	28	unsatisfactory	unsatisfactory	ADJ
dpc-5639	101	29	.	.	PUNCT
dpc-5639	102	1	in	in	ADP
dpc-5639	102	2	our	our	PRON
dpc-5639	102	3	real	real	ADJ
dpc-5639	102	4	-	-	PUNCT
dpc-5639	102	5	life	life	NOUN
dpc-5639	102	6	setting	setting	NOUN
dpc-5639	102	7	,	,	PUNCT
dpc-5639	102	8	40.0	40.0	NUM
dpc-5639	102	9	%	%	NOUN
dpc-5639	102	10	of	of	ADP
dpc-5639	102	11	patients	patient	NOUN
dpc-5639	102	12	presented	present	VERB
dpc-5639	102	13	grade	grade	NOUN
dpc-5639	102	14	2	2	NUM
dpc-5639	102	15	and	and	CCONJ
dpc-5639	102	16	21.2	21.2	NUM
dpc-5639	102	17	%	%	NOUN
dpc-5639	102	18	grade	grade	NOUN
dpc-5639	102	19	3	3	NUM
dpc-5639	102	20	iga	iga	PROPN
dpc-5639	102	21	scores	score	NOUN
dpc-5639	102	22	at	at	ADP
dpc-5639	102	23	baseline	baseline	NOUN
dpc-5639	102	24	;	;	PUNCT
dpc-5639	102	25	81.1	81.1	NUM
dpc-5639	102	26	%	%	NOUN
dpc-5639	102	27	had	have	VERB
dpc-5639	102	28	an	an	DET
dpc-5639	102	29	nrs	nrs	NOUN
dpc-5639	102	30	itching	itching	NOUN
dpc-5639	102	31	score	score	NOUN
dpc-5639	102	32	between	between	ADP
dpc-5639	102	33	6–10	6–10	NOUN
dpc-5639	102	34	,	,	PUNCT
dpc-5639	102	35	suggesting	suggest	VERB
dpc-5639	102	36	a	a	DET
dpc-5639	102	37	moderate	moderate	ADJ
dpc-5639	102	38	-	-	PUNCT
dpc-5639	102	39	to	to	ADP
dpc-5639	102	40	-	-	PUNCT
dpc-5639	102	41	severe	severe	ADJ
dpc-5639	102	42	disease	disease	NOUN
dpc-5639	102	43	with	with	ADP
dpc-5639	102	44	a	a	DET
dpc-5639	102	45	very	very	ADV
dpc-5639	102	46	high	high	ADJ
dpc-5639	102	47	level	level	NOUN
dpc-5639	102	48	of	of	ADP
dpc-5639	102	49	pruritus	pruritus	PROPN
dpc-5639	102	50	.	.	PUNCT
dpc-5639	103	1	in	in	ADP
dpc-5639	103	2	line	line	NOUN
dpc-5639	103	3	with	with	ADP
dpc-5639	103	4	the	the	DET
dpc-5639	103	5	literature	literature	NOUN
dpc-5639	103	6	,	,	PUNCT
dpc-5639	103	7	topical	topical	ADJ
dpc-5639	103	8	corticosteroids	corticosteroid	NOUN
dpc-5639	103	9	,	,	PUNCT
dpc-5639	103	10	antidepressants	antidepressant	NOUN
dpc-5639	103	11	,	,	PUNCT
dpc-5639	103	12	and	and	CCONJ
dpc-5639	103	13	antihistamines	antihistamine	NOUN
dpc-5639	103	14	were	be	AUX
dpc-5639	103	15	the	the	DET
dpc-5639	103	16	treatments	treatment	NOUN
dpc-5639	103	17	most	most	ADV
dpc-5639	103	18	frequently	frequently	ADV
dpc-5639	103	19	used	use	VERB
dpc-5639	103	20	previously	previously	ADV
dpc-5639	103	21	.	.	PUNCT
dpc-5639	104	1	at	at	ADP
dpc-5639	104	2	w0	w0	PROPN
dpc-5639	104	3	,	,	PUNCT
dpc-5639	104	4	patients	patient	NOUN
dpc-5639	104	5	enrolled	enrol	VERB
dpc-5639	104	6	in	in	ADP
dpc-5639	104	7	the	the	DET
dpc-5639	104	8	study	study	NOUN
dpc-5639	104	9	were	be	AUX
dpc-5639	104	10	prescribed	prescribe	VERB
dpc-5639	104	11	with	with	ADP
dpc-5639	104	12	antidepressants	antidepressant	NOUN
dpc-5639	104	13	(	(	PUNCT
dpc-5639	104	14	41.0	41.0	NUM
dpc-5639	104	15	%	%	NOUN
dpc-5639	104	16	)	)	PUNCT
dpc-5639	104	17	,	,	PUNCT
dpc-5639	104	18	dupilumab	dupilumab	NOUN
dpc-5639	104	19	(	(	PUNCT
dpc-5639	104	20	34.0	34.0	NUM
dpc-5639	104	21	%	%	NOUN
dpc-5639	104	22	)	)	PUNCT
dpc-5639	104	23	,	,	PUNCT
dpc-5639	104	24	antihistamines	antihistamine	NOUN
dpc-5639	104	25	(	(	PUNCT
dpc-5639	104	26	23.0	23.0	NUM
dpc-5639	104	27	%	%	NOUN
dpc-5639	104	28	)	)	PUNCT
dpc-5639	104	29	,	,	PUNCT
dpc-5639	104	30	phototherapy	phototherapy	NOUN
dpc-5639	104	31	(	(	PUNCT
dpc-5639	104	32	4.0	4.0	NUM
dpc-5639	104	33	%	%	NOUN
dpc-5639	104	34	)	)	PUNCT
dpc-5639	104	35	,	,	PUNCT
dpc-5639	104	36	or	or	CCONJ
dpc-5639	104	37	nemolizumab	nemolizumab	NOUN
dpc-5639	104	38	(	(	PUNCT
dpc-5639	104	39	2.0	2.0	NUM
dpc-5639	104	40	%	%	NOUN
dpc-5639	104	41	)	)	PUNCT
dpc-5639	104	42	.	.	PUNCT
dpc-5639	105	1	we	we	PRON
dpc-5639	105	2	therefore	therefore	ADV
dpc-5639	105	3	decided	decide	VERB
dpc-5639	105	4	to	to	PART
dpc-5639	105	5	verify	verify	VERB
dpc-5639	105	6	the	the	DET
dpc-5639	105	7	improvement	improvement	NOUN
dpc-5639	105	8	of	of	ADP
dpc-5639	105	9	the	the	DET
dpc-5639	105	10	selected	select	VERB
dpc-5639	105	11	study	study	NOUN
dpc-5639	105	12	indices	indice	VERB
dpc-5639	105	13	in	in	ADP
dpc-5639	105	14	the	the	DET
dpc-5639	105	15	two	two	NUM
dpc-5639	105	16	most	most	ADV
dpc-5639	105	17	represented	represent	VERB
dpc-5639	105	18	treatment	treatment	NOUN
dpc-5639	105	19	groups	group	NOUN
dpc-5639	105	20	(	(	PUNCT
dpc-5639	105	21	antidepressants	antidepressant	NOUN
dpc-5639	105	22	and	and	CCONJ
dpc-5639	105	23	dupilumab	dupilumab	NOUN
dpc-5639	105	24	)	)	PUNCT
dpc-5639	105	25	.	.	PUNCT
dpc-5639	106	1	our	our	PRON
dpc-5639	106	2	results	result	NOUN
dpc-5639	106	3	demonstrated	demonstrate	VERB
dpc-5639	106	4	a	a	DET
dpc-5639	106	5	significantly	significantly	ADV
dpc-5639	106	6	greater	great	ADJ
dpc-5639	106	7	reduction	reduction	NOUN
dpc-5639	106	8	in	in	ADP
dpc-5639	106	9	all	all	DET
dpc-5639	106	10	disease	disease	NOUN
dpc-5639	106	11	parameters	parameter	NOUN
dpc-5639	106	12	in	in	ADP
dpc-5639	106	13	the	the	DET
dpc-5639	106	14	patients	patient	NOUN
dpc-5639	106	15	treated	treat	VERB
dpc-5639	106	16	with	with	ADP
dpc-5639	106	17	dupilumab	dupilumab	NOUN
dpc-5639	106	18	compared	compare	VERB
dpc-5639	106	19	to	to	ADP
dpc-5639	106	20	those	those	PRON
dpc-5639	106	21	treated	treat	VERB
dpc-5639	106	22	with	with	ADP
dpc-5639	106	23	antidepressants	antidepressant	NOUN
dpc-5639	106	24	.	.	PUNCT
dpc-5639	107	1	in	in	ADP
dpc-5639	107	2	particular	particular	ADJ
dpc-5639	107	3	,	,	PUNCT
dpc-5639	107	4	after	after	ADP
dpc-5639	107	5	24	24	NUM
dpc-5639	107	6	weeks	week	NOUN
dpc-5639	107	7	of	of	ADP
dpc-5639	107	8	treatment	treatment	NOUN
dpc-5639	107	9	,	,	PUNCT
dpc-5639	107	10	44.5	44.5	NUM
dpc-5639	107	11	%	%	NOUN
dpc-5639	107	12	of	of	ADP
dpc-5639	107	13	dupilumab	dupilumab	NOUN
dpc-5639	107	14	-	-	PUNCT
dpc-5639	107	15	treated	treat	VERB
dpc-5639	107	16	patients	patient	NOUN
dpc-5639	107	17	achieved	achieve	VERB
dpc-5639	107	18	an	an	DET
dpc-5639	107	19	iga	iga	PROPN
dpc-5639	107	20	score	score	NOUN
dpc-5639	107	21	of	of	ADP
dpc-5639	107	22	0	0	NUM
dpc-5639	107	23	or	or	CCONJ
dpc-5639	107	24	1	1	NUM
dpc-5639	107	25	,	,	PUNCT
dpc-5639	107	26	indicating	indicate	VERB
dpc-5639	107	27	clear	clear	ADJ
dpc-5639	107	28	or	or	CCONJ
dpc-5639	107	29	almost	almost	ADV
dpc-5639	107	30	clear	clear	ADJ
dpc-5639	107	31	skin	skin	NOUN
dpc-5639	107	32	,	,	PUNCT
dpc-5639	107	33	vs	vs	ADP
dpc-5639	107	34	16.7	16.7	NUM
dpc-5639	107	35	%	%	NOUN
dpc-5639	107	36	of	of	ADP
dpc-5639	107	37	those	those	PRON
dpc-5639	107	38	on	on	ADP
dpc-5639	107	39	antidepressants	antidepressant	NOUN
dpc-5639	107	40	.	.	PUNCT
dpc-5639	108	1	moreover	moreover	ADV
dpc-5639	108	2	,	,	PUNCT
dpc-5639	108	3	regarding	regard	VERB
dpc-5639	108	4	pruritus	pruritus	NOUN
dpc-5639	108	5	and	and	CCONJ
dpc-5639	108	6	scratching	scratching	NOUN
dpc-5639	108	7	,	,	PUNCT
dpc-5639	108	8	54.4	54.4	NUM
dpc-5639	108	9	%	%	NOUN
dpc-5639	108	10	of	of	ADP
dpc-5639	108	11	patients	patient	NOUN
dpc-5639	108	12	receiving	receive	VERB
dpc-5639	108	13	dupilumab	dupilumab	NOUN
dpc-5639	108	14	had	have	VERB
dpc-5639	108	15	a	a	DET
dpc-5639	108	16	≥4	≥4	ADJ
dpc-5639	108	17	-	-	PUNCT
dpc-5639	108	18	point	point	NOUN
dpc-5639	108	19	nrs	nrs	NOUN
dpc-5639	108	20	reduction	reduction	NOUN
dpc-5639	108	21	compared	compare	VERB
dpc-5639	108	22	to	to	ADP
dpc-5639	108	23	16.7	16.7	NUM
dpc-5639	108	24	%	%	NOUN
dpc-5639	108	25	of	of	ADP
dpc-5639	108	26	patients	patient	NOUN
dpc-5639	108	27	on	on	ADP
dpc-5639	108	28	antidepressant	antidepressant	ADJ
dpc-5639	108	29	therapy	therapy	NOUN
dpc-5639	108	30	.	.	PUNCT
dpc-5639	109	1	as	as	SCONJ
dpc-5639	109	2	expected	expect	VERB
dpc-5639	109	3	,	,	PUNCT
dpc-5639	109	4	pruritus	pruritus	NOUN
dpc-5639	109	5	relief	relief	NOUN
dpc-5639	109	6	greatly	greatly	ADV
dpc-5639	109	7	improved	improve	VERB
dpc-5639	109	8	patients	patient	NOUN
dpc-5639	109	9	’	'	PUNCT
dpc-5639	109	10	qol	qol	PROPN
dpc-5639	109	11	.	.	PUNCT
dpc-5639	110	1	indeed	indeed	ADV
dpc-5639	110	2	,	,	PUNCT
dpc-5639	110	3	the	the	DET
dpc-5639	110	4	mean	mean	ADJ
dpc-5639	110	5	dlqi	dlqi	ADJ
dpc-5639	110	6	score	score	NOUN
dpc-5639	110	7	at	at	ADP
dpc-5639	110	8	w24	w24	PROPN
dpc-5639	110	9	was	be	AUX
dpc-5639	110	10	reduced	reduce	VERB
dpc-5639	110	11	by	by	ADP
dpc-5639	110	12	14	14	NUM
dpc-5639	110	13	points	point	NOUN
dpc-5639	110	14	in	in	ADP
dpc-5639	110	15	the	the	DET
dpc-5639	110	16	dupilumab	dupilumab	NOUN
dpc-5639	110	17	group	group	NOUN
dpc-5639	110	18	,	,	PUNCT
dpc-5639	110	19	compared	compare	VERB
dpc-5639	110	20	to	to	ADP
dpc-5639	110	21	the	the	DET
dpc-5639	110	22	6	6	NUM
dpc-5639	110	23	-	-	PUNCT
dpc-5639	110	24	point	point	NOUN
dpc-5639	110	25	reduction	reduction	NOUN
dpc-5639	110	26	we	we	PRON
dpc-5639	110	27	found	find	VERB
dpc-5639	110	28	in	in	ADP
dpc-5639	110	29	the	the	DET
dpc-5639	110	30	antidepressant	antidepressant	ADJ
dpc-5639	110	31	group	group	NOUN
dpc-5639	110	32	.	.	PUNCT
dpc-5639	111	1	these	these	DET
dpc-5639	111	2	findings	finding	NOUN
dpc-5639	111	3	are	be	AUX
dpc-5639	111	4	partially	partially	ADV
dpc-5639	111	5	in	in	ADP
dpc-5639	111	6	line	line	NOUN
dpc-5639	111	7	with	with	ADP
dpc-5639	111	8	previous	previous	ADJ
dpc-5639	111	9	studies	study	NOUN
dpc-5639	111	10	.	.	PUNCT
dpc-5639	112	1	in	in	ADP
dpc-5639	112	2	a	a	DET
dpc-5639	112	3	real	real	ADJ
dpc-5639	112	4	-	-	PUNCT
dpc-5639	112	5	world	world	NOUN
dpc-5639	112	6	observational	observational	ADJ
dpc-5639	112	7	study	study	NOUN
dpc-5639	112	8	,	,	PUNCT
dpc-5639	112	9	zhang	zhang	PROPN
dpc-5639	112	10	et	et	PROPN
dpc-5639	112	11	al	al	PROPN
dpc-5639	112	12	.	.	PROPN
dpc-5639	112	13	demonstrated	demonstrate	VERB
dpc-5639	112	14	a	a	DET
dpc-5639	112	15	significant	significant	ADJ
dpc-5639	112	16	reduction	reduction	NOUN
dpc-5639	112	17	in	in	ADP
dpc-5639	112	18	iga	iga	PROPN
dpc-5639	112	19	score	score	NOUN
dpc-5639	112	20	,	,	PUNCT
dpc-5639	112	21	mean	mean	VERB
dpc-5639	112	22	nrs	nrs	PROPN
dpc-5639	112	23	itch	itch	NOUN
dpc-5639	112	24	intensity	intensity	NOUN
dpc-5639	112	25	(	(	PUNCT
dpc-5639	112	26	nrsi	nrsi	ADJ
dpc-5639	112	27	)	)	PUNCT
dpc-5639	112	28	,	,	PUNCT
dpc-5639	112	29	and	and	CCONJ
dpc-5639	112	30	dlqi	dlqi	VERB
dpc-5639	112	31	,	,	PUNCT
dpc-5639	112	32	from	from	ADP
dpc-5639	112	33	3.75	3.75	NUM
dpc-5639	112	34	,	,	PUNCT
dpc-5639	112	35	8.625	8.625	NUM
dpc-5639	112	36	and	and	CCONJ
dpc-5639	112	37	15.13	15.13	NUM
dpc-5639	112	38	to	to	ADP
dpc-5639	112	39	1.50	1.50	NUM
dpc-5639	112	40	,	,	PUNCT
dpc-5639	112	41	1.563	1.563	NUM
dpc-5639	112	42	,	,	PUNCT
dpc-5639	112	43	and	and	CCONJ
dpc-5639	112	44	4.625	4.625	NUM
dpc-5639	112	45	,	,	PUNCT
dpc-5639	112	46	respectively	respectively	ADV
dpc-5639	112	47	,	,	PUNCT
dpc-5639	112	48	in	in	ADP
dpc-5639	112	49	eight	eight	NUM
dpc-5639	112	50	adult	adult	NOUN
dpc-5639	112	51	patients	patient	NOUN
dpc-5639	112	52	diagnosed	diagnose	VERB
dpc-5639	112	53	with	with	ADP
dpc-5639	112	54	pn	pn	PROPN
dpc-5639	112	55	after	after	ADP
dpc-5639	112	56	16	16	NUM
dpc-5639	112	57	weeks	week	NOUN
dpc-5639	112	58	of	of	ADP
dpc-5639	112	59	treatment	treatment	NOUN
dpc-5639	112	60	were	be	AUX
dpc-5639	112	61	prescribed	prescribe	VERB
dpc-5639	112	62	as	as	SCONJ
dpc-5639	112	63	follows	follow	VERB
dpc-5639	112	64	:	:	PUNCT
dpc-5639	112	65	37	37	NUM
dpc-5639	112	66	(	(	PUNCT
dpc-5639	112	67	41.0	41.0	NUM
dpc-5639	112	68	%	%	NOUN
dpc-5639	112	69	)	)	PUNCT
dpc-5639	112	70	antidepressants	antidepressant	NOUN
dpc-5639	112	71	,	,	PUNCT
dpc-5639	112	72	30	30	NUM
dpc-5639	112	73	(	(	PUNCT
dpc-5639	112	74	34.0	34.0	NUM
dpc-5639	112	75	%	%	NOUN
dpc-5639	112	76	)	)	PUNCT
dpc-5639	112	77	dupilumab	dupilumab	NOUN
dpc-5639	112	78	,	,	PUNCT
dpc-5639	112	79	21	21	NUM
dpc-5639	112	80	(	(	PUNCT
dpc-5639	112	81	23.0	23.0	NUM
dpc-5639	112	82	%	%	NOUN
dpc-5639	112	83	)	)	PUNCT
dpc-5639	112	84	antihistamines	antihistamine	NOUN
dpc-5639	112	85	(	(	PUNCT
dpc-5639	112	86	57.0	57.0	NUM
dpc-5639	112	87	%	%	NOUN
dpc-5639	112	88	sedating	sedating	NOUN
dpc-5639	112	89	and	and	CCONJ
dpc-5639	112	90	43.0	43.0	NUM
dpc-5639	112	91	%	%	NOUN
dpc-5639	112	92	non	non	ADJ
dpc-5639	112	93	-	-	NOUN
dpc-5639	112	94	sedating	sedating	ADJ
dpc-5639	112	95	)	)	PUNCT
dpc-5639	112	96	,	,	PUNCT
dpc-5639	112	97	four	four	NUM
dpc-5639	112	98	(	(	PUNCT
dpc-5639	112	99	4.0	4.0	NUM
dpc-5639	112	100	%	%	NOUN
dpc-5639	112	101	)	)	PUNCT
dpc-5639	112	102	phototherapy	phototherapy	NOUN
dpc-5639	112	103	,	,	PUNCT
dpc-5639	112	104	and	and	CCONJ
dpc-5639	112	105	two	two	NUM
dpc-5639	112	106	(	(	PUNCT
dpc-5639	112	107	2.0	2.0	NUM
dpc-5639	112	108	%	%	NOUN
dpc-5639	112	109	)	)	PUNCT
dpc-5639	112	110	,	,	PUNCT
dpc-5639	112	111	nemolizumab	nemolizumab	NOUN
dpc-5639	112	112	(	(	PUNCT
dpc-5639	112	113	figure	figure	NOUN
dpc-5639	112	114	1	1	NUM
dpc-5639	112	115	)	)	PUNCT
dpc-5639	112	116	.	.	PUNCT
dpc-5639	113	1	the	the	DET
dpc-5639	113	2	latter	latter	ADJ
dpc-5639	113	3	were	be	AUX
dpc-5639	113	4	two	two	NUM
dpc-5639	113	5	patients	patient	NOUN
dpc-5639	113	6	referred	refer	VERB
dpc-5639	113	7	by	by	ADP
dpc-5639	113	8	the	the	DET
dpc-5639	113	9	dermatologist	dermatologist	NOUN
dpc-5639	113	10	to	to	PART
dpc-5639	113	11	participate	participate	VERB
dpc-5639	113	12	in	in	ADP
dpc-5639	113	13	a	a	DET
dpc-5639	113	14	clinical	clinical	ADJ
dpc-5639	113	15	trial	trial	NOUN
dpc-5639	113	16	evaluating	evaluate	VERB
dpc-5639	113	17	the	the	DET
dpc-5639	113	18	efficacy	efficacy	NOUN
dpc-5639	113	19	and	and	CCONJ
dpc-5639	113	20	safety	safety	NOUN
dpc-5639	113	21	of	of	ADP
dpc-5639	113	22	nemolizumab	nemolizumab	NOUN
dpc-5639	113	23	for	for	ADP
dpc-5639	113	24	the	the	DET
dpc-5639	113	25	treatment	treatment	NOUN
dpc-5639	113	26	of	of	ADP
dpc-5639	113	27	pn	pn	PROPN
dpc-5639	113	28	(	(	PUNCT
dpc-5639	113	29	nct04921345	nct04921345	ADJ
dpc-5639	113	30	)	)	PUNCT
dpc-5639	113	31	.	.	PUNCT
dpc-5639	114	1	thus	thus	ADV
dpc-5639	114	2	,	,	PUNCT
dpc-5639	114	3	since	since	SCONJ
dpc-5639	114	4	75	75	NUM
dpc-5639	114	5	%	%	NOUN
dpc-5639	114	6	of	of	ADP
dpc-5639	114	7	patients	patient	NOUN
dpc-5639	114	8	were	be	AUX
dpc-5639	114	9	in	in	ADP
dpc-5639	114	10	treatment	treatment	NOUN
dpc-5639	114	11	with	with	ADP
dpc-5639	114	12	antidepressants	antidepressant	NOUN
dpc-5639	114	13	or	or	CCONJ
dpc-5639	114	14	dupilumab	dupilumab	NOUN
dpc-5639	114	15	,	,	PUNCT
dpc-5639	114	16	the	the	DET
dpc-5639	114	17	subsequent	subsequent	ADJ
dpc-5639	114	18	analysis	analysis	NOUN
dpc-5639	114	19	was	be	AUX
dpc-5639	114	20	performed	perform	VERB
dpc-5639	114	21	on	on	ADP
dpc-5639	114	22	this	this	DET
dpc-5639	114	23	subpopulation	subpopulation	NOUN
dpc-5639	114	24	.	.	PUNCT
dpc-5639	115	1	at	at	ADP
dpc-5639	115	2	w24	w24	PROPN
dpc-5639	115	3	,	,	PUNCT
dpc-5639	115	4	after	after	ADP
dpc-5639	115	5	six	six	NUM
dpc-5639	115	6	months	month	NOUN
dpc-5639	115	7	of	of	ADP
dpc-5639	115	8	treatment	treatment	NOUN
dpc-5639	115	9	,	,	PUNCT
dpc-5639	115	10	iga	iga	PROPN
dpc-5639	115	11	0–1	0–1	PROPN
dpc-5639	115	12	was	be	AUX
dpc-5639	115	13	attained	attain	VERB
dpc-5639	115	14	by	by	ADP
dpc-5639	115	15	14	14	NUM
dpc-5639	115	16	(	(	PUNCT
dpc-5639	115	17	44.5	44.5	NUM
dpc-5639	115	18	%	%	NOUN
dpc-5639	115	19	)	)	PUNCT
dpc-5639	115	20	patients	patient	NOUN
dpc-5639	115	21	on	on	ADP
dpc-5639	115	22	dupilumab	dupilumab	NOUN
dpc-5639	115	23	,	,	PUNCT
dpc-5639	115	24	indicating	indicate	VERB
dpc-5639	115	25	clear	clear	ADJ
dpc-5639	115	26	or	or	CCONJ
dpc-5639	115	27	almost	almost	ADV
dpc-5639	115	28	clear	clear	ADJ
dpc-5639	115	29	skin	skin	NOUN
dpc-5639	115	30	,	,	PUNCT
dpc-5639	115	31	compared	compare	VERB
dpc-5639	115	32	to	to	ADP
dpc-5639	115	33	six	six	NUM
dpc-5639	115	34	(	(	PUNCT
dpc-5639	115	35	16.7	16.7	NUM
dpc-5639	115	36	%	%	NOUN
dpc-5639	115	37	)	)	PUNCT
dpc-5639	115	38	of	of	ADP
dpc-5639	115	39	those	those	PRON
dpc-5639	115	40	on	on	ADP
dpc-5639	115	41	antidepressants	antidepressant	NOUN
dpc-5639	115	42	(	(	PUNCT
dpc-5639	115	43	figure	figure	NOUN
dpc-5639	115	44	2	2	NUM
dpc-5639	115	45	;	;	PUNCT
dpc-5639	115	46	*	*	PUNCT
dpc-5639	115	47	*	*	PUNCT
dpc-5639	115	48	p<0.01	p<0.01	PROPN
dpc-5639	115	49	)	)	PUNCT
dpc-5639	115	50	.	.	PUNCT
dpc-5639	116	1	furthermore	furthermore	ADV
dpc-5639	116	2	,	,	PUNCT
dpc-5639	116	3	16	16	NUM
dpc-5639	116	4	(	(	PUNCT
dpc-5639	116	5	54.4	54.4	NUM
dpc-5639	116	6	%	%	NOUN
dpc-5639	116	7	)	)	PUNCT
dpc-5639	116	8	patients	patient	NOUN
dpc-5639	116	9	receiving	receive	VERB
dpc-5639	116	10	dupilumab	dupilumab	NOUN
dpc-5639	116	11	had	have	VERB
dpc-5639	116	12	a	a	DET
dpc-5639	116	13	≥4	≥4	ADJ
dpc-5639	116	14	-	-	PUNCT
dpc-5639	116	15	point	point	NOUN
dpc-5639	116	16	nrs	nrs	NOUN
dpc-5639	116	17	reduction	reduction	NOUN
dpc-5639	116	18	compared	compare	VERB
dpc-5639	116	19	to	to	ADP
dpc-5639	116	20	six	six	NUM
dpc-5639	116	21	(	(	PUNCT
dpc-5639	116	22	16.7	16.7	NUM
dpc-5639	116	23	%	%	NOUN
dpc-5639	116	24	)	)	PUNCT
dpc-5639	116	25	patients	patient	NOUN
dpc-5639	116	26	on	on	ADP
dpc-5639	116	27	antidepressant	antidepressant	ADJ
dpc-5639	116	28	therapy	therapy	NOUN
dpc-5639	116	29	(	(	PUNCT
dpc-5639	116	30	figure	figure	NOUN
dpc-5639	116	31	3	3	NUM
dpc-5639	116	32	;	;	PUNCT
dpc-5639	116	33	*	*	PUNCT
dpc-5639	116	34	*	*	PUNCT
dpc-5639	116	35	p<0.01	p<0.01	PROPN
dpc-5639	116	36	)	)	PUNCT
dpc-5639	117	1	[	[	X
dpc-5639	117	2	14	14	NUM
dpc-5639	117	3	]	]	PUNCT
dpc-5639	117	4	.	.	PUNCT
dpc-5639	118	1	in	in	ADP
dpc-5639	118	2	terms	term	NOUN
dpc-5639	118	3	of	of	ADP
dpc-5639	118	4	the	the	DET
dpc-5639	118	5	impact	impact	NOUN
dpc-5639	118	6	on	on	ADP
dpc-5639	118	7	quality	quality	NOUN
dpc-5639	118	8	of	of	ADP
dpc-5639	118	9	life	life	NOUN
dpc-5639	118	10	,	,	PUNCT
dpc-5639	118	11	the	the	DET
dpc-5639	118	12	average	average	ADJ
dpc-5639	118	13	dlqi	dlqi	ADJ
dpc-5639	118	14	score	score	NOUN
dpc-5639	118	15	at	at	ADP
dpc-5639	118	16	w24	w24	PROPN
dpc-5639	118	17	was	be	AUX
dpc-5639	118	18	reduced	reduce	VERB
dpc-5639	118	19	by	by	ADP
dpc-5639	118	20	14	14	NUM
dpc-5639	118	21	points	point	NOUN
dpc-5639	118	22	in	in	ADP
dpc-5639	118	23	the	the	DET
dpc-5639	118	24	dupilumab	dupilumab	NOUN
dpc-5639	118	25	group	group	NOUN
dpc-5639	118	26	,	,	PUNCT
dpc-5639	118	27	compared	compare	VERB
dpc-5639	118	28	to	to	ADP
dpc-5639	118	29	a	a	DET
dpc-5639	118	30	6	6	NUM
dpc-5639	118	31	-	-	PUNCT
dpc-5639	118	32	point	point	NOUN
dpc-5639	118	33	reduction	reduction	NOUN
dpc-5639	118	34	in	in	ADP
dpc-5639	118	35	the	the	DET
dpc-5639	118	36	antidepressant	antidepressant	ADJ
dpc-5639	118	37	one	one	NOUN
dpc-5639	118	38	(	(	PUNCT
dpc-5639	118	39	figure	figure	NOUN
dpc-5639	118	40	4	4	NUM
dpc-5639	118	41	,	,	PUNCT
dpc-5639	118	42	*	*	PUNCT
dpc-5639	118	43	*	*	PUNCT
dpc-5639	118	44	*	*	PUNCT
dpc-5639	118	45	p<0.1	p<0.1	NUM
dpc-5639	118	46	)	)	PUNCT
dpc-5639	118	47	.	.	PUNCT
dpc-5639	119	1	patients	patient	NOUN
dpc-5639	119	2	withdrawing	withdraw	VERB
dpc-5639	119	3	from	from	ADP
dpc-5639	119	4	the	the	DET
dpc-5639	119	5	study	study	NOUN
dpc-5639	119	6	were	be	AUX
dpc-5639	119	7	defined	define	VERB
dpc-5639	119	8	as	as	ADP
dpc-5639	119	9	non	non	NOUN
dpc-5639	119	10	-	-	NOUN
dpc-5639	119	11	responders	responder	NOUN
dpc-5639	119	12	according	accord	VERB
dpc-5639	119	13	to	to	ADP
dpc-5639	119	14	the	the	DET
dpc-5639	119	15	non	non	ADJ
dpc-5639	119	16	-	-	ADJ
dpc-5639	119	17	responder	responder	ADJ
dpc-5639	119	18	imputation	imputation	NOUN
dpc-5639	119	19	method	method	NOUN
dpc-5639	119	20	.	.	PUNCT
dpc-5639	120	1	discussion	discussion	NOUN
dpc-5639	120	2	in	in	ADP
dpc-5639	120	3	this	this	DET
dpc-5639	120	4	prospective	prospective	ADJ
dpc-5639	120	5	observational	observational	ADJ
dpc-5639	120	6	study	study	NOUN
dpc-5639	120	7	,	,	PUNCT
dpc-5639	120	8	we	we	PRON
dpc-5639	120	9	assessed	assess	VERB
dpc-5639	120	10	the	the	DET
dpc-5639	120	11	therapeutic	therapeutic	ADJ
dpc-5639	120	12	management	management	NOUN
dpc-5639	120	13	of	of	ADP
dpc-5639	120	14	pn	pn	PROPN
dpc-5639	120	15	in	in	ADP
dpc-5639	120	16	a	a	DET
dpc-5639	120	17	real	real	ADJ
dpc-5639	120	18	-	-	PUNCT
dpc-5639	120	19	world	world	NOUN
dpc-5639	120	20	setting	setting	NOUN
dpc-5639	120	21	since	since	SCONJ
dpc-5639	120	22	it	it	PRON
dpc-5639	120	23	still	still	ADV
dpc-5639	120	24	poses	pose	VERB
dpc-5639	120	25	considerable	considerable	ADJ
dpc-5639	120	26	challenges	challenge	NOUN
dpc-5639	120	27	for	for	ADP
dpc-5639	120	28	both	both	DET
dpc-5639	120	29	patients	patient	NOUN
dpc-5639	120	30	and	and	CCONJ
dpc-5639	120	31	physicians	physician	NOUN
dpc-5639	120	32	.	.	PUNCT
dpc-5639	121	1	indeed	indeed	ADV
dpc-5639	121	2	,	,	PUNCT
dpc-5639	121	3	until	until	ADP
dpc-5639	121	4	fda	fda	PROPN
dpc-5639	121	5	approval	approval	NOUN
dpc-5639	121	6	of	of	ADP
dpc-5639	121	7	dupilumab	dupilumab	NOUN
dpc-5639	121	8	as	as	ADP
dpc-5639	121	9	the	the	DET
dpc-5639	121	10	first	first	ADJ
dpc-5639	121	11	specific	specific	ADJ
dpc-5639	121	12	biologic	biologic	NOUN
dpc-5639	121	13	agent	agent	NOUN
dpc-5639	121	14	for	for	ADP
dpc-5639	121	15	the	the	DET
dpc-5639	121	16	treatment	treatment	NOUN
dpc-5639	121	17	of	of	ADP
dpc-5639	121	18	pn	pn	PROPN
dpc-5639	121	19	,	,	PUNCT
dpc-5639	121	20	these	these	DET
dpc-5639	121	21	patients	patient	NOUN
dpc-5639	121	22	were	be	AUX
dpc-5639	121	23	often	often	ADV
dpc-5639	121	24	treated	treat	VERB
dpc-5639	121	25	with	with	ADP
dpc-5639	121	26	a	a	DET
dpc-5639	121	27	multimodal	multimodal	NOUN
dpc-5639	121	28	,	,	PUNCT
dpc-5639	121	29	long	long	ADJ
dpc-5639	121	30	-	-	PUNCT
dpc-5639	121	31	term	term	NOUN
dpc-5639	121	32	regimen	regiman	NOUN
dpc-5639	121	33	of	of	ADP
dpc-5639	121	34	both	both	DET
dpc-5639	121	35	topical	topical	ADJ
dpc-5639	121	36	and	and	CCONJ
dpc-5639	121	37	systemic	systemic	ADJ
dpc-5639	121	38	therapies	therapy	NOUN
dpc-5639	121	39	;	;	PUNCT
dpc-5639	121	40	however	however	ADV
dpc-5639	121	41	,	,	PUNCT
dpc-5639	121	42	treatment	treatment	NOUN
dpc-5639	121	43	effectiveness	effectiveness	NOUN
dpc-5639	121	44	was	be	AUX
dpc-5639	121	45	poor	poor	ADJ
dpc-5639	121	46	[	[	X
dpc-5639	121	47	7	7	NUM
dpc-5639	121	48	-	-	SYM
dpc-5639	121	49	9	9	NUM
dpc-5639	121	50	]	]	PUNCT
dpc-5639	121	51	.	.	PUNCT
dpc-5639	122	1	when	when	SCONJ
dpc-5639	122	2	treating	treat	VERB
dpc-5639	122	3	pn	pn	PROPN
dpc-5639	122	4	,	,	PUNCT
dpc-5639	122	5	the	the	DET
dpc-5639	122	6	primary	primary	ADJ
dpc-5639	122	7	goal	goal	NOUN
dpc-5639	122	8	is	be	AUX
dpc-5639	122	9	to	to	PART
dpc-5639	122	10	reduce	reduce	VERB
dpc-5639	122	11	pruritus	pruritus	PROPN
dpc-5639	122	12	and	and	CCONJ
dpc-5639	122	13	break	break	VERB
dpc-5639	122	14	the	the	DET
dpc-5639	122	15	itch	itch	NOUN
dpc-5639	122	16	-	-	PUNCT
dpc-5639	122	17	scratch	scratch	NOUN
dpc-5639	122	18	cycle	cycle	NOUN
dpc-5639	122	19	,	,	PUNCT
dpc-5639	122	20	thereby	thereby	ADV
dpc-5639	122	21	allowing	allow	VERB
dpc-5639	122	22	the	the	DET
dpc-5639	122	23	skin	skin	NOUN
dpc-5639	122	24	to	to	PART
dpc-5639	122	25	heal	heal	VERB
dpc-5639	122	26	.	.	PUNCT
dpc-5639	123	1	in	in	ADP
dpc-5639	123	2	support	support	NOUN
dpc-5639	123	3	of	of	ADP
dpc-5639	123	4	this	this	PRON
dpc-5639	123	5	,	,	PUNCT
dpc-5639	123	6	first	first	ADV
dpc-5639	123	7	,	,	PUNCT
dpc-5639	123	8	a	a	DET
dpc-5639	123	9	correct	correct	ADJ
dpc-5639	123	10	diagnostic	diagnostic	ADJ
dpc-5639	123	11	approach	approach	NOUN
dpc-5639	123	12	is	be	AUX
dpc-5639	123	13	mandatory	mandatory	ADJ
dpc-5639	123	14	to	to	PART
dpc-5639	123	15	identify	identify	VERB
dpc-5639	123	16	dermatological	dermatological	ADJ
dpc-5639	123	17	or	or	CCONJ
dpc-5639	123	18	systemic	systemic	ADJ
dpc-5639	123	19	diseases	disease	NOUN
dpc-5639	123	20	associated	associate	VERB
dpc-5639	123	21	with	with	ADP
dpc-5639	123	22	pn	pn	PROPN
dpc-5639	123	23	and	and	CCONJ
dpc-5639	123	24	to	to	PART
dpc-5639	123	25	choose	choose	VERB
dpc-5639	123	26	the	the	DET
dpc-5639	123	27	best	good	ADJ
dpc-5639	123	28	therapy	therapy	NOUN
dpc-5639	123	29	for	for	ADP
dpc-5639	123	30	the	the	DET
dpc-5639	123	31	patient	patient	NOUN
dpc-5639	123	32	.	.	PUNCT
dpc-5639	124	1	the	the	DET
dpc-5639	124	2	approval	approval	NOUN
dpc-5639	124	3	of	of	ADP
dpc-5639	124	4	dupilumab	dupilumab	NOUN
dpc-5639	124	5	has	have	AUX
dpc-5639	124	6	changed	change	VERB
dpc-5639	124	7	the	the	DET
dpc-5639	124	8	scenario	scenario	NOUN
dpc-5639	124	9	of	of	ADP
dpc-5639	124	10	pn	pn	PROPN
dpc-5639	124	11	management	management	PROPN
dpc-5639	124	12	[	[	X
dpc-5639	124	13	19	19	NUM
dpc-5639	124	14	]	]	PUNCT
dpc-5639	124	15	.	.	PUNCT
dpc-5639	125	1	data	datum	NOUN
dpc-5639	125	2	from	from	ADP
dpc-5639	125	3	recent	recent	ADJ
dpc-5639	125	4	clinical	clinical	ADJ
dpc-5639	125	5	trials	trial	NOUN
dpc-5639	125	6	have	have	AUX
dpc-5639	125	7	demonstrated	demonstrate	VERB
dpc-5639	125	8	its	its	PRON
dpc-5639	125	9	effectiveness	effectiveness	NOUN
dpc-5639	125	10	in	in	ADP
dpc-5639	125	11	alleviating	alleviate	VERB
dpc-5639	125	12	both	both	CCONJ
dpc-5639	125	13	itching	itching	NOUN
dpc-5639	125	14	and	and	CCONJ
dpc-5639	125	15	nodule	nodule	NOUN
dpc-5639	125	16	development	development	NOUN
dpc-5639	125	17	figure	figure	NOUN
dpc-5639	125	18	1	1	NUM
dpc-5639	125	19	.	.	PUNCT
dpc-5639	125	20	percentage	percentage	NOUN
dpc-5639	125	21	of	of	ADP
dpc-5639	125	22	patients	patient	NOUN
dpc-5639	125	23	receiving	receive	VERB
dpc-5639	125	24	different	different	ADJ
dpc-5639	125	25	systemic	systemic	ADJ
dpc-5639	125	26	therapies	therapy	NOUN
dpc-5639	125	27	at	at	ADP
dpc-5639	125	28	week	week	NOUN
dpc-5639	125	29	0	0	NUM
dpc-5639	125	30	.	.	PUNCT
dpc-5639	126	1	original	original	ADJ
dpc-5639	126	2	article	article	NOUN
dpc-5639	126	3	|	|	ADV
dpc-5639	126	4	dermatol	dermatol	ADJ
dpc-5639	126	5	pract	pract	NOUN
dpc-5639	126	6	concept	concept	NOUN
dpc-5639	126	7	.	.	PUNCT
dpc-5639	127	1	2025;15(4):5639	2025;15(4):5639	NUM
dpc-5639	127	2	5	5	NUM
dpc-5639	127	3	figure	figure	NOUN
dpc-5639	127	4	2	2	NUM
dpc-5639	127	5	.	.	PUNCT
dpc-5639	127	6	improvement	improvement	NOUN
dpc-5639	127	7	in	in	ADP
dpc-5639	127	8	iga	iga	PROPN
dpc-5639	127	9	and	and	CCONJ
dpc-5639	127	10	iga	iga	PROPN
dpc-5639	127	11	activity	activity	NOUN
dpc-5639	127	12	score	score	NOUN
dpc-5639	127	13	at	at	ADP
dpc-5639	127	14	week	week	NOUN
dpc-5639	127	15	24	24	NUM
dpc-5639	127	16	(	(	PUNCT
dpc-5639	127	17	w24	w24	PROPN
dpc-5639	127	18	)	)	PUNCT
dpc-5639	127	19	.	.	PUNCT
dpc-5639	128	1	statistical	statistical	ADJ
dpc-5639	128	2	analysis	analysis	NOUN
dpc-5639	128	3	was	be	AUX
dpc-5639	128	4	performed	perform	VERB
dpc-5639	128	5	using	use	VERB
dpc-5639	128	6	the	the	DET
dpc-5639	128	7	mann	mann	PROPN
dpc-5639	128	8	-	-	PUNCT
dpc-5639	128	9	whitney	whitney	PROPN
dpc-5639	128	10	test	test	NOUN
dpc-5639	128	11	(	(	PUNCT
dpc-5639	128	12	with	with	ADP
dpc-5639	128	13	bonferroni	bonferroni	NOUN
dpc-5639	128	14	correction	correction	NOUN
dpc-5639	128	15	)	)	PUNCT
dpc-5639	128	16	between	between	ADP
dpc-5639	128	17	the	the	DET
dpc-5639	128	18	two	two	NUM
dpc-5639	128	19	most	most	ADV
dpc-5639	128	20	represented	represent	VERB
dpc-5639	128	21	treatment	treatment	NOUN
dpc-5639	128	22	groups	group	NOUN
dpc-5639	128	23	(	(	PUNCT
dpc-5639	128	24	antidepressants	antidepressant	NOUN
dpc-5639	128	25	and	and	CCONJ
dpc-5639	128	26	dupilumab	dupilumab	NOUN
dpc-5639	128	27	)	)	PUNCT
dpc-5639	128	28	,	,	PUNCT
dpc-5639	128	29	*	*	PUNCT
dpc-5639	128	30	*	*	PUNCT
dpc-5639	128	31	p<0.01	p<0.01	PROPN
dpc-5639	128	32	.	.	PUNCT
dpc-5639	129	1	the	the	DET
dpc-5639	129	2	rectangles	rectangle	NOUN
dpc-5639	129	3	highlight	highlight	VERB
dpc-5639	129	4	patients	patient	NOUN
dpc-5639	129	5	achieving	achieve	VERB
dpc-5639	129	6	iga0–1	iga0–1	NOUN
dpc-5639	129	7	in	in	ADP
dpc-5639	129	8	both	both	DET
dpc-5639	129	9	dupilumab	dupilumab	NOUN
dpc-5639	129	10	(	(	PUNCT
dpc-5639	129	11	5	5	NUM
dpc-5639	129	12	+	+	NOUN
dpc-5639	129	13	9=14	9=14	NUM
dpc-5639	129	14	patients	patient	NOUN
dpc-5639	129	15	)	)	PUNCT
dpc-5639	129	16	and	and	CCONJ
dpc-5639	129	17	antidepressants	antidepressant	NOUN
dpc-5639	129	18	(	(	PUNCT
dpc-5639	129	19	2	2	NUM
dpc-5639	129	20	+	+	NOUN
dpc-5639	129	21	4=6	4=6	NUM
dpc-5639	129	22	patients	patient	NOUN
dpc-5639	129	23	)	)	PUNCT
dpc-5639	129	24	groups	group	NOUN
dpc-5639	129	25	.	.	PUNCT
dpc-5639	130	1	figure	figure	VERB
dpc-5639	130	2	3	3	NUM
dpc-5639	130	3	.	.	NOUN
dpc-5639	130	4	percentage	percentage	NOUN
dpc-5639	130	5	of	of	ADP
dpc-5639	130	6	patients	patient	NOUN
dpc-5639	130	7	who	who	PRON
dpc-5639	130	8	achieved	achieve	VERB
dpc-5639	130	9	nrs	nrs	NOUN
dpc-5639	130	10	improvement	improvement	NOUN
dpc-5639	130	11	(	(	PUNCT
dpc-5639	130	12	reduction	reduction	NOUN
dpc-5639	130	13	)	)	PUNCT
dpc-5639	130	14	by	by	ADP
dpc-5639	130	15	≥4	≥4	PROPN
dpc-5639	130	16	points	point	NOUN
dpc-5639	130	17	from	from	ADP
dpc-5639	130	18	baseline	baseline	PROPN
dpc-5639	130	19	(	(	PUNCT
dpc-5639	130	20	w0	w0	PROPN
dpc-5639	130	21	)	)	PUNCT
dpc-5639	130	22	at	at	ADP
dpc-5639	130	23	week	week	NOUN
dpc-5639	130	24	24	24	NUM
dpc-5639	130	25	(	(	PUNCT
dpc-5639	130	26	w24	w24	PROPN
dpc-5639	130	27	)	)	PUNCT
dpc-5639	130	28	,	,	PUNCT
dpc-5639	130	29	respectively	respectively	ADV
dpc-5639	130	30	.	.	PUNCT
dpc-5639	131	1	statistical	statistical	ADJ
dpc-5639	131	2	analysis	analysis	NOUN
dpc-5639	131	3	was	be	AUX
dpc-5639	131	4	performed	perform	VERB
dpc-5639	131	5	using	use	VERB
dpc-5639	131	6	the	the	DET
dpc-5639	131	7	mann	mann	PROPN
dpc-5639	131	8	-	-	PUNCT
dpc-5639	131	9	whitney	whitney	PROPN
dpc-5639	131	10	test	test	NOUN
dpc-5639	131	11	(	(	PUNCT
dpc-5639	131	12	with	with	ADP
dpc-5639	131	13	bonferroni	bonferroni	NOUN
dpc-5639	131	14	correction	correction	NOUN
dpc-5639	131	15	)	)	PUNCT
dpc-5639	131	16	between	between	ADP
dpc-5639	131	17	the	the	DET
dpc-5639	131	18	two	two	NUM
dpc-5639	131	19	most	most	ADV
dpc-5639	131	20	represented	represent	VERB
dpc-5639	131	21	treatment	treatment	NOUN
dpc-5639	131	22	groups	group	NOUN
dpc-5639	131	23	(	(	PUNCT
dpc-5639	131	24	antidepressants	antidepressant	NOUN
dpc-5639	131	25	and	and	CCONJ
dpc-5639	131	26	dupilumab	dupilumab	NOUN
dpc-5639	131	27	)	)	PUNCT
dpc-5639	131	28	,	,	PUNCT
dpc-5639	131	29	*	*	PUNCT
dpc-5639	131	30	*	*	PUNCT
dpc-5639	131	31	p<0.01	p<0.01	PROPN
dpc-5639	131	32	.	.	PUNCT
dpc-5639	131	33	figure	figure	NOUN
dpc-5639	131	34	4	4	NUM
dpc-5639	131	35	.	.	PUNCT
dpc-5639	132	1	mean	mean	VERB
dpc-5639	132	2	dlqi	dlqi	ADJ
dpc-5639	132	3	reduction	reduction	NOUN
dpc-5639	132	4	from	from	ADP
dpc-5639	132	5	baseline	baseline	PROPN
dpc-5639	132	6	(	(	PUNCT
dpc-5639	132	7	w0	w0	PROPN
dpc-5639	132	8	)	)	PUNCT
dpc-5639	132	9	at	at	ADP
dpc-5639	132	10	week	week	NOUN
dpc-5639	132	11	24	24	NUM
dpc-5639	132	12	(	(	PUNCT
dpc-5639	132	13	w24	w24	PROPN
dpc-5639	132	14	)	)	PUNCT
dpc-5639	132	15	,	,	PUNCT
dpc-5639	132	16	respectively	respectively	ADV
dpc-5639	132	17	.	.	PUNCT
dpc-5639	133	1	statistical	statistical	ADJ
dpc-5639	133	2	analysis	analysis	NOUN
dpc-5639	133	3	was	be	AUX
dpc-5639	133	4	performed	perform	VERB
dpc-5639	133	5	using	use	VERB
dpc-5639	133	6	the	the	DET
dpc-5639	133	7	mann	mann	PROPN
dpc-5639	133	8	-	-	PUNCT
dpc-5639	133	9	whitney	whitney	PROPN
dpc-5639	133	10	test	test	NOUN
dpc-5639	133	11	(	(	PUNCT
dpc-5639	133	12	with	with	ADP
dpc-5639	133	13	bonferroni	bonferroni	NOUN
dpc-5639	133	14	correction	correction	NOUN
dpc-5639	133	15	)	)	PUNCT
dpc-5639	133	16	between	between	ADP
dpc-5639	133	17	the	the	DET
dpc-5639	133	18	two	two	NUM
dpc-5639	133	19	most	most	ADV
dpc-5639	133	20	represented	represent	VERB
dpc-5639	133	21	treatment	treatment	NOUN
dpc-5639	133	22	groups	group	NOUN
dpc-5639	133	23	(	(	PUNCT
dpc-5639	133	24	antidepressants	antidepressant	NOUN
dpc-5639	133	25	and	and	CCONJ
dpc-5639	133	26	dupilumab	dupilumab	NOUN
dpc-5639	133	27	)	)	PUNCT
dpc-5639	133	28	,	,	PUNCT
dpc-5639	133	29	*	*	PUNCT
dpc-5639	133	30	*	*	PUNCT
dpc-5639	133	31	*	*	PUNCT
dpc-5639	133	32	p<0.1	p<0.1	NUM
dpc-5639	133	33	.	.	NOUN
dpc-5639	133	34	6	6	NUM
dpc-5639	133	35	original	original	ADJ
dpc-5639	133	36	article	article	NOUN
dpc-5639	133	37	|	|	ADV
dpc-5639	133	38	dermatol	dermatol	ADJ
dpc-5639	133	39	pract	pract	NOUN
dpc-5639	133	40	concept	concept	NOUN
dpc-5639	133	41	.	.	PUNCT
dpc-5639	134	1	2025;15(4):5639	2025;15(4):5639	NUM
dpc-5639	134	2	references	reference	NOUN
dpc-5639	134	3	1	1	NUM
dpc-5639	134	4	.	.	PUNCT
dpc-5639	135	1	huang	huang	PROPN
dpc-5639	135	2	ah	ah	PROPN
dpc-5639	135	3	,	,	PUNCT
dpc-5639	135	4	williams	williams	PROPN
dpc-5639	135	5	ka	ka	PROPN
dpc-5639	135	6	,	,	PUNCT
dpc-5639	135	7	kwatra	kwatra	PROPN
dpc-5639	135	8	sg	sg	PROPN
dpc-5639	135	9	.	.	PROPN
dpc-5639	135	10	prurigo	prurigo	PROPN
dpc-5639	135	11	nodularis	nodularis	PROPN
dpc-5639	135	12	:	:	PUNCT
dpc-5639	135	13	epidemiology	epidemiology	NOUN
dpc-5639	135	14	and	and	CCONJ
dpc-5639	135	15	clinical	clinical	ADJ
dpc-5639	135	16	features	feature	NOUN
dpc-5639	135	17	.	.	PUNCT
dpc-5639	136	1	j	j	PROPN
dpc-5639	136	2	am	be	AUX
dpc-5639	136	3	acad	acad	ADJ
dpc-5639	136	4	dermatol	dermatol	NOUN
dpc-5639	136	5	.	.	PUNCT
dpc-5639	137	1	2020	2020	NUM
dpc-5639	137	2	;	;	PUNCT
dpc-5639	137	3	83(6	83(6	NUM
dpc-5639	137	4	):	):	PUNCT
dpc-5639	137	5	1559	1559	NUM
dpc-5639	137	6	-	-	SYM
dpc-5639	137	7	1565	1565	NUM
dpc-5639	137	8	.	.	PUNCT
dpc-5639	138	1	doi	doi	NOUN
dpc-5639	138	2	:	:	PUNCT
dpc-5639	138	3	10.1016	10.1016	NUM
dpc-5639	138	4	/	/	SYM
dpc-5639	138	5	j.jaad.2020.04.183	j.jaad.2020.04.183	PROPN
dpc-5639	138	6	.	.	PUNCT
dpc-5639	139	1	epub	epub	PROPN
dpc-5639	139	2	2020	2020	NUM
dpc-5639	139	3	may	may	AUX
dpc-5639	139	4	23	23	NUM
dpc-5639	139	5	.	.	PUNCT
dpc-5639	140	1	pmid	pmid	NOUN
dpc-5639	140	2	:	:	PUNCT
dpc-5639	140	3	32454098	32454098	NUM
dpc-5639	140	4	.	.	PUNCT
dpc-5639	141	1	2	2	X
dpc-5639	141	2	.	.	X
dpc-5639	141	3	ferreira	ferreira	PROPN
dpc-5639	141	4	br	br	PROPN
dpc-5639	141	5	,	,	PUNCT
dpc-5639	141	6	misery	misery	NOUN
dpc-5639	141	7	l.	l.	NOUN
dpc-5639	141	8	psychopathology	psychopathology	NOUN
dpc-5639	141	9	associated	associate	VERB
dpc-5639	141	10	with	with	ADP
dpc-5639	141	11	chronic	chronic	ADJ
dpc-5639	141	12	pruritus	pruritus	NOUN
dpc-5639	141	13	:	:	PUNCT
dpc-5639	141	14	a	a	DET
dpc-5639	141	15	systematic	systematic	ADJ
dpc-5639	141	16	review	review	NOUN
dpc-5639	141	17	.	.	PUNCT
dpc-5639	142	1	acta	acta	PROPN
dpc-5639	142	2	derm	derm	PROPN
dpc-5639	142	3	venereol	venereol	NOUN
dpc-5639	142	4	.	.	PUNCT
dpc-5639	143	1	2023	2023	NUM
dpc-5639	143	2	;	;	PUNCT
dpc-5639	143	3	103	103	NUM
dpc-5639	143	4	:	:	PUNCT
dpc-5639	143	5	adv8488	adv8488	NOUN
dpc-5639	143	6	.	.	PUNCT
dpc-5639	144	1	doi	doi	NOUN
dpc-5639	144	2	:	:	PUNCT
dpc-5639	144	3	10.2340	10.2340	NUM
dpc-5639	144	4	/	/	SYM
dpc-5639	144	5	actadv.v103.8488	actadv.v103.8488	NOUN
dpc-5639	144	6	.	.	PUNCT
dpc-5639	145	1	pmid	pmid	NOUN
dpc-5639	145	2	:	:	PUNCT
dpc-5639	145	3	37606153	37606153	NUM
dpc-5639	145	4	;	;	PUNCT
dpc-5639	145	5	pmcid	pmcid	ADJ
dpc-5639	145	6	:	:	PUNCT
dpc-5639	145	7	pmc10461306	pmc10461306	NOUN
dpc-5639	145	8	.	.	PUNCT
dpc-5639	146	1	3	3	X
dpc-5639	146	2	.	.	X
dpc-5639	146	3	wong	wong	PROPN
dpc-5639	146	4	ls	ls	PROPN
dpc-5639	146	5	,	,	PUNCT
dpc-5639	146	6	yen	yen	NOUN
dpc-5639	146	7	yt	yt	PROPN
dpc-5639	146	8	.	.	PROPN
dpc-5639	146	9	chronic	chronic	PROPN
dpc-5639	146	10	nodular	nodular	ADJ
dpc-5639	146	11	prurigo	prurigo	NOUN
dpc-5639	146	12	:	:	PUNCT
dpc-5639	146	13	an	an	DET
dpc-5639	146	14	update	update	NOUN
dpc-5639	146	15	on	on	ADP
dpc-5639	146	16	the	the	DET
dpc-5639	146	17	pathogenesis	pathogenesis	NOUN
dpc-5639	146	18	and	and	CCONJ
dpc-5639	146	19	treatment	treatment	NOUN
dpc-5639	146	20	.	.	PUNCT
dpc-5639	147	1	int	int	PROPN
dpc-5639	147	2	j	j	PROPN
dpc-5639	147	3	mol	mol	ADP
dpc-5639	147	4	sci	sci	PROPN
dpc-5639	147	5	.	.	PUNCT
dpc-5639	148	1	2022;23(20):12390	2022;23(20):12390	X
dpc-5639	148	2	.	.	PUNCT
dpc-5639	149	1	doi	doi	NOUN
dpc-5639	149	2	:	:	PUNCT
dpc-5639	149	3	10.3390	10.3390	NUM
dpc-5639	149	4	/	/	SYM
dpc-5639	149	5	ijms232012390	ijms232012390	PROPN
dpc-5639	149	6	.	.	PUNCT
dpc-5639	150	1	pmid	pmid	NOUN
dpc-5639	150	2	:	:	PUNCT
dpc-5639	150	3	36293248	36293248	NUM
dpc-5639	150	4	;	;	PUNCT
dpc-5639	150	5	pmcid	pmcid	ADJ
dpc-5639	150	6	:	:	PUNCT
dpc-5639	150	7	pmc9604302	pmc9604302	NOUN
dpc-5639	150	8	.	.	PUNCT
dpc-5639	151	1	4	4	X
dpc-5639	151	2	.	.	X
dpc-5639	151	3	williams	williams	PROPN
dpc-5639	151	4	ka	ka	PROPN
dpc-5639	151	5	,	,	PUNCT
dpc-5639	151	6	huang	huang	PROPN
dpc-5639	151	7	ah	ah	INTJ
dpc-5639	151	8	,	,	PUNCT
dpc-5639	151	9	belzberg	belzberg	PROPN
dpc-5639	151	10	m	m	PROPN
dpc-5639	151	11	,	,	PUNCT
dpc-5639	151	12	kwatra	kwatra	PROPN
dpc-5639	151	13	sg	sg	PROPN
dpc-5639	151	14	.	.	PROPN
dpc-5639	151	15	prurigo	prurigo	PROPN
dpc-5639	151	16	nodularis	nodularis	PROPN
dpc-5639	151	17	:	:	PUNCT
dpc-5639	151	18	pathogenesis	pathogenesis	NOUN
dpc-5639	151	19	and	and	CCONJ
dpc-5639	151	20	management	management	NOUN
dpc-5639	151	21	.	.	PUNCT
dpc-5639	152	1	j	j	PROPN
dpc-5639	152	2	am	be	AUX
dpc-5639	152	3	acad	acad	ADJ
dpc-5639	152	4	dermatol	dermatol	NOUN
dpc-5639	152	5	.	.	PUNCT
dpc-5639	153	1	2020	2020	NUM
dpc-5639	153	2	;	;	PUNCT
dpc-5639	154	1	83(6):1567	83(6):1567	NUM
dpc-5639	154	2	-	-	SYM
dpc-5639	154	3	1575	1575	NUM
dpc-5639	154	4	.	.	PUNCT
dpc-5639	155	1	doi	doi	NOUN
dpc-5639	155	2	:	:	PUNCT
dpc-5639	155	3	10.1016	10.1016	NUM
dpc-5639	155	4	/	/	SYM
dpc-5639	155	5	j.jaad.2020.04.182	j.jaad.2020.04.182	NOUN
dpc-5639	155	6	.	.	PUNCT
dpc-5639	156	1	epub	epub	NOUN
dpc-5639	156	2	2020	2020	NUM
dpc-5639	156	3	may	may	AUX
dpc-5639	156	4	24	24	NUM
dpc-5639	156	5	.	.	PUNCT
dpc-5639	157	1	pmid	pmid	NOUN
dpc-5639	157	2	:	:	PUNCT
dpc-5639	157	3	32461078	32461078	NUM
dpc-5639	157	4	.	.	PUNCT
dpc-5639	158	1	5	5	X
dpc-5639	158	2	.	.	X
dpc-5639	158	3	garcovich	garcovich	PROPN
dpc-5639	158	4	s	s	PROPN
dpc-5639	158	5	,	,	PUNCT
dpc-5639	158	6	maurelli	maurelli	PROPN
dpc-5639	158	7	m	m	PROPN
dpc-5639	158	8	,	,	PUNCT
dpc-5639	158	9	gisondi	gisondi	NOUN
dpc-5639	158	10	p	p	NOUN
dpc-5639	158	11	,	,	PUNCT
dpc-5639	158	12	et	et	PROPN
dpc-5639	158	13	al	al	PROPN
dpc-5639	158	14	.	.	PUNCT
dpc-5639	159	1	pruritus	pruritus	PROPN
dpc-5639	159	2	as	as	ADP
dpc-5639	159	3	a	a	DET
dpc-5639	159	4	distinctive	distinctive	ADJ
dpc-5639	159	5	feature	feature	NOUN
dpc-5639	159	6	of	of	ADP
dpc-5639	159	7	type	type	NOUN
dpc-5639	159	8	2	2	NUM
dpc-5639	159	9	inflammation	inflammation	NOUN
dpc-5639	159	10	.	.	PUNCT
dpc-5639	160	1	vaccines	vaccine	NOUN
dpc-5639	160	2	(	(	PUNCT
dpc-5639	160	3	basel	basel	PROPN
dpc-5639	160	4	)	)	PUNCT
dpc-5639	160	5	.	.	PUNCT
dpc-5639	161	1	2021;9(3):303	2021;9(3):303	X
dpc-5639	161	2	.	.	PUNCT
dpc-5639	162	1	doi	doi	NOUN
dpc-5639	162	2	:	:	PUNCT
dpc-5639	162	3	10.3390	10.3390	NUM
dpc-5639	162	4	/	/	SYM
dpc-5639	162	5	vaccines9030303	vaccines9030303	PROPN
dpc-5639	162	6	.	.	PUNCT
dpc-5639	163	1	pmid	pmid	NOUN
dpc-5639	163	2	:	:	PUNCT
dpc-5639	163	3	33807098	33807098	NUM
dpc-5639	163	4	;	;	PUNCT
dpc-5639	163	5	pmcid	pmcid	ADJ
dpc-5639	163	6	:	:	PUNCT
dpc-5639	163	7	pmc8005108	pmc8005108	NOUN
dpc-5639	163	8	.	.	PUNCT
dpc-5639	164	1	6	6	X
dpc-5639	164	2	.	.	X
dpc-5639	164	3	shao	shao	PROPN
dpc-5639	164	4	y	y	PROPN
dpc-5639	164	5	,	,	PUNCT
dpc-5639	164	6	wang	wang	PROPN
dpc-5639	164	7	d	d	PROPN
dpc-5639	164	8	,	,	PUNCT
dpc-5639	164	9	zhu	zhu	PROPN
dpc-5639	164	10	y	y	PROPN
dpc-5639	164	11	,	,	PUNCT
dpc-5639	164	12	et	et	PROPN
dpc-5639	164	13	al	al	PROPN
dpc-5639	164	14	.	.	PUNCT
dpc-5639	164	15	molecular	molecular	ADJ
dpc-5639	164	16	mechanisms	mechanism	NOUN
dpc-5639	164	17	of	of	ADP
dpc-5639	164	18	pruritus	pruritus	PROPN
dpc-5639	164	19	in	in	ADP
dpc-5639	164	20	prurigo	prurigo	PROPN
dpc-5639	164	21	nodularis	nodularis	PROPN
dpc-5639	164	22	.	.	PUNCT
dpc-5639	165	1	front	front	ADJ
dpc-5639	165	2	immunol	immunol	NOUN
dpc-5639	165	3	.	.	PUNCT
dpc-5639	166	1	2023;14:1301817	2023;14:1301817	X
dpc-5639	166	2	.	.	PUNCT
dpc-5639	166	3	doi	doi	NOUN
dpc-5639	166	4	:	:	PUNCT
dpc-5639	166	5	10.3389	10.3389	NUM
dpc-5639	166	6	/	/	SYM
dpc-5639	166	7	fimmu.2023.1301817	fimmu.2023.1301817	NOUN
dpc-5639	166	8	.	.	PUNCT
dpc-5639	167	1	pmid	pmid	NOUN
dpc-5639	167	2	:	:	PUNCT
dpc-5639	167	3	38077377	38077377	NUM
dpc-5639	167	4	;	;	PUNCT
dpc-5639	167	5	pmcid	pmcid	NOUN
dpc-5639	167	6	:	:	PUNCT
dpc-5639	167	7	pmc10701428	pmc10701428	ADJ
dpc-5639	167	8	.	.	PUNCT
dpc-5639	168	1	7	7	X
dpc-5639	168	2	.	.	X
dpc-5639	168	3	kowalski	kowalski	PROPN
dpc-5639	168	4	eh	eh	INTJ
dpc-5639	168	5	,	,	PUNCT
dpc-5639	168	6	kneiber	kneiber	PROPN
dpc-5639	168	7	d	d	PROPN
dpc-5639	168	8	,	,	PUNCT
dpc-5639	168	9	valdebran	valdebran	PROPN
dpc-5639	168	10	m	m	PROPN
dpc-5639	168	11	,	,	PUNCT
dpc-5639	168	12	patel	patel	PROPN
dpc-5639	168	13	u	u	PROPN
dpc-5639	168	14	,	,	PUNCT
dpc-5639	168	15	amber	amber	PROPN
dpc-5639	168	16	kt	kt	PROPN
dpc-5639	168	17	.	.	PUNCT
dpc-5639	168	18	treatment	treatment	NOUN
dpc-5639	168	19	-	-	PUNCT
dpc-5639	168	20	resistant	resistant	ADJ
dpc-5639	168	21	prurigo	prurigo	ADJ
dpc-5639	168	22	nodularis	nodularis	NOUN
dpc-5639	168	23	:	:	PUNCT
dpc-5639	168	24	challenges	challenge	NOUN
dpc-5639	168	25	and	and	CCONJ
dpc-5639	168	26	solutions	solution	NOUN
dpc-5639	168	27	.	.	PUNCT
dpc-5639	169	1	clin	clin	PROPN
dpc-5639	169	2	cosmet	cosmet	PROPN
dpc-5639	169	3	investig	investig	NOUN
dpc-5639	169	4	dermatol	dermatol	NOUN
dpc-5639	169	5	.	.	PUNCT
dpc-5639	170	1	2019;12:163	2019;12:163	NUM
dpc-5639	170	2	-	-	SYM
dpc-5639	170	3	172	172	NUM
dpc-5639	170	4	.	.	PUNCT
dpc-5639	170	5	doi	doi	NOUN
dpc-5639	170	6	:	:	PUNCT
dpc-5639	170	7	10.2147	10.2147	NUM
dpc-5639	170	8	/	/	SYM
dpc-5639	170	9	ccid.s188070	ccid.s188070	NOUN
dpc-5639	170	10	.	.	PUNCT
dpc-5639	171	1	pmid	pmid	NOUN
dpc-5639	171	2	:	:	PUNCT
dpc-5639	171	3	30881076	30881076	NUM
dpc-5639	171	4	;	;	PUNCT
dpc-5639	171	5	pmcid	pmcid	NOUN
dpc-5639	171	6	:	:	PUNCT
dpc-5639	171	7	pmc6400231	pmc6400231	ADJ
dpc-5639	171	8	.	.	PUNCT
dpc-5639	172	1	8	8	X
dpc-5639	172	2	.	.	PUNCT
dpc-5639	173	1	müller	müller	PROPN
dpc-5639	173	2	s	s	PROPN
dpc-5639	173	3	,	,	PUNCT
dpc-5639	173	4	zeidler	zeidler	PROPN
dpc-5639	173	5	c	c	NOUN
dpc-5639	173	6	,	,	PUNCT
dpc-5639	173	7	ständer	ständer	NOUN
dpc-5639	173	8	s.	s.	PROPN
dpc-5639	173	9	chronic	chronic	PROPN
dpc-5639	173	10	prurigo	prurigo	PROPN
dpc-5639	173	11	including	include	VERB
dpc-5639	173	12	prurigo	prurigo	PROPN
dpc-5639	173	13	nodularis	nodularis	PROPN
dpc-5639	173	14	:	:	PUNCT
dpc-5639	173	15	new	new	ADJ
dpc-5639	173	16	insights	insight	NOUN
dpc-5639	173	17	and	and	CCONJ
dpc-5639	173	18	treatments	treatment	NOUN
dpc-5639	173	19	.	.	PUNCT
dpc-5639	173	20	am	be	AUX
dpc-5639	173	21	j	j	PROPN
dpc-5639	173	22	clin	clin	PROPN
dpc-5639	173	23	dermatol	dermatol	NOUN
dpc-5639	173	24	.	.	PUNCT
dpc-5639	174	1	2024;25(1):15	2024;25(1):15	X
dpc-5639	174	2	-	-	SYM
dpc-5639	174	3	33	33	NUM
dpc-5639	174	4	.	.	PUNCT
dpc-5639	175	1	doi	doi	NOUN
dpc-5639	175	2	:	:	PUNCT
dpc-5639	175	3	10.1007	10.1007	NUM
dpc-5639	175	4	/	/	SYM
dpc-5639	175	5	s40257	s40257	NOUN
dpc-5639	175	6	-	-	PUNCT
dpc-5639	175	7	02300818	02300818	NUM
dpc-5639	175	8	-	-	PUNCT
dpc-5639	175	9	z.	z.	PROPN
dpc-5639	175	10	epub	epub	PROPN
dpc-5639	175	11	2023	2023	NUM
dpc-5639	175	12	sep	sep	PROPN
dpc-5639	175	13	17	17	NUM
dpc-5639	175	14	.	.	PUNCT
dpc-5639	176	1	pmid	pmid	NOUN
dpc-5639	176	2	:	:	PUNCT
dpc-5639	176	3	37717255	37717255	NUM
dpc-5639	176	4	;	;	PUNCT
dpc-5639	176	5	pmcid	pmcid	NOUN
dpc-5639	176	6	:	:	PUNCT
dpc-5639	176	7	pmc10796623	pmc10796623	ADJ
dpc-5639	176	8	.	.	PUNCT
dpc-5639	177	1	9	9	X
dpc-5639	177	2	.	.	X
dpc-5639	177	3	whang	whang	PROPN
dpc-5639	177	4	ka	ka	PROPN
dpc-5639	177	5	,	,	PUNCT
dpc-5639	177	6	kang	kang	PROPN
dpc-5639	177	7	s	s	PROPN
dpc-5639	177	8	,	,	PUNCT
dpc-5639	177	9	kwatra	kwatra	PROPN
dpc-5639	177	10	sg	sg	PROPN
dpc-5639	177	11	.	.	PUNCT
dpc-5639	178	1	inpatient	inpatient	PROPN
dpc-5639	178	2	burden	burden	NOUN
dpc-5639	178	3	of	of	ADP
dpc-5639	178	4	prurigo	prurigo	PROPN
dpc-5639	178	5	nodularis	nodularis	PROPN
dpc-5639	178	6	in	in	ADP
dpc-5639	178	7	the	the	DET
dpc-5639	178	8	united	united	PROPN
dpc-5639	178	9	states	states	PROPN
dpc-5639	178	10	.	.	PUNCT
dpc-5639	179	1	medicines	medicine	NOUN
dpc-5639	179	2	(	(	PUNCT
dpc-5639	179	3	basel	basel	PROPN
dpc-5639	179	4	)	)	PUNCT
dpc-5639	179	5	.	.	PUNCT
dpc-5639	180	1	2019	2019	NUM
dpc-5639	180	2	;	;	PUNCT
dpc-5639	180	3	6(3):88	6(3):88	NUM
dpc-5639	180	4	.	.	PUNCT
dpc-5639	181	1	doi	doi	NOUN
dpc-5639	181	2	:	:	PUNCT
dpc-5639	181	3	10.3390	10.3390	NUM
dpc-5639	181	4	/	/	SYM
dpc-5639	181	5	medicines6030088	medicines6030088	PROPN
dpc-5639	181	6	.	.	PUNCT
dpc-5639	182	1	pmid	pmid	NOUN
dpc-5639	182	2	:	:	PUNCT
dpc-5639	182	3	31405223	31405223	NUM
dpc-5639	182	4	;	;	PUNCT
dpc-5639	182	5	pmcid	pmcid	NOUN
dpc-5639	182	6	:	:	PUNCT
dpc-5639	182	7	pmc6789607	pmc6789607	ADJ
dpc-5639	182	8	.	.	PUNCT
dpc-5639	183	1	10	10	X
dpc-5639	183	2	.	.	X
dpc-5639	183	3	le	le	PROPN
dpc-5639	183	4	floc’h	floc’h	PROPN
dpc-5639	183	5	a	a	PRON
dpc-5639	183	6	,	,	PUNCT
dpc-5639	183	7	allinne	allinne	PROPN
dpc-5639	183	8	j	j	PROPN
dpc-5639	183	9	,	,	PUNCT
dpc-5639	183	10	nagashima	nagashima	PROPN
dpc-5639	183	11	k	k	PROPN
dpc-5639	183	12	,	,	PUNCT
dpc-5639	183	13	et	et	PROPN
dpc-5639	183	14	al	al	PROPN
dpc-5639	183	15	.	.	PUNCT
dpc-5639	184	1	dual	dual	ADJ
dpc-5639	184	2	blockade	blockade	NOUN
dpc-5639	184	3	of	of	ADP
dpc-5639	184	4	il-4	il-4	NOUN
dpc-5639	184	5	and	and	CCONJ
dpc-5639	184	6	il-13	il-13	ADP
dpc-5639	184	7	with	with	ADP
dpc-5639	184	8	dupilumab	dupilumab	NOUN
dpc-5639	184	9	,	,	PUNCT
dpc-5639	184	10	an	an	DET
dpc-5639	184	11	il-4rα	il-4rα	ADJ
dpc-5639	184	12	antibody	antibody	NOUN
dpc-5639	184	13	,	,	PUNCT
dpc-5639	184	14	is	be	AUX
dpc-5639	184	15	required	require	VERB
dpc-5639	184	16	to	to	PART
dpc-5639	184	17	broadly	broadly	ADV
dpc-5639	184	18	inhibit	inhibit	VERB
dpc-5639	184	19	type	type	NOUN
dpc-5639	184	20	2	2	NUM
dpc-5639	184	21	inflammation	inflammation	NOUN
dpc-5639	184	22	.	.	PUNCT
dpc-5639	185	1	allergy	allergy	NOUN
dpc-5639	185	2	.	.	PUNCT
dpc-5639	186	1	2020;75(5	2020;75(5	NUM
dpc-5639	186	2	):	):	PUNCT
dpc-5639	186	3	1188	1188	NUM
dpc-5639	186	4	-	-	SYM
dpc-5639	186	5	1204	1204	NUM
dpc-5639	186	6	.	.	PUNCT
dpc-5639	187	1	doi	doi	NOUN
dpc-5639	187	2	:	:	PUNCT
dpc-5639	187	3	10.1111	10.1111	NUM
dpc-5639	187	4	/	/	SYM
dpc-5639	187	5	all.14151	all.14151	NOUN
dpc-5639	187	6	.	.	PUNCT
dpc-5639	188	1	epub	epub	PROPN
dpc-5639	188	2	2020	2020	NUM
dpc-5639	188	3	jan	jan	PROPN
dpc-5639	188	4	3	3	NUM
dpc-5639	188	5	.	.	PUNCT
dpc-5639	188	6	pmid	pmid	NOUN
dpc-5639	188	7	:	:	PUNCT
dpc-5639	188	8	31838750	31838750	NUM
dpc-5639	188	9	;	;	PUNCT
dpc-5639	188	10	pmcid	pmcid	ADJ
dpc-5639	188	11	:	:	PUNCT
dpc-5639	188	12	pmc7317958	pmc7317958	NOUN
dpc-5639	188	13	.	.	PUNCT
dpc-5639	189	1	11	11	NUM
dpc-5639	189	2	.	.	X
dpc-5639	189	3	pappa	pappa	NOUN
dpc-5639	189	4	g	g	PROPN
dpc-5639	189	5	,	,	PUNCT
dpc-5639	189	6	sgouros	sgouros	PROPN
dpc-5639	189	7	d	d	NOUN
dpc-5639	189	8	,	,	PUNCT
dpc-5639	189	9	theodoropoulos	theodoropoulos	PROPN
dpc-5639	189	10	k	k	PROPN
dpc-5639	189	11	,	,	PUNCT
dpc-5639	189	12	et	et	PROPN
dpc-5639	189	13	al	al	PROPN
dpc-5639	189	14	.	.	PUNCT
dpc-5639	190	1	the	the	DET
dpc-5639	190	2	il-4/-13	il-4/-13	NOUN
dpc-5639	190	3	axis	axis	NOUN
dpc-5639	190	4	and	and	CCONJ
dpc-5639	190	5	its	its	PRON
dpc-5639	190	6	blocking	blocking	NOUN
dpc-5639	190	7	in	in	ADP
dpc-5639	190	8	the	the	DET
dpc-5639	190	9	treatment	treatment	NOUN
dpc-5639	190	10	of	of	ADP
dpc-5639	190	11	atopic	atopic	NOUN
dpc-5639	190	12	dermatitis	dermatitis	NOUN
dpc-5639	190	13	.	.	PUNCT
dpc-5639	191	1	j	j	PROPN
dpc-5639	191	2	clin	clin	PROPN
dpc-5639	191	3	med	med	PROPN
dpc-5639	191	4	.	.	PUNCT
dpc-5639	192	1	2022;11(19):5633	2022;11(19):5633	X
dpc-5639	192	2	.	.	PUNCT
dpc-5639	193	1	doi	doi	NOUN
dpc-5639	193	2	:	:	PUNCT
dpc-5639	193	3	10.3390	10.3390	NUM
dpc-5639	193	4	/	/	SYM
dpc-5639	193	5	jcm11195633	jcm11195633	NOUN
dpc-5639	193	6	.	.	PUNCT
dpc-5639	194	1	pmid	pmid	NOUN
dpc-5639	194	2	:	:	PUNCT
dpc-5639	194	3	36233501	36233501	NUM
dpc-5639	194	4	;	;	PUNCT
dpc-5639	194	5	pmcid	pmcid	ADJ
dpc-5639	194	6	:	:	PUNCT
dpc-5639	194	7	pmc9570949	pmc9570949	NOUN
dpc-5639	194	8	.	.	PUNCT
dpc-5639	195	1	12	12	NUM
dpc-5639	195	2	.	.	PUNCT
dpc-5639	196	1	yosipovitch	yosipovitch	PROPN
dpc-5639	196	2	g	g	PROPN
dpc-5639	196	3	,	,	PUNCT
dpc-5639	196	4	mollanazar	mollanazar	NOUN
dpc-5639	196	5	n	n	CCONJ
dpc-5639	196	6	,	,	PUNCT
dpc-5639	196	7	ständer	ständer	NOUN
dpc-5639	196	8	s	s	PROPN
dpc-5639	196	9	,	,	PUNCT
dpc-5639	196	10	et	et	PROPN
dpc-5639	196	11	al	al	PROPN
dpc-5639	196	12	.	.	PROPN
dpc-5639	196	13	dupilumab	dupilumab	NOUN
dpc-5639	196	14	in	in	ADP
dpc-5639	196	15	patients	patient	NOUN
dpc-5639	196	16	with	with	ADP
dpc-5639	196	17	prurigo	prurigo	PROPN
dpc-5639	196	18	nodularis	nodularis	PROPN
dpc-5639	196	19	:	:	PUNCT
dpc-5639	196	20	two	two	NUM
dpc-5639	196	21	randomized	randomized	ADJ
dpc-5639	196	22	,	,	PUNCT
dpc-5639	196	23	double	double	ADJ
dpc-5639	196	24	-	-	PUNCT
dpc-5639	196	25	blind	blind	ADJ
dpc-5639	196	26	,	,	PUNCT
dpc-5639	196	27	placebo	placebo	NOUN
dpc-5639	196	28	-	-	PUNCT
dpc-5639	196	29	controlled	control	VERB
dpc-5639	196	30	phase	phase	NOUN
dpc-5639	196	31	3	3	NUM
dpc-5639	196	32	trials	trial	NOUN
dpc-5639	196	33	.	.	PUNCT
dpc-5639	197	1	nat	nat	PROPN
dpc-5639	197	2	med	me	VERB
dpc-5639	197	3	.	.	PUNCT
dpc-5639	198	1	2023;29(5	2023;29(5	NUM
dpc-5639	198	2	):	):	PUNCT
dpc-5639	198	3	1180	1180	NUM
dpc-5639	198	4	-	-	SYM
dpc-5639	198	5	1190	1190	NUM
dpc-5639	198	6	.	.	PUNCT
dpc-5639	199	1	doi	doi	NOUN
dpc-5639	199	2	:	:	PUNCT
dpc-5639	199	3	10.1038	10.1038	NUM
dpc-5639	199	4	/	/	SYM
dpc-5639	199	5	s41591	s41591	VERB
dpc-5639	199	6	-	-	PUNCT
dpc-5639	199	7	023	023	NUM
dpc-5639	199	8	-	-	PUNCT
dpc-5639	199	9	02320	02320	NUM
dpc-5639	199	10	-	-	SYM
dpc-5639	199	11	9	9	NUM
dpc-5639	199	12	.	.	PUNCT
dpc-5639	200	1	epub	epub	NOUN
dpc-5639	200	2	2023	2023	NUM
dpc-5639	200	3	may	may	PROPN
dpc-5639	200	4	4	4	NUM
dpc-5639	200	5	.	.	PUNCT
dpc-5639	201	1	pmid	pmid	NOUN
dpc-5639	201	2	:	:	PUNCT
dpc-5639	201	3	37142763	37142763	NUM
dpc-5639	201	4	;	;	PUNCT
dpc-5639	201	5	pmcid	pmcid	NOUN
dpc-5639	201	6	:	:	PUNCT
dpc-5639	201	7	pmc10202800	pmc10202800	NOUN
dpc-5639	201	8	.	.	PUNCT
dpc-5639	202	1	13	13	NUM
dpc-5639	202	2	.	.	X
dpc-5639	202	3	satoh	satoh	PROPN
dpc-5639	202	4	t	t	PROPN
dpc-5639	202	5	,	,	PUNCT
dpc-5639	202	6	yokozeki	yokozeki	NOUN
dpc-5639	202	7	h	h	NOUN
dpc-5639	202	8	,	,	PUNCT
dpc-5639	202	9	murota	murota	NOUN
dpc-5639	202	10	h	h	NOUN
dpc-5639	202	11	,	,	PUNCT
dpc-5639	202	12	et	et	PROPN
dpc-5639	202	13	al	al	PROPN
dpc-5639	202	14	.	.	PROPN
dpc-5639	202	15	2020	2020	NUM
dpc-5639	202	16	guidelines	guideline	NOUN
dpc-5639	202	17	for	for	ADP
dpc-5639	202	18	the	the	DET
dpc-5639	202	19	diagnosis	diagnosis	NOUN
dpc-5639	202	20	and	and	CCONJ
dpc-5639	202	21	treatment	treatment	NOUN
dpc-5639	202	22	of	of	ADP
dpc-5639	202	23	prurigo	prurigo	NOUN
dpc-5639	202	24	.	.	PUNCT
dpc-5639	203	1	j	j	PROPN
dpc-5639	203	2	dermatol	dermatol	NOUN
dpc-5639	203	3	.	.	PUNCT
dpc-5639	204	1	2021;48(9):e414	2021;48(9):e414	NUM
dpc-5639	204	2	-	-	PUNCT
dpc-5639	204	3	e431	e431	PROPN
dpc-5639	204	4	.	.	PUNCT
dpc-5639	205	1	doi	doi	NOUN
dpc-5639	205	2	:	:	PUNCT
dpc-5639	205	3	10.1111/1346	10.1111/1346	NUM
dpc-5639	205	4	-	-	SYM
dpc-5639	205	5	8138.16067	8138.16067	NUM
dpc-5639	205	6	.	.	PUNCT
dpc-5639	206	1	epub	epub	NOUN
dpc-5639	206	2	2021	2021	NUM
dpc-5639	206	3	jul	jul	PROPN
dpc-5639	206	4	27	27	NUM
dpc-5639	206	5	.	.	PUNCT
dpc-5639	207	1	pmid	pmid	NOUN
dpc-5639	207	2	:	:	PUNCT
dpc-5639	207	3	34314056	34314056	NUM
dpc-5639	207	4	.	.	PUNCT
dpc-5639	208	1	14	14	NUM
dpc-5639	208	2	.	.	PUNCT
dpc-5639	209	1	reich	reich	PROPN
dpc-5639	209	2	a	a	PRON
dpc-5639	209	3	,	,	PUNCT
dpc-5639	209	4	riepe	riepe	NOUN
dpc-5639	209	5	c	c	NOUN
dpc-5639	209	6	,	,	PUNCT
dpc-5639	209	7	anastasiadou	anastasiadou	NOUN
dpc-5639	209	8	z	z	PROPN
dpc-5639	209	9	,	,	PUNCT
dpc-5639	209	10	et	et	PROPN
dpc-5639	209	11	al	al	PROPN
dpc-5639	209	12	.	.	PUNCT
dpc-5639	210	1	itch	itch	PROPN
dpc-5639	210	2	assessment	assessment	NOUN
dpc-5639	210	3	with	with	ADP
dpc-5639	210	4	visual	visual	ADJ
dpc-5639	210	5	analogue	analogue	NOUN
dpc-5639	210	6	scale	scale	NOUN
dpc-5639	210	7	and	and	CCONJ
dpc-5639	210	8	numerical	numerical	ADJ
dpc-5639	210	9	rating	rating	NOUN
dpc-5639	210	10	scale	scale	NOUN
dpc-5639	210	11	:	:	PUNCT
dpc-5639	210	12	determination	determination	NOUN
dpc-5639	210	13	with	with	ADP
dpc-5639	210	14	dupilumab	dupilumab	NOUN
dpc-5639	211	1	[	[	X
dpc-5639	211	2	20	20	NUM
dpc-5639	211	3	]	]	PUNCT
dpc-5639	211	4	.	.	PUNCT
dpc-5639	212	1	similarly	similarly	ADV
dpc-5639	212	2	,	,	PUNCT
dpc-5639	212	3	chiricozzi	chiricozzi	NOUN
dpc-5639	212	4	et	et	PROPN
dpc-5639	212	5	al	al	PROPN
dpc-5639	212	6	.	.	PROPN
dpc-5639	212	7	reported	report	VERB
dpc-5639	212	8	a	a	DET
dpc-5639	212	9	reduction	reduction	NOUN
dpc-5639	212	10	in	in	ADP
dpc-5639	212	11	iga	iga	PROPN
dpc-5639	212	12	for	for	ADP
dpc-5639	212	13	at	at	ADV
dpc-5639	212	14	least	least	ADJ
dpc-5639	212	15	2	2	NUM
dpc-5639	212	16	grades	grade	NOUN
dpc-5639	212	17	in	in	ADP
dpc-5639	212	18	82.6	82.6	NUM
dpc-5639	212	19	%	%	NOUN
dpc-5639	212	20	of	of	ADP
dpc-5639	212	21	the	the	DET
dpc-5639	212	22	patients	patient	NOUN
dpc-5639	212	23	after	after	ADP
dpc-5639	212	24	16	16	NUM
dpc-5639	212	25	weeks	week	NOUN
dpc-5639	212	26	of	of	ADP
dpc-5639	212	27	treatment	treatment	NOUN
dpc-5639	212	28	[	[	X
dpc-5639	212	29	21	21	NUM
dpc-5639	212	30	]	]	PUNCT
dpc-5639	212	31	.	.	PUNCT
dpc-5639	213	1	in	in	ADP
dpc-5639	213	2	a	a	DET
dpc-5639	213	3	retrospective	retrospective	ADJ
dpc-5639	213	4	cohort	cohort	NOUN
dpc-5639	213	5	study	study	NOUN
dpc-5639	213	6	,	,	PUNCT
dpc-5639	213	7	pruritus	pruritus	NOUN
dpc-5639	213	8	peak	peak	NOUN
dpc-5639	213	9	(	(	PUNCT
dpc-5639	213	10	pp)-nrs	pp)-nrs	VERB
dpc-5639	213	11	and	and	CCONJ
dpc-5639	213	12	dlqi	dlqi	NOUN
dpc-5639	213	13	significantly	significantly	ADV
dpc-5639	213	14	improved	improve	VERB
dpc-5639	213	15	in	in	ADP
dpc-5639	213	16	all	all	DET
dpc-5639	213	17	the	the	DET
dpc-5639	213	18	45	45	NUM
dpc-5639	213	19	enrolled	enrol	VERB
dpc-5639	213	20	patients	patient	NOUN
dpc-5639	213	21	from	from	ADP
dpc-5639	213	22	baseline	baseline	NOUN
dpc-5639	213	23	to	to	ADP
dpc-5639	213	24	16	16	NUM
dpc-5639	213	25	 	 	SPACE
dpc-5639	213	26	weeks	week	NOUN
dpc-5639	213	27	after	after	ADP
dpc-5639	213	28	dupilumab	dupilumab	NOUN
dpc-5639	213	29	treatment	treatment	NOUN
dpc-5639	213	30	(	(	PUNCT
dpc-5639	213	31	p	p	X
dpc-5639	213	32	<	<	X
dpc-5639	213	33	 	 	SPACE
dpc-5639	213	34	0.001	0.001	NUM
dpc-5639	213	35	for	for	ADP
dpc-5639	213	36	both	both	PRON
dpc-5639	213	37	[	[	X
dpc-5639	213	38	22	22	NUM
dpc-5639	213	39	]	]	PUNCT
dpc-5639	213	40	.	.	PUNCT
dpc-5639	214	1	moreover	moreover	ADV
dpc-5639	214	2	,	,	PUNCT
dpc-5639	214	3	compared	compare	VERB
dpc-5639	214	4	to	to	ADP
dpc-5639	214	5	antidepressants	antidepressant	NOUN
dpc-5639	214	6	,	,	PUNCT
dpc-5639	214	7	dupilumab	dupilumab	NOUN
dpc-5639	214	8	has	have	AUX
dpc-5639	214	9	been	be	AUX
dpc-5639	214	10	proven	prove	VERB
dpc-5639	214	11	to	to	PART
dpc-5639	214	12	elicit	elicit	VERB
dpc-5639	214	13	fast	fast	ADJ
dpc-5639	214	14	and	and	CCONJ
dpc-5639	214	15	notable	notable	ADJ
dpc-5639	214	16	symptom	symptom	NOUN
dpc-5639	214	17	reduction	reduction	NOUN
dpc-5639	214	18	in	in	ADP
dpc-5639	214	19	pn	pn	PROPN
dpc-5639	214	20	patients	patient	NOUN
dpc-5639	214	21	.	.	PUNCT
dpc-5639	215	1	zhai	zhai	PROPN
dpc-5639	215	2	et	et	PROPN
dpc-5639	215	3	al	al	PROPN
dpc-5639	215	4	.	.	PROPN
dpc-5639	215	5	observed	observe	VERB
dpc-5639	215	6	a	a	DET
dpc-5639	215	7	mean	mean	ADJ
dpc-5639	215	8	nrsi	nrsi	ADJ
dpc-5639	215	9	reduction	reduction	NOUN
dpc-5639	215	10	of	of	ADP
dpc-5639	215	11	7.89	7.89	NUM
dpc-5639	215	12	points	point	NOUN
dpc-5639	215	13	after	after	ADP
dpc-5639	215	14	only	only	ADV
dpc-5639	215	15	two	two	NUM
dpc-5639	215	16	weeks	week	NOUN
dpc-5639	215	17	of	of	ADP
dpc-5639	215	18	dupilumab	dupilumab	NOUN
dpc-5639	215	19	,	,	PUNCT
dpc-5639	215	20	whereas	whereas	SCONJ
dpc-5639	215	21	beck	beck	PROPN
dpc-5639	215	22	et	et	PROPN
dpc-5639	215	23	al	al	PROPN
dpc-5639	215	24	.	.	PROPN
dpc-5639	215	25	reported	report	VERB
dpc-5639	215	26	a	a	DET
dpc-5639	215	27	pruritus	pruritus	NOUN
dpc-5639	215	28	improvement	improvement	NOUN
dpc-5639	215	29	to	to	ADP
dpc-5639	215	30	nearly	nearly	ADV
dpc-5639	215	31	0	0	NUM
dpc-5639	215	32	in	in	ADP
dpc-5639	215	33	terms	term	NOUN
dpc-5639	215	34	of	of	ADP
dpc-5639	215	35	nrsi	nrsi	NOUN
dpc-5639	215	36	in	in	ADP
dpc-5639	215	37	12	12	NUM
dpc-5639	215	38	weeks	week	NOUN
dpc-5639	215	39	of	of	ADP
dpc-5639	215	40	treatment	treatment	NOUN
dpc-5639	215	41	[	[	X
dpc-5639	215	42	23,24	23,24	NOUN
dpc-5639	215	43	]	]	PUNCT
dpc-5639	215	44	.	.	PUNCT
dpc-5639	216	1	in	in	ADP
dpc-5639	216	2	addition	addition	NOUN
dpc-5639	216	3	,	,	PUNCT
dpc-5639	216	4	beyond	beyond	ADP
dpc-5639	216	5	clinical	clinical	ADJ
dpc-5639	216	6	symptom	symptom	NOUN
dpc-5639	216	7	relief	relief	NOUN
dpc-5639	216	8	,	,	PUNCT
dpc-5639	216	9	patients	patient	NOUN
dpc-5639	216	10	’	'	PUNCT
dpc-5639	216	11	mental	mental	ADJ
dpc-5639	216	12	health	health	NOUN
dpc-5639	216	13	and	and	CCONJ
dpc-5639	216	14	quality	quality	NOUN
dpc-5639	216	15	of	of	ADP
dpc-5639	216	16	life	life	NOUN
dpc-5639	216	17	also	also	ADV
dpc-5639	216	18	saw	see	VERB
dpc-5639	216	19	subjective	subjective	ADJ
dpc-5639	216	20	improvements	improvement	NOUN
dpc-5639	216	21	after	after	ADP
dpc-5639	216	22	biological	biological	ADJ
dpc-5639	216	23	therapy	therapy	NOUN
dpc-5639	216	24	.	.	PUNCT
dpc-5639	217	1	conversely	conversely	ADV
dpc-5639	217	2	,	,	PUNCT
dpc-5639	217	3	antidepressants	antidepressant	VERB
dpc-5639	217	4	’	'	PUNCT
dpc-5639	217	5	effects	effect	NOUN
dpc-5639	217	6	on	on	ADP
dpc-5639	217	7	chronic	chronic	ADJ
dpc-5639	217	8	pruritus	pruritus	NOUN
dpc-5639	217	9	are	be	AUX
dpc-5639	217	10	variable	variable	ADJ
dpc-5639	217	11	and	and	CCONJ
dpc-5639	217	12	may	may	AUX
dpc-5639	217	13	appear	appear	VERB
dpc-5639	217	14	modest	modest	ADJ
dpc-5639	217	15	in	in	ADP
dpc-5639	217	16	patients	patient	NOUN
dpc-5639	217	17	with	with	ADP
dpc-5639	217	18	pn	pn	PROPN
dpc-5639	217	19	.	.	PUNCT
dpc-5639	218	1	kouwenhoven	kouwenhoven	VERB
dpc-5639	218	2	et	et	PROPN
dpc-5639	218	3	al	al	PROPN
dpc-5639	218	4	.	.	PROPN
dpc-5639	218	5	showed	show	VERB
dpc-5639	218	6	that	that	SCONJ
dpc-5639	218	7	systemic	systemic	ADJ
dpc-5639	218	8	treatment	treatment	NOUN
dpc-5639	218	9	with	with	ADP
dpc-5639	218	10	gabapentin	gabapentin	NOUN
dpc-5639	218	11	and/or	and/or	CCONJ
dpc-5639	218	12	antidepressants	antidepressant	NOUN
dpc-5639	218	13	decreased	decrease	VERB
dpc-5639	218	14	the	the	DET
dpc-5639	218	15	median	median	ADJ
dpc-5639	218	16	average	average	ADJ
dpc-5639	218	17	pruritus	pruritus	NOUN
dpc-5639	218	18	nrs	nrs	PROPN
dpc-5639	218	19	score	score	NOUN
dpc-5639	218	20	from	from	ADP
dpc-5639	218	21	7.0	7.0	NUM
dpc-5639	218	22	to	to	ADP
dpc-5639	218	23	5.5	5.5	NUM
dpc-5639	218	24	in	in	ADP
dpc-5639	218	25	31	31	NUM
dpc-5639	218	26	patients	patient	NOUN
dpc-5639	218	27	with	with	ADP
dpc-5639	218	28	severe	severe	ADJ
dpc-5639	218	29	chronic	chronic	ADJ
dpc-5639	218	30	pruritus	pruritus	NOUN
dpc-5639	218	31	after	after	ADP
dpc-5639	218	32	4	4	NUM
dpc-5639	218	33	weeks	week	NOUN
dpc-5639	218	34	and	and	CCONJ
dpc-5639	218	35	remained	remain	VERB
dpc-5639	218	36	stable	stable	ADJ
dpc-5639	218	37	with	with	ADP
dpc-5639	218	38	up	up	ADP
dpc-5639	218	39	to	to	PART
dpc-5639	218	40	24	24	NUM
dpc-5639	218	41	weeks	week	NOUN
dpc-5639	218	42	of	of	ADP
dpc-5639	218	43	treatment	treatment	NOUN
dpc-5639	218	44	[	[	X
dpc-5639	218	45	25	25	NUM
dpc-5639	218	46	]	]	PUNCT
dpc-5639	218	47	.	.	PUNCT
dpc-5639	219	1	however	however	ADV
dpc-5639	219	2	,	,	PUNCT
dpc-5639	219	3	the	the	DET
dpc-5639	219	4	common	common	ADJ
dpc-5639	219	5	side	side	NOUN
dpc-5639	219	6	effects	effect	NOUN
dpc-5639	219	7	of	of	ADP
dpc-5639	219	8	antidepressants	antidepressant	NOUN
dpc-5639	219	9	result	result	VERB
dpc-5639	219	10	in	in	ADP
dpc-5639	219	11	considerable	considerable	ADJ
dpc-5639	219	12	rates	rate	NOUN
dpc-5639	219	13	of	of	ADP
dpc-5639	219	14	discontinuation	discontinuation	NOUN
dpc-5639	219	15	.	.	PUNCT
dpc-5639	220	1	after	after	ADP
dpc-5639	220	2	initiation	initiation	NOUN
dpc-5639	220	3	of	of	ADP
dpc-5639	220	4	gabapentin	gabapentin	NOUN
dpc-5639	220	5	and/or	and/or	CCONJ
dpc-5639	220	6	antidepressants	antidepressant	NOUN
dpc-5639	220	7	,	,	PUNCT
dpc-5639	220	8	vertigo	vertigo	NOUN
dpc-5639	220	9	and	and	CCONJ
dpc-5639	220	10	drowsiness	drowsiness	NOUN
dpc-5639	220	11	were	be	AUX
dpc-5639	220	12	most	most	ADV
dpc-5639	220	13	frequently	frequently	ADV
dpc-5639	220	14	and	and	CCONJ
dpc-5639	220	15	particularly	particularly	ADV
dpc-5639	220	16	present	present	ADJ
dpc-5639	220	17	in	in	ADP
dpc-5639	220	18	the	the	DET
dpc-5639	220	19	first	first	ADJ
dpc-5639	220	20	few	few	ADJ
dpc-5639	220	21	days	day	NOUN
dpc-5639	220	22	of	of	ADP
dpc-5639	220	23	treatment	treatment	NOUN
dpc-5639	220	24	[	[	X
dpc-5639	220	25	26	26	NUM
dpc-5639	220	26	]	]	PUNCT
dpc-5639	220	27	.	.	PUNCT
dpc-5639	221	1	moreover	moreover	ADV
dpc-5639	221	2	,	,	PUNCT
dpc-5639	221	3	even	even	ADV
dpc-5639	221	4	if	if	SCONJ
dpc-5639	221	5	previous	previous	ADJ
dpc-5639	221	6	clinical	clinical	ADJ
dpc-5639	221	7	trials	trial	NOUN
dpc-5639	221	8	for	for	ADP
dpc-5639	221	9	gabapentin	gabapentin	NOUN
dpc-5639	221	10	in	in	ADP
dpc-5639	221	11	neuropathic	neuropathic	ADJ
dpc-5639	221	12	pain	pain	NOUN
dpc-5639	221	13	did	do	AUX
dpc-5639	221	14	not	not	PART
dpc-5639	221	15	find	find	VERB
dpc-5639	221	16	a	a	DET
dpc-5639	221	17	higher	high	ADJ
dpc-5639	221	18	incidence	incidence	NOUN
dpc-5639	221	19	of	of	ADP
dpc-5639	221	20	these	these	DET
dpc-5639	221	21	adverse	adverse	ADJ
dpc-5639	221	22	reactions	reaction	NOUN
dpc-5639	221	23	in	in	ADP
dpc-5639	221	24	older	old	ADJ
dpc-5639	221	25	adults	adult	NOUN
dpc-5639	221	26	,	,	PUNCT
dpc-5639	221	27	clinicians	clinician	NOUN
dpc-5639	221	28	should	should	AUX
dpc-5639	221	29	be	be	AUX
dpc-5639	221	30	careful	careful	ADJ
dpc-5639	221	31	in	in	ADP
dpc-5639	221	32	these	these	DET
dpc-5639	221	33	patients	patient	NOUN
dpc-5639	221	34	with	with	ADP
dpc-5639	221	35	preexisting	preexist	VERB
dpc-5639	221	36	dizziness	dizziness	NOUN
dpc-5639	221	37	or	or	CCONJ
dpc-5639	221	38	somnolence	somnolence	NOUN
dpc-5639	221	39	,	,	PUNCT
dpc-5639	221	40	with	with	ADP
dpc-5639	221	41	adjusted	adjust	VERB
dpc-5639	221	42	dosing	dosing	NOUN
dpc-5639	221	43	,	,	PUNCT
dpc-5639	221	44	patient	patient	ADJ
dpc-5639	221	45	instructions	instruction	NOUN
dpc-5639	221	46	,	,	PUNCT
dpc-5639	221	47	and	and	CCONJ
dpc-5639	221	48	close	close	ADJ
dpc-5639	221	49	follow	follow	NOUN
dpc-5639	221	50	-	-	PUNCT
dpc-5639	221	51	up	up	NOUN
dpc-5639	221	52	[	[	X
dpc-5639	221	53	27	27	NUM
dpc-5639	221	54	]	]	PUNCT
dpc-5639	221	55	.	.	PUNCT
dpc-5639	222	1	limitations	limitation	NOUN
dpc-5639	222	2	our	our	PRON
dpc-5639	222	3	study	study	NOUN
dpc-5639	222	4	presents	present	VERB
dpc-5639	222	5	some	some	DET
dpc-5639	222	6	limitations	limitation	NOUN
dpc-5639	222	7	.	.	PUNCT
dpc-5639	223	1	first	first	ADV
dpc-5639	223	2	,	,	PUNCT
dpc-5639	223	3	the	the	DET
dpc-5639	223	4	sample	sample	NOUN
dpc-5639	223	5	size	size	NOUN
dpc-5639	223	6	of	of	ADP
dpc-5639	223	7	the	the	DET
dpc-5639	223	8	enrolled	enrol	VERB
dpc-5639	223	9	patients	patient	NOUN
dpc-5639	223	10	,	,	PUNCT
dpc-5639	223	11	although	although	SCONJ
dpc-5639	223	12	higher	high	ADJ
dpc-5639	223	13	than	than	ADP
dpc-5639	223	14	others	other	NOUN
dpc-5639	223	15	,	,	PUNCT
dpc-5639	223	16	was	be	AUX
dpc-5639	223	17	relatively	relatively	ADV
dpc-5639	223	18	small	small	ADJ
dpc-5639	223	19	,	,	PUNCT
dpc-5639	223	20	which	which	PRON
dpc-5639	223	21	may	may	AUX
dpc-5639	223	22	limit	limit	VERB
dpc-5639	223	23	the	the	DET
dpc-5639	223	24	generalizability	generalizability	NOUN
dpc-5639	223	25	of	of	ADP
dpc-5639	223	26	the	the	DET
dpc-5639	223	27	findings	finding	NOUN
dpc-5639	223	28	and	and	CCONJ
dpc-5639	223	29	results	result	NOUN
dpc-5639	223	30	.	.	PUNCT
dpc-5639	224	1	second	second	ADV
dpc-5639	224	2	,	,	PUNCT
dpc-5639	224	3	the	the	DET
dpc-5639	224	4	study	study	NOUN
dpc-5639	224	5	was	be	AUX
dpc-5639	224	6	conducted	conduct	VERB
dpc-5639	224	7	over	over	ADP
dpc-5639	224	8	a	a	DET
dpc-5639	224	9	6	6	NUM
dpc-5639	224	10	-	-	PUNCT
dpc-5639	224	11	month	month	NOUN
dpc-5639	224	12	period	period	NOUN
dpc-5639	224	13	,	,	PUNCT
dpc-5639	224	14	which	which	PRON
dpc-5639	224	15	may	may	AUX
dpc-5639	224	16	not	not	PART
dpc-5639	224	17	be	be	AUX
dpc-5639	224	18	sufficient	sufficient	ADJ
dpc-5639	224	19	to	to	PART
dpc-5639	224	20	evaluate	evaluate	VERB
dpc-5639	224	21	the	the	DET
dpc-5639	224	22	long	long	ADJ
dpc-5639	224	23	-	-	PUNCT
dpc-5639	224	24	term	term	NOUN
dpc-5639	224	25	efficacy	efficacy	NOUN
dpc-5639	224	26	and	and	CCONJ
dpc-5639	224	27	safety	safety	NOUN
dpc-5639	224	28	of	of	ADP
dpc-5639	224	29	the	the	DET
dpc-5639	224	30	treatments	treatment	NOUN
dpc-5639	224	31	.	.	PUNCT
dpc-5639	225	1	in	in	ADP
dpc-5639	225	2	this	this	DET
dpc-5639	225	3	regard	regard	NOUN
dpc-5639	225	4	,	,	PUNCT
dpc-5639	225	5	paganini	paganini	PROPN
dpc-5639	225	6	et	et	PROPN
dpc-5639	225	7	al	al	PROPN
dpc-5639	225	8	.	.	PROPN
dpc-5639	225	9	have	have	AUX
dpc-5639	225	10	recently	recently	ADV
dpc-5639	225	11	demonstrated	demonstrate	VERB
dpc-5639	225	12	the	the	DET
dpc-5639	225	13	effectiveness	effectiveness	NOUN
dpc-5639	225	14	of	of	ADP
dpc-5639	225	15	dupilumab	dupilumab	NOUN
dpc-5639	225	16	in	in	ADP
dpc-5639	225	17	all	all	DET
dpc-5639	225	18	the	the	DET
dpc-5639	225	19	parameters	parameter	NOUN
dpc-5639	225	20	considered	consider	VERB
dpc-5639	225	21	for	for	ADP
dpc-5639	225	22	the	the	DET
dpc-5639	225	23	disease	disease	NOUN
dpc-5639	225	24	,	,	PUNCT
dpc-5639	225	25	up	up	ADP
dpc-5639	225	26	to	to	ADP
dpc-5639	225	27	week	week	NOUN
dpc-5639	225	28	84	84	NUM
dpc-5639	225	29	of	of	ADP
dpc-5639	225	30	treatment	treatment	NOUN
dpc-5639	225	31	[	[	X
dpc-5639	225	32	19	19	NUM
dpc-5639	225	33	]	]	PUNCT
dpc-5639	225	34	.	.	PUNCT
dpc-5639	226	1	conclusion	conclusion	NOUN
dpc-5639	226	2	our	our	PRON
dpc-5639	226	3	findings	finding	NOUN
dpc-5639	226	4	reflect	reflect	VERB
dpc-5639	226	5	the	the	DET
dpc-5639	226	6	real	real	ADJ
dpc-5639	226	7	-	-	PUNCT
dpc-5639	226	8	world	world	NOUN
dpc-5639	226	9	practice	practice	NOUN
dpc-5639	226	10	of	of	ADP
dpc-5639	226	11	treating	treat	VERB
dpc-5639	226	12	pn	pn	PROPN
dpc-5639	226	13	and	and	CCONJ
dpc-5639	226	14	support	support	VERB
dpc-5639	226	15	the	the	DET
dpc-5639	226	16	use	use	NOUN
dpc-5639	226	17	of	of	ADP
dpc-5639	226	18	dupilumab	dupilumab	NOUN
dpc-5639	226	19	as	as	ADP
dpc-5639	226	20	a	a	DET
dpc-5639	226	21	new	new	ADJ
dpc-5639	226	22	effective	effective	ADJ
dpc-5639	226	23	treatment	treatment	NOUN
dpc-5639	226	24	option	option	NOUN
dpc-5639	226	25	,	,	PUNCT
dpc-5639	226	26	with	with	ADP
dpc-5639	226	27	significant	significant	ADJ
dpc-5639	226	28	improvements	improvement	NOUN
dpc-5639	226	29	in	in	ADP
dpc-5639	226	30	pruritus	pruritus	PROPN
dpc-5639	226	31	,	,	PUNCT
dpc-5639	226	32	quality	quality	NOUN
dpc-5639	226	33	of	of	ADP
dpc-5639	226	34	life	life	NOUN
dpc-5639	226	35	,	,	PUNCT
dpc-5639	226	36	and	and	CCONJ
dpc-5639	226	37	disease	disease	NOUN
dpc-5639	226	38	severity	severity	NOUN
dpc-5639	226	39	compared	compare	VERB
dpc-5639	226	40	to	to	ADP
dpc-5639	226	41	antidepressant	antidepressant	ADJ
dpc-5639	226	42	therapy	therapy	NOUN
dpc-5639	226	43	.	.	PUNCT
dpc-5639	227	1	however	however	ADV
dpc-5639	227	2	,	,	PUNCT
dpc-5639	227	3	further	further	ADJ
dpc-5639	227	4	large	large	ADJ
dpc-5639	227	5	-	-	PUNCT
dpc-5639	227	6	scale	scale	NOUN
dpc-5639	227	7	,	,	PUNCT
dpc-5639	227	8	longer	long	ADJ
dpc-5639	227	9	-	-	PUNCT
dpc-5639	227	10	term	term	NOUN
dpc-5639	227	11	studies	study	NOUN
dpc-5639	227	12	are	be	AUX
dpc-5639	227	13	needed	need	VERB
dpc-5639	227	14	to	to	PART
dpc-5639	227	15	confirm	confirm	VERB
dpc-5639	227	16	these	these	DET
dpc-5639	227	17	findings	finding	NOUN
dpc-5639	227	18	and	and	CCONJ
dpc-5639	227	19	to	to	PART
dpc-5639	227	20	evaluate	evaluate	VERB
dpc-5639	227	21	the	the	DET
dpc-5639	227	22	long	long	ADJ
dpc-5639	227	23	-	-	PUNCT
dpc-5639	227	24	term	term	NOUN
dpc-5639	227	25	efficacy	efficacy	NOUN
dpc-5639	227	26	and	and	CCONJ
dpc-5639	227	27	safety	safety	NOUN
dpc-5639	227	28	of	of	ADP
dpc-5639	227	29	dupilumab	dupilumab	NOUN
dpc-5639	227	30	in	in	ADP
dpc-5639	227	31	the	the	DET
dpc-5639	227	32	management	management	NOUN
dpc-5639	227	33	of	of	ADP
dpc-5639	227	34	pn	pn	PROPN
dpc-5639	227	35	.	.	PUNCT
dpc-5639	227	36	original	original	ADJ
dpc-5639	227	37	article	article	NOUN
dpc-5639	227	38	|	|	ADV
dpc-5639	227	39	dermatol	dermatol	ADJ
dpc-5639	227	40	pract	pract	NOUN
dpc-5639	227	41	concept	concept	NOUN
dpc-5639	227	42	.	.	PUNCT
dpc-5639	228	1	2025;15(4):5639	2025;15(4):5639	NUM
dpc-5639	228	2	7	7	NUM
dpc-5639	228	3	21	21	NUM
dpc-5639	228	4	.	.	PUNCT
dpc-5639	229	1	chiricozzi	chiricozzi	PROPN
dpc-5639	229	2	a	a	PRON
dpc-5639	229	3	,	,	PUNCT
dpc-5639	229	4	gori	gori	PROPN
dpc-5639	229	5	n	n	CCONJ
dpc-5639	229	6	,	,	PUNCT
dpc-5639	229	7	ippoliti	ippoliti	NOUN
dpc-5639	229	8	e	e	NOUN
dpc-5639	229	9	,	,	PUNCT
dpc-5639	229	10	et	et	PROPN
dpc-5639	229	11	al	al	PROPN
dpc-5639	229	12	.	.	PUNCT
dpc-5639	230	1	long	long	ADJ
dpc-5639	230	2	-	-	PUNCT
dpc-5639	230	3	term	term	NOUN
dpc-5639	230	4	therapeutic	therapeutic	ADJ
dpc-5639	230	5	response	response	NOUN
dpc-5639	230	6	to	to	AUX
dpc-5639	230	7	dupilumab	dupilumab	NOUN
dpc-5639	230	8	in	in	ADP
dpc-5639	230	9	patients	patient	NOUN
dpc-5639	230	10	affected	affect	VERB
dpc-5639	230	11	by	by	ADP
dpc-5639	230	12	prurigo	prurigo	PROPN
dpc-5639	230	13	nodularis	nodularis	PROPN
dpc-5639	230	14	:	:	PUNCT
dpc-5639	230	15	a	a	DET
dpc-5639	230	16	real	real	ADJ
dpc-5639	230	17	-	-	PUNCT
dpc-5639	230	18	world	world	NOUN
dpc-5639	230	19	retrospective	retrospective	ADJ
dpc-5639	230	20	study	study	NOUN
dpc-5639	230	21	.	.	PUNCT
dpc-5639	231	1	j	j	PROPN
dpc-5639	231	2	eur	eur	PROPN
dpc-5639	231	3	acad	acad	PROPN
dpc-5639	231	4	dermatol	dermatol	NOUN
dpc-5639	231	5	venereol	venereol	NOUN
dpc-5639	231	6	.	.	PUNCT
dpc-5639	232	1	2024;38(10):e892	2024;38(10):e892	X
dpc-5639	232	2	-	-	PUNCT
dpc-5639	232	3	e895.doi	e895.doi	X
dpc-5639	232	4	:	:	PUNCT
dpc-5639	232	5	10.1111	10.1111	NUM
dpc-5639	232	6	/	/	SYM
dpc-5639	232	7	jdv.19980	jdv.19980	PROPN
dpc-5639	232	8	.	.	PUNCT
dpc-5639	233	1	epub	epub	PROPN
dpc-5639	233	2	2024	2024	NUM
dpc-5639	233	3	mar	mar	PROPN
dpc-5639	233	4	27	27	NUM
dpc-5639	233	5	.	.	PUNCT
dpc-5639	234	1	pmid	pmid	NOUN
dpc-5639	234	2	:	:	PUNCT
dpc-5639	234	3	38534078	38534078	NUM
dpc-5639	234	4	.	.	PUNCT
dpc-5639	235	1	22	22	NUM
dpc-5639	235	2	.	.	X
dpc-5639	235	3	fang	fang	PROPN
dpc-5639	235	4	hy	hy	PROPN
dpc-5639	235	5	,	,	PUNCT
dpc-5639	235	6	lian	lian	PROPN
dpc-5639	235	7	ch	ch	NOUN
dpc-5639	235	8	.	.	PUNCT
dpc-5639	236	1	the	the	DET
dpc-5639	236	2	effectiveness	effectiveness	NOUN
dpc-5639	236	3	and	and	CCONJ
dpc-5639	236	4	safety	safety	NOUN
dpc-5639	236	5	of	of	ADP
dpc-5639	236	6	dupilumab	dupilumab	NOUN
dpc-5639	236	7	in	in	ADP
dpc-5639	236	8	the	the	DET
dpc-5639	236	9	management	management	NOUN
dpc-5639	236	10	of	of	ADP
dpc-5639	236	11	refractory	refractory	PROPN
dpc-5639	236	12	prurigo	prurigo	PROPN
dpc-5639	236	13	nodularis	nodularis	PROPN
dpc-5639	236	14	in	in	ADP
dpc-5639	236	15	45	45	NUM
dpc-5639	236	16	chinese	chinese	ADJ
dpc-5639	236	17	patients	patient	NOUN
dpc-5639	236	18	:	:	PUNCT
dpc-5639	236	19	a	a	DET
dpc-5639	236	20	real	real	ADJ
dpc-5639	236	21	-	-	PUNCT
dpc-5639	236	22	life	life	NOUN
dpc-5639	236	23	observational	observational	ADJ
dpc-5639	236	24	study	study	NOUN
dpc-5639	236	25	.	.	PUNCT
dpc-5639	237	1	j	j	PROPN
dpc-5639	237	2	dermatol	dermatol	NOUN
dpc-5639	237	3	.	.	PUNCT
dpc-5639	238	1	2023	2023	NUM
dpc-5639	238	2	;	;	PUNCT
dpc-5639	238	3	50(8):1084	50(8):1084	NUM
dpc-5639	238	4	-	-	SYM
dpc-5639	238	5	1087	1087	NUM
dpc-5639	238	6	.	.	PUNCT
dpc-5639	239	1	doi	doi	NOUN
dpc-5639	239	2	:	:	PUNCT
dpc-5639	239	3	10.1111/1346	10.1111/1346	NUM
dpc-5639	239	4	-	-	SYM
dpc-5639	239	5	8138.16803	8138.16803	NUM
dpc-5639	239	6	.	.	PUNCT
dpc-5639	240	1	epub	epub	NOUN
dpc-5639	240	2	2023	2023	NUM
dpc-5639	240	3	apr	apr	NOUN
dpc-5639	240	4	23	23	NUM
dpc-5639	240	5	.	.	PUNCT
dpc-5639	241	1	pmid	pmid	NOUN
dpc-5639	241	2	:	:	PUNCT
dpc-5639	241	3	37088954	37088954	NUM
dpc-5639	241	4	.	.	PUNCT
dpc-5639	242	1	23	23	NUM
dpc-5639	242	2	.	.	PUNCT
dpc-5639	243	1	zhai	zhai	PROPN
dpc-5639	243	2	ll	ll	NOUN
dpc-5639	243	3	,	,	PUNCT
dpc-5639	243	4	savage	savage	NOUN
dpc-5639	243	5	kt	kt	PROPN
dpc-5639	243	6	,	,	PUNCT
dpc-5639	243	7	qiu	qiu	PROPN
dpc-5639	243	8	cc	cc	PROPN
dpc-5639	243	9	,	,	PUNCT
dpc-5639	243	10	et	et	PROPN
dpc-5639	243	11	al	al	PROPN
dpc-5639	243	12	.	.	PROPN
dpc-5639	243	13	chronic	chronic	ADJ
dpc-5639	243	14	pruritus	pruritus	PROPN
dpc-5639	243	15	responding	respond	VERB
dpc-5639	243	16	to	to	ADP
dpc-5639	243	17	dupilumab	dupilumab	NOUN
dpc-5639	243	18	-	-	PUNCT
dpc-5639	243	19	a	a	DET
dpc-5639	243	20	case	case	NOUN
dpc-5639	243	21	series	series	NOUN
dpc-5639	243	22	.	.	PUNCT
dpc-5639	244	1	medicines	medicine	NOUN
dpc-5639	244	2	(	(	PUNCT
dpc-5639	244	3	basel	basel	PROPN
dpc-5639	244	4	)	)	PUNCT
dpc-5639	244	5	.	.	PUNCT
dpc-5639	245	1	2019	2019	NUM
dpc-5639	245	2	;	;	PUNCT
dpc-5639	245	3	6(3):72	6(3):72	NUM
dpc-5639	245	4	.	.	PUNCT
dpc-5639	245	5	doi	doi	NOUN
dpc-5639	245	6	:	:	PUNCT
dpc-5639	245	7	10.3390	10.3390	NUM
dpc-5639	245	8	/	/	SYM
dpc-5639	245	9	medicines6030072	medicines6030072	PROPN
dpc-5639	245	10	.	.	PUNCT
dpc-5639	246	1	pmid	pmid	NOUN
dpc-5639	246	2	:	:	PUNCT
dpc-5639	246	3	31261951	31261951	NUM
dpc-5639	246	4	;	;	PUNCT
dpc-5639	246	5	pmcid	pmcid	PROPN
dpc-5639	246	6	:	:	PUNCT
dpc-5639	246	7	pmc6789555	pmc6789555	NOUN
dpc-5639	246	8	.	.	PUNCT
dpc-5639	247	1	24	24	NUM
dpc-5639	247	2	.	.	PUNCT
dpc-5639	247	3	beck	beck	PROPN
dpc-5639	247	4	tc	tc	PROPN
dpc-5639	247	5	,	,	PUNCT
dpc-5639	247	6	wilson	wilson	PROPN
dpc-5639	247	7	em	em	PRON
dpc-5639	247	8	,	,	PUNCT
dpc-5639	247	9	wilkes	wilkes	PROPN
dpc-5639	247	10	e	e	PROPN
dpc-5639	247	11	,	,	PUNCT
dpc-5639	247	12	et	et	PROPN
dpc-5639	247	13	al	al	PROPN
dpc-5639	247	14	.	.	PROPN
dpc-5639	247	15	kappa	kappa	PROPN
dpc-5639	248	1	opioid	opioid	PROPN
dpc-5639	248	2	agonists	agonist	NOUN
dpc-5639	248	3	in	in	ADP
dpc-5639	248	4	the	the	DET
dpc-5639	248	5	treatment	treatment	NOUN
dpc-5639	248	6	of	of	ADP
dpc-5639	248	7	itch	itch	NOUN
dpc-5639	248	8	:	:	PUNCT
dpc-5639	248	9	just	just	ADV
dpc-5639	248	10	scratching	scratch	VERB
dpc-5639	248	11	the	the	DET
dpc-5639	248	12	surface	surface	NOUN
dpc-5639	248	13	?	?	PUNCT
dpc-5639	249	1	itch	itch	NOUN
dpc-5639	249	2	(	(	PUNCT
dpc-5639	249	3	phila	phila	PROPN
dpc-5639	249	4	)	)	PUNCT
dpc-5639	249	5	.	.	PUNCT
dpc-5639	250	1	2023	2023	NUM
dpc-5639	250	2	;	;	PUNCT
dpc-5639	250	3	8(4):e0072	8(4):e0072	X
dpc-5639	250	4	.	.	PUNCT
dpc-5639	251	1	doi	doi	NOUN
dpc-5639	251	2	:	:	PUNCT
dpc-5639	251	3	10.1097	10.1097	NUM
dpc-5639	251	4	/	/	SYM
dpc-5639	251	5	itx.0000000000000072	itx.0000000000000072	NOUN
dpc-5639	251	6	.	.	PUNCT
dpc-5639	252	1	epub	epub	PROPN
dpc-5639	252	2	2023	2023	NUM
dpc-5639	252	3	dec	dec	PROPN
dpc-5639	252	4	6	6	NUM
dpc-5639	252	5	.	.	PUNCT
dpc-5639	253	1	pmid	pmid	NOUN
dpc-5639	253	2	:	:	PUNCT
dpc-5639	253	3	38099236	38099236	NUM
dpc-5639	253	4	;	;	PUNCT
dpc-5639	253	5	pmcid	pmcid	ADJ
dpc-5639	253	6	:	:	PUNCT
dpc-5639	253	7	pmc10720604	pmc10720604	PROPN
dpc-5639	253	8	.	.	PUNCT
dpc-5639	254	1	25	25	NUM
dpc-5639	254	2	.	.	X
dpc-5639	255	1	kouwenhoven	kouwenhoven	VERB
dpc-5639	255	2	ta	ta	PROPN
dpc-5639	255	3	,	,	PUNCT
dpc-5639	255	4	van	van	PROPN
dpc-5639	255	5	de	de	X
dpc-5639	255	6	kerkhof	kerkhof	PROPN
dpc-5639	255	7	pcm	pcm	PROPN
dpc-5639	255	8	,	,	PUNCT
dpc-5639	255	9	kamsteeg	kamsteeg	ADJ
dpc-5639	255	10	m.	m.	NOUN
dpc-5639	255	11	gabapentin	gabapentin	NOUN
dpc-5639	255	12	and	and	CCONJ
dpc-5639	255	13	oral	oral	ADJ
dpc-5639	255	14	antidepressants	antidepressant	NOUN
dpc-5639	255	15	for	for	ADP
dpc-5639	255	16	chronic	chronic	ADJ
dpc-5639	255	17	pruritus	pruritus	NOUN
dpc-5639	255	18	:	:	PUNCT
dpc-5639	255	19	a	a	DET
dpc-5639	255	20	prospective	prospective	ADJ
dpc-5639	255	21	cohort	cohort	NOUN
dpc-5639	255	22	study	study	NOUN
dpc-5639	255	23	evaluating	evaluating	NOUN
dpc-5639	255	24	efficacy	efficacy	NOUN
dpc-5639	255	25	and	and	CCONJ
dpc-5639	255	26	side	side	NOUN
dpc-5639	255	27	effects	effect	NOUN
dpc-5639	255	28	in	in	ADP
dpc-5639	255	29	daily	daily	ADJ
dpc-5639	255	30	dermatological	dermatological	ADJ
dpc-5639	255	31	practice	practice	NOUN
dpc-5639	255	32	.	.	PUNCT
dpc-5639	256	1	j	j	PROPN
dpc-5639	256	2	dermatolog	dermatolog	PROPN
dpc-5639	256	3	treat	treat	NOUN
dpc-5639	256	4	.	.	PUNCT
dpc-5639	257	1	2023	2023	NUM
dpc-5639	257	2	;	;	PUNCT
dpc-5639	257	3	34(1):2274291	34(1):2274291	NUM
dpc-5639	257	4	.	.	PUNCT
dpc-5639	257	5	doi	doi	PROPN
dpc-5639	257	6	:	:	PUNCT
dpc-5639	257	7	10.1080/09546634.2023.2274291	10.1080/09546634.2023.2274291	NUM
dpc-5639	257	8	.	.	PUNCT
dpc-5639	258	1	epub	epub	PROPN
dpc-5639	258	2	2023	2023	NUM
dpc-5639	258	3	oct	oct	NOUN
dpc-5639	258	4	31	31	NUM
dpc-5639	258	5	.	.	PUNCT
dpc-5639	259	1	pmid	pmid	NOUN
dpc-5639	259	2	:	:	PUNCT
dpc-5639	259	3	37905412	37905412	NUM
dpc-5639	259	4	.	.	PUNCT
dpc-5639	260	1	26	26	NUM
dpc-5639	260	2	.	.	X
dpc-5639	261	1	sreekantaswamy	sreekantaswamy	PROPN
dpc-5639	261	2	sa	sa	PROPN
dpc-5639	261	3	,	,	PUNCT
dpc-5639	261	4	mollanazar	mollanazar	PROPN
dpc-5639	261	5	n	n	CCONJ
dpc-5639	261	6	,	,	PUNCT
dpc-5639	261	7	butler	butler	PROPN
dpc-5639	261	8	dc	dc	PROPN
dpc-5639	261	9	.	.	PUNCT
dpc-5639	261	10	gabapentinoids	gabapentinoids	PROPN
dpc-5639	261	11	for	for	ADP
dpc-5639	261	12	pruritus	pruritus	PROPN
dpc-5639	261	13	in	in	ADP
dpc-5639	261	14	older	old	ADJ
dpc-5639	261	15	adults	adult	NOUN
dpc-5639	261	16	:	:	PUNCT
dpc-5639	261	17	a	a	DET
dpc-5639	261	18	narrative	narrative	NOUN
dpc-5639	261	19	review	review	NOUN
dpc-5639	261	20	.	.	PUNCT
dpc-5639	262	1	dermatol	dermatol	NOUN
dpc-5639	262	2	ther	ther	ADV
dpc-5639	262	3	(	(	PUNCT
dpc-5639	262	4	heidelb	heidelb	NOUN
dpc-5639	262	5	)	)	PUNCT
dpc-5639	262	6	.	.	PUNCT
dpc-5639	263	1	2021	2021	NUM
dpc-5639	263	2	;	;	PUNCT
dpc-5639	263	3	11(3):669	11(3):669	NUM
dpc-5639	263	4	-	-	PUNCT
dpc-5639	263	5	679	679	NUM
dpc-5639	263	6	.	.	PUNCT
dpc-5639	264	1	doi	doi	NOUN
dpc-5639	264	2	:	:	PUNCT
dpc-5639	264	3	10.1007	10.1007	NUM
dpc-5639	264	4	/	/	SYM
dpc-5639	264	5	s13555	s13555	PROPN
dpc-5639	264	6	-021	-021	PROPN
dpc-5639	264	7	-	-	PUNCT
dpc-5639	264	8	00513	00513	NUM
dpc-5639	264	9	-	-	PUNCT
dpc-5639	264	10	z.	z.	PROPN
dpc-5639	264	11	epub	epub	PROPN
dpc-5639	264	12	2021	2021	NUM
dpc-5639	264	13	mar	mar	PROPN
dpc-5639	264	14	15	15	NUM
dpc-5639	264	15	.	.	PUNCT
dpc-5639	265	1	pmid	pmid	NOUN
dpc-5639	265	2	:	:	PUNCT
dpc-5639	265	3	33721214	33721214	NUM
dpc-5639	265	4	;	;	PUNCT
dpc-5639	265	5	pmcid	pmcid	NOUN
dpc-5639	265	6	:	:	PUNCT
dpc-5639	265	7	pmc8163906	pmc8163906	X
dpc-5639	265	8	.	.	PROPN
dpc-5639	266	1	27	27	NUM
dpc-5639	266	2	.	.	PUNCT
dpc-5639	266	3	serpell	serpell	PROPN
dpc-5639	266	4	mg	mg	PROPN
dpc-5639	266	5	.	.	PUNCT
dpc-5639	267	1	neuropathic	neuropathic	ADJ
dpc-5639	267	2	pain	pain	PROPN
dpc-5639	267	3	study	study	NOUN
dpc-5639	267	4	group	group	NOUN
dpc-5639	267	5	.	.	PUNCT
dpc-5639	268	1	gabapentin	gabapentin	PROPN
dpc-5639	268	2	in	in	ADP
dpc-5639	268	3	neuropathic	neuropathic	ADJ
dpc-5639	268	4	pain	pain	NOUN
dpc-5639	268	5	syndromes	syndrome	NOUN
dpc-5639	268	6	:	:	PUNCT
dpc-5639	268	7	a	a	DET
dpc-5639	268	8	randomised	randomised	ADJ
dpc-5639	268	9	,	,	PUNCT
dpc-5639	268	10	double	double	ADJ
dpc-5639	268	11	-	-	PUNCT
dpc-5639	268	12	blind	blind	ADJ
dpc-5639	268	13	,	,	PUNCT
dpc-5639	268	14	of	of	ADP
dpc-5639	268	15	minimal	minimal	ADJ
dpc-5639	268	16	clinically	clinically	ADV
dpc-5639	268	17	important	important	ADJ
dpc-5639	268	18	difference	difference	NOUN
dpc-5639	268	19	in	in	ADP
dpc-5639	268	20	chronic	chronic	ADJ
dpc-5639	268	21	itch	itch	NOUN
dpc-5639	268	22	.	.	PUNCT
dpc-5639	269	1	acta	acta	PROPN
dpc-5639	269	2	derm	derm	PROPN
dpc-5639	269	3	venereol	venereol	NOUN
dpc-5639	269	4	.	.	PUNCT
dpc-5639	270	1	2016	2016	NUM
dpc-5639	270	2	;	;	PUNCT
dpc-5639	270	3	96(7):978	96(7):978	NUM
dpc-5639	270	4	-	-	SYM
dpc-5639	270	5	980	980	NUM
dpc-5639	270	6	.	.	PUNCT
dpc-5639	271	1	doi	doi	NOUN
dpc-5639	271	2	:	:	PUNCT
dpc-5639	271	3	10.2340/00015555	10.2340/00015555	NUM
dpc-5639	271	4	-	-	SYM
dpc-5639	271	5	2433	2433	NUM
dpc-5639	271	6	.	.	PUNCT
dpc-5639	272	1	pmid	pmid	NOUN
dpc-5639	272	2	:	:	PUNCT
dpc-5639	272	3	27068455	27068455	NUM
dpc-5639	272	4	.	.	PUNCT
dpc-5639	273	1	15	15	NUM
dpc-5639	273	2	.	.	PUNCT
dpc-5639	273	3	phan	phan	PROPN
dpc-5639	273	4	nq	nq	PROPN
dpc-5639	273	5	,	,	PUNCT
dpc-5639	273	6	blome	blome	NOUN
dpc-5639	273	7	c	c	NOUN
dpc-5639	273	8	,	,	PUNCT
dpc-5639	273	9	fritz	fritz	PROPN
dpc-5639	273	10	f	f	PROPN
dpc-5639	273	11	,	,	PUNCT
dpc-5639	273	12	et	et	PROPN
dpc-5639	273	13	al	al	PROPN
dpc-5639	273	14	.	.	PROPN
dpc-5639	273	15	assessment	assessment	NOUN
dpc-5639	273	16	of	of	ADP
dpc-5639	273	17	pruritus	pruritus	PROPN
dpc-5639	273	18	intensity	intensity	NOUN
dpc-5639	273	19	:	:	PUNCT
dpc-5639	273	20	prospective	prospective	ADJ
dpc-5639	273	21	study	study	NOUN
dpc-5639	273	22	on	on	ADP
dpc-5639	273	23	validity	validity	NOUN
dpc-5639	273	24	and	and	CCONJ
dpc-5639	273	25	reliability	reliability	NOUN
dpc-5639	273	26	of	of	ADP
dpc-5639	273	27	the	the	DET
dpc-5639	273	28	visual	visual	ADJ
dpc-5639	273	29	analogue	analogue	NOUN
dpc-5639	273	30	scale	scale	NOUN
dpc-5639	273	31	,	,	PUNCT
dpc-5639	273	32	numerical	numerical	ADJ
dpc-5639	273	33	rating	rating	NOUN
dpc-5639	273	34	scale	scale	NOUN
dpc-5639	273	35	and	and	CCONJ
dpc-5639	273	36	verbal	verbal	ADJ
dpc-5639	273	37	rating	rating	NOUN
dpc-5639	273	38	scale	scale	NOUN
dpc-5639	273	39	in	in	ADP
dpc-5639	273	40	471	471	NUM
dpc-5639	273	41	patients	patient	NOUN
dpc-5639	273	42	with	with	ADP
dpc-5639	273	43	chronic	chronic	ADJ
dpc-5639	273	44	pruritus	pruritus	NOUN
dpc-5639	273	45	.	.	PUNCT
dpc-5639	274	1	acta	acta	PROPN
dpc-5639	274	2	derm	derm	PROPN
dpc-5639	274	3	venereol	venereol	NOUN
dpc-5639	274	4	.	.	PUNCT
dpc-5639	275	1	2012	2012	NUM
dpc-5639	275	2	;	;	PUNCT
dpc-5639	275	3	92(5	92(5	NOUN
dpc-5639	275	4	):	):	PUNCT
dpc-5639	275	5	502	502	NUM
dpc-5639	275	6	-	-	SYM
dpc-5639	275	7	507	507	NUM
dpc-5639	275	8	.	.	PUNCT
dpc-5639	276	1	doi	doi	NOUN
dpc-5639	276	2	:	:	PUNCT
dpc-5639	276	3	10.2340/00015555	10.2340/00015555	NUM
dpc-5639	276	4	-	-	SYM
dpc-5639	276	5	1246	1246	NUM
dpc-5639	276	6	.	.	PUNCT
dpc-5639	277	1	pmid	pmid	NOUN
dpc-5639	277	2	:	:	PUNCT
dpc-5639	277	3	22170091	22170091	NUM
dpc-5639	277	4	.	.	PUNCT
dpc-5639	278	1	16	16	NUM
dpc-5639	278	2	.	.	PUNCT
dpc-5639	279	1	finlay	finlay	VERB
dpc-5639	279	2	ay	ay	PROPN
dpc-5639	279	3	,	,	PUNCT
dpc-5639	279	4	khan	khan	PROPN
dpc-5639	279	5	gk	gk	PROPN
dpc-5639	279	6	.	.	PROPN
dpc-5639	279	7	dermatology	dermatology	NOUN
dpc-5639	279	8	life	life	NOUN
dpc-5639	279	9	quality	quality	NOUN
dpc-5639	279	10	index	index	NOUN
dpc-5639	279	11	(	(	PUNCT
dpc-5639	279	12	dlqi	dlqi	PROPN
dpc-5639	279	13	)	)	PUNCT
dpc-5639	279	14	a	a	DET
dpc-5639	279	15	simple	simple	ADJ
dpc-5639	279	16	practical	practical	ADJ
dpc-5639	279	17	measure	measure	NOUN
dpc-5639	279	18	for	for	ADP
dpc-5639	279	19	routine	routine	ADJ
dpc-5639	279	20	clinical	clinical	ADJ
dpc-5639	279	21	use	use	NOUN
dpc-5639	279	22	.	.	PUNCT
dpc-5639	280	1	clin	clin	PROPN
dpc-5639	280	2	exp	exp	NOUN
dpc-5639	280	3	dermatol	dermatol	NOUN
dpc-5639	280	4	.	.	PUNCT
dpc-5639	280	5	1994	1994	NUM
dpc-5639	280	6	;	;	PUNCT
dpc-5639	280	7	19(3):210	19(3):210	NUM
dpc-5639	280	8	-	-	PUNCT
dpc-5639	280	9	216	216	NUM
dpc-5639	280	10	.	.	PUNCT
dpc-5639	281	1	doi	doi	NOUN
dpc-5639	281	2	:	:	PUNCT
dpc-5639	281	3	10.1111	10.1111	NUM
dpc-5639	281	4	/j.1365	/j.1365	NOUN
dpc-5639	281	5	-	-	PUNCT
dpc-5639	281	6	2230.1994.tb01167.x	2230.1994.tb01167.x	NUM
dpc-5639	281	7	.	.	PUNCT
dpc-5639	282	1	pmid	pmid	NOUN
dpc-5639	282	2	:	:	PUNCT
dpc-5639	282	3	8033378	8033378	NUM
dpc-5639	282	4	.	.	PUNCT
dpc-5639	283	1	17	17	NUM
dpc-5639	283	2	.	.	PUNCT
dpc-5639	284	1	hongbo	hongbo	PROPN
dpc-5639	284	2	y	y	PROPN
dpc-5639	284	3	,	,	PUNCT
dpc-5639	284	4	thomas	thomas	PROPN
dpc-5639	284	5	cl	cl	PROPN
dpc-5639	284	6	,	,	PUNCT
dpc-5639	284	7	harrison	harrison	PROPN
dpc-5639	284	8	ma	ma	PROPN
dpc-5639	284	9	,	,	PUNCT
dpc-5639	284	10	et	et	PROPN
dpc-5639	284	11	al	al	PROPN
dpc-5639	284	12	.	.	PUNCT
dpc-5639	285	1	translating	translate	VERB
dpc-5639	285	2	the	the	DET
dpc-5639	285	3	science	science	NOUN
dpc-5639	285	4	of	of	ADP
dpc-5639	285	5	quality	quality	NOUN
dpc-5639	285	6	of	of	ADP
dpc-5639	285	7	life	life	NOUN
dpc-5639	285	8	into	into	ADP
dpc-5639	285	9	practice	practice	NOUN
dpc-5639	285	10	:	:	PUNCT
dpc-5639	285	11	what	what	PRON
dpc-5639	285	12	do	do	AUX
dpc-5639	285	13	dermatology	dermatology	NOUN
dpc-5639	285	14	life	life	NOUN
dpc-5639	285	15	quality	quality	NOUN
dpc-5639	285	16	index	index	NOUN
dpc-5639	285	17	scores	score	NOUN
dpc-5639	285	18	mean	mean	VERB
dpc-5639	285	19	?	?	PUNCT
dpc-5639	286	1	j	j	PROPN
dpc-5639	286	2	invest	invest	VERB
dpc-5639	286	3	dermatol	dermatol	NOUN
dpc-5639	286	4	.	.	PUNCT
dpc-5639	287	1	2005	2005	NUM
dpc-5639	287	2	;	;	PUNCT
dpc-5639	287	3	125(4):659	125(4):659	NOUN
dpc-5639	287	4	-	-	PUNCT
dpc-5639	287	5	664	664	NUM
dpc-5639	287	6	.	.	PUNCT
dpc-5639	288	1	doi	doi	NOUN
dpc-5639	288	2	:	:	PUNCT
dpc-5639	288	3	10.1111	10.1111	NUM
dpc-5639	288	4	/	/	SYM
dpc-5639	288	5	j.0022	j.0022	NOUN
dpc-5639	288	6	-	-	PUNCT
dpc-5639	288	7	202x.2005.23621.x	202x.2005.23621.x	NOUN
dpc-5639	288	8	.	.	PUNCT
dpc-5639	289	1	pmid	pmid	NOUN
dpc-5639	289	2	:	:	PUNCT
dpc-5639	289	3	16185263	16185263	NUM
dpc-5639	289	4	.	.	PUNCT
dpc-5639	290	1	18	18	NUM
dpc-5639	290	2	.	.	PUNCT
dpc-5639	291	1	riepe	riepe	PROPN
dpc-5639	291	2	c	c	PROPN
dpc-5639	291	3	,	,	PUNCT
dpc-5639	291	4	osada	osada	PROPN
dpc-5639	291	5	n	n	CCONJ
dpc-5639	291	6	,	,	PUNCT
dpc-5639	291	7	reich	reich	PROPN
dpc-5639	291	8	a	a	X
dpc-5639	291	9	,	,	PUNCT
dpc-5639	291	10	et	et	PROPN
dpc-5639	291	11	al	al	PROPN
dpc-5639	291	12	..	..	PUNCT
dpc-5639	291	13	minimal	minimal	ADJ
dpc-5639	291	14	clinically	clinically	ADV
dpc-5639	291	15	important	important	ADJ
dpc-5639	291	16	difference	difference	NOUN
dpc-5639	291	17	in	in	ADP
dpc-5639	291	18	chronic	chronic	ADJ
dpc-5639	291	19	pruritus	pruritus	NOUN
dpc-5639	291	20	appears	appear	VERB
dpc-5639	291	21	to	to	PART
dpc-5639	291	22	be	be	AUX
dpc-5639	291	23	dependent	dependent	ADJ
dpc-5639	291	24	on	on	ADP
dpc-5639	291	25	baseline	baseline	ADJ
dpc-5639	291	26	itch	itch	NOUN
dpc-5639	291	27	severity	severity	NOUN
dpc-5639	291	28	.	.	PUNCT
dpc-5639	292	1	acta	acta	PROPN
dpc-5639	292	2	derm	derm	PROPN
dpc-5639	292	3	venereol	venereol	NOUN
dpc-5639	292	4	.	.	PUNCT
dpc-5639	293	1	2019	2019	NUM
dpc-5639	293	2	;	;	PUNCT
dpc-5639	293	3	99	99	NUM
dpc-5639	293	4	:	:	SYM
dpc-5639	293	5	1288	1288	NUM
dpc-5639	293	6	-	-	SYM
dpc-5639	293	7	1290	1290	NUM
dpc-5639	293	8	.	.	PUNCT
dpc-5639	294	1	doi	doi	NOUN
dpc-5639	294	2	:	:	PUNCT
dpc-5639	294	3	10.2340/00015555	10.2340/00015555	NUM
dpc-5639	294	4	-	-	SYM
dpc-5639	294	5	3332	3332	NUM
dpc-5639	294	6	.	.	PUNCT
dpc-5639	295	1	pmid	pmid	NOUN
dpc-5639	295	2	:	:	PUNCT
dpc-5639	295	3	31580464	31580464	NUM
dpc-5639	295	4	.	.	PUNCT
dpc-5639	296	1	19	19	NUM
dpc-5639	296	2	.	.	PUNCT
dpc-5639	296	3	paganini	paganini	PROPN
dpc-5639	296	4	c	c	PROPN
dpc-5639	296	5	,	,	PUNCT
dpc-5639	296	6	talamonti	talamonti	PROPN
dpc-5639	296	7	m	m	PROPN
dpc-5639	296	8	,	,	PUNCT
dpc-5639	296	9	maffei	maffei	PROPN
dpc-5639	296	10	v	v	PROPN
dpc-5639	296	11	,	,	PUNCT
dpc-5639	296	12	et	et	PROPN
dpc-5639	296	13	al	al	PROPN
dpc-5639	296	14	.	.	PROPN
dpc-5639	296	15	dupilumab	dupilumab	NOUN
dpc-5639	296	16	for	for	ADP
dpc-5639	296	17	treatment	treatment	NOUN
dpc-5639	296	18	of	of	ADP
dpc-5639	296	19	prurigo	prurigo	PROPN
dpc-5639	296	20	nodularis	nodularis	PROPN
dpc-5639	296	21	:	:	PUNCT
dpc-5639	296	22	real	real	ADJ
dpc-5639	296	23	-	-	PUNCT
dpc-5639	296	24	life	life	NOUN
dpc-5639	296	25	effectiveness	effectiveness	NOUN
dpc-5639	296	26	for	for	ADP
dpc-5639	296	27	up	up	ADP
dpc-5639	296	28	to	to	PART
dpc-5639	296	29	84	84	NUM
dpc-5639	296	30	weeks	week	NOUN
dpc-5639	296	31	.	.	PUNCT
dpc-5639	297	1	j	j	PROPN
dpc-5639	297	2	clin	clin	PROPN
dpc-5639	297	3	med	med	PROPN
dpc-5639	297	4	.	.	PUNCT
dpc-5639	297	5	2024	2024	NUM
dpc-5639	297	6	;	;	PUNCT
dpc-5639	297	7	13(3):878	13(3):878	NUM
dpc-5639	297	8	.	.	PUNCT
dpc-5639	298	1	doi	doi	NOUN
dpc-5639	298	2	:	:	PUNCT
dpc-5639	298	3	10.3390	10.3390	NUM
dpc-5639	298	4	/jcm13030878	/jcm13030878	ADJ
dpc-5639	298	5	.	.	PUNCT
dpc-5639	299	1	pmid	pmid	NOUN
dpc-5639	299	2	:	:	PUNCT
dpc-5639	299	3	38337572	38337572	NUM
dpc-5639	299	4	;	;	PUNCT
dpc-5639	299	5	pmcid	pmcid	ADJ
dpc-5639	299	6	:	:	PUNCT
dpc-5639	299	7	pmc10856572	pmc10856572	NOUN
dpc-5639	299	8	.	.	PUNCT
dpc-5639	300	1	20	20	NUM
dpc-5639	300	2	.	.	PUNCT
dpc-5639	301	1	zhang	zhang	PROPN
dpc-5639	301	2	z	z	PROPN
dpc-5639	301	3	,	,	PUNCT
dpc-5639	301	4	li	li	PROPN
dpc-5639	301	5	s	s	PROPN
dpc-5639	301	6	,	,	PUNCT
dpc-5639	301	7	wang	wang	PROPN
dpc-5639	301	8	y	y	PROPN
dpc-5639	301	9	,	,	PUNCT
dpc-5639	301	10	zhao	zhao	PROPN
dpc-5639	301	11	j.	j.	PROPN
dpc-5639	301	12	a	a	DET
dpc-5639	301	13	real	real	ADJ
dpc-5639	301	14	-	-	PUNCT
dpc-5639	301	15	world	world	NOUN
dpc-5639	301	16	observational	observational	ADJ
dpc-5639	301	17	study	study	NOUN
dpc-5639	301	18	of	of	ADP
dpc-5639	301	19	dupilumab	dupilumab	NOUN
dpc-5639	301	20	treatment	treatment	NOUN
dpc-5639	301	21	in	in	ADP
dpc-5639	301	22	adult	adult	NOUN
dpc-5639	301	23	patients	patient	NOUN
dpc-5639	301	24	with	with	ADP
dpc-5639	301	25	prurigo	prurigo	PROPN
dpc-5639	301	26	nodularis	nodularis	PROPN
dpc-5639	301	27	.	.	PUNCT
dpc-5639	302	1	an	an	DET
dpc-5639	302	2	bras	bras	NOUN
dpc-5639	302	3	dermatol	dermatol	NOUN
dpc-5639	302	4	.	.	PUNCT
dpc-5639	303	1	2023	2023	NUM
dpc-5639	303	2	;	;	PUNCT
dpc-5639	303	3	98(4):440	98(4):440	PROPN
dpc-5639	303	4	-	-	SYM
dpc-5639	303	5	448	448	NUM
dpc-5639	303	6	.	.	PUNCT
dpc-5639	304	1	doi	doi	NOUN
dpc-5639	304	2	:	:	PUNCT
dpc-5639	304	3	10.1016	10.1016	NUM
dpc-5639	304	4	/	/	SYM
dpc-5639	304	5	j.	j.	PROPN
dpc-5639	304	6	abd.2022.09.008	abd.2022.09.008	PROPN
dpc-5639	304	7	.	.	PUNCT
dpc-5639	305	1	epub	epub	PROPN
dpc-5639	305	2	2023	2023	NUM
dpc-5639	305	3	mar	mar	PROPN
dpc-5639	305	4	23	23	NUM
dpc-5639	305	5	.	.	PUNCT
dpc-5639	306	1	pmid	pmid	NOUN
dpc-5639	306	2	:	:	PUNCT
dpc-5639	306	3	36966024	36966024	NUM
dpc-5639	306	4	;	;	PUNCT
dpc-5639	306	5	pmcid	pmcid	ADJ
dpc-5639	306	6	:	:	PUNCT
dpc-5639	306	7	pmc10334323	pmc10334323	NOUN
dpc-5639	306	8	.	.	PUNCT